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There are many unanswered questions at the molecular level of biology, and a 
chemical approach is most often necessary to answer those questions. A chemical 
approach in this instance is a combination of synthetic organic chemistry, analytical 
chemistry, and computational chemistry. Three unrelated projects will be discussed in 
this document, which utilize a combination of chemical tools to make sense of what is 
happening at the molecular level in these systems. Each of the projects described in this 
dissertation rely on my abilities as an analytical and organic chemist to propose 
substantiated hypotheses on molecular feature, structure, and biological function. I 
believe that through this work, progress has been made to better understand the 
chemical knowledge of these systems for future investigations. 
Chapter 1 will address drug-induced diabetes, which is a condition that is usually 
brought on from treatment of inflammation with glucocorticoids; Although these drugs 
are powerful anti-inflammatory agents, they have a propensity to hinder the secretion of 
insulin from pancreatic β [beta]-cells. To address this issue, a library of glucocorticoid 
analogues exhibiting a non-steroidal scaffold were synthesized, characterized, 
computationally modeled, and tested in-vitro as anti-inflammatory drug candidates with 
little to no effect on insulin production.  
Chapter 2 focuses on an isotope tracing experiment using synthetic lipids to 
differentiate straight-chain lipid species from isobaric congeners containing a terminal 
isopropyl moiety. This was devised to investigate plausible semiochemicals in Myxococcus 
xanthus towards a developmental phenotype initiated by an unknown lipid potentially 
containing this motif. This method has several implications in lipidomic and metabolomic 
analyses of biological systems, being that these isobars are impossible to distinguish from 
one another without analytical standards.  
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Chapter 3 is an investigation of microbial iron-sequestration, which is essential for 
nearly all life forms but is of particular interest in marine microbes. Many microbes use 
specialized molecules known as siderophores to capture iron from the environment to 
use for several life-sustaining functions. This final chapter spotlights the use of 
chromatographic and mass spectrometric techniques to investigate uncharacterized 
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 Chemistry is a fascinating science that is becoming more interdisciplinary as time 
moves forward, especially in the dependence of biological research on the disciplines of 
analytical and organic chemistry. The development of new analytical tools and the days 
of developing novel molecular transformations is certainly not past, but a large focus of 
this field of physical science has adapted to be more directly influential in probing and 
analyzing living systems. Analytical chemists are called upon to give detailed information 
of the molecular makeup of things, from the composition of biological tissues to the rates 
of enzymatic reactions in living organisms. There is increasing need for analytical 
technologies and approaches to determine the biochemical mechanisms of disease 
pathology, chemically resistant microbes, and the understanding of normal function in 
any number of biological systems. Organic chemists use known techniques and reactions 
to develop medicines, investigate structure-activity relationships, synthesize 
commercially unavailable standards to aid analytical chemists in their work, or create 
isotopically labeled molecular analogues to probe metabolism in microbes or higher-
order organisms. Organic chemists are constantly improving on existing molecular 
scaffolds to improve the action and outcome of medicinal therapies and treatments. The 
creation of novel drugs with precise biological activities is paramount in the battle against 
disease and dysfunction in all parts of the animal kingdom. This type of work is highly 
valued; not only in the medical field, but also in others such as agriculture, sustainable 
energies, cosmetics, and even the flavor and fragrance industry. The applications of 
chemical technologies to answer questions about the nature of life seems to be unending 
and ever-transforming, which is an intellectually invigorating notion. 
 Medicinal chemistry is an area of research that is constantly evolving, to 
achieve newer medicines with greater activities and fewer side effects. This can be said 
for practically every available medicinal treatment that humans have discovered or 
developed. Even now with the advent of targeted immunotherapies for cancers and other 
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maladies, previous treatments such as chemotherapy agents that at one time had 
revolutionized the prognosis of a cancer diagnosis are becoming obsolete in their 
comparable efficacy, yet combinatorial studies of these therapies are finding promising 
outcomes for patients.1-2 Side effects from effective drug therapies are another aspect of 
medicinal chemistry that is constantly being improved upon. One such class of molecules 
that have a huge impact on medicine are anti-inflammatory drugs, which are used 
eponymously to alleviate inflammation and the downstream conditions caused by an 
inflammatory response. A major draw-back to the use of these medications is their 
undesired effects on the immune system, as well as their effect on other signaling 
cascades that result in damage to by-standing systems such as the insulin producing β-
cells of the pancreas.3 It is becoming well-established that diabetes is an inflammatory 
condition beginning with inflammation of pancreatic β-cells and the subsequent immune 
response that destroys the β-cells, leading to a diabetic disease-state.3-6 The reason that 
anti-inflammatory drugs, specifically glucocorticoids, are causing this immune-mediated 
β-cell death is that although these medications repress inflammation, they also cause cells 
to produce pro-inflammatory cytokines that turn the immune system against the same 
cells the therapy is intended to target.7 
Glucocorticoid-induced diabetes is a condition that could be eradicated by the 
implementation of an appropriate anti-inflammatory agent that addresses the initial 
inflammation of the β-cells but does not lead to an immune response that invariably 
destroys the insulin producing ability of the patient undergoing treatment. Chapter 1 of 
this dissertation focuses on a series of molecules that have implications as being 
important in treating inflammation in patients that have a predisposition to diabetes 
being induced by typical glucocorticoid therapies. Structure-activity relationships were 
assessed with molecular docking experiments and density functional theory (DFT) 
calculations to support further research into optimizing a structure with the desired 
therapeutic profile. Though the molecules synthesized and evaluated for this study are by 
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no means perfect candidates for replacing dexamethasone or hydrocortisone as anti-
inflammatory agents, this work will provide strong evidence that a therapy of this 
specificity is well within our capabilities as scientists to develop and implement.  
 Mass spectrometry (MS) has become invaluable in the analysis of a wide variety 
of samples and liquid chromatography coupled mass spectrometry (LCMS) has become a 
powerful tool in the analysis of biological systems. The inquiries of recent past, present, 
and future are focused on unknown aspects of life at the molecular level. Metabolomics 
is the final stage of the ‘-omics’ cascade, which seeks to identify and quantify small 
molecules (metabolites) in a biological system and relate them back to phenotype – being 
that metabolic mass space is a direct consequence of the proteomic, transcriptomic, and 
genomic capability of a system taking post-translational modification into account. 
Lipidomics is a subset of metabolomics that seeks to identify and quantify the 
hydrophobic small molecules present in a biological sample. Chemists have the 
instrumentation to directly analyze the large and complex pool of molecules such as the 
metabolome and lipidome but can also utilize isotopically labeled molecules to probe how 
an organism might metabolize biogenic and xenobiotic compounds into useful things. This 
gives an analytical chemist the ability to analyze the small molecule differences between 
mutant strains of microbes, or genetically similar organisms grown in different 
environmental conditions to see what metabolites are responsible for observable 
changes in phenotype. Lipids have been thought of to be important in cell-cell 
communication and other signaling pathways since the mid-twentieth century, but only 
recently have become routinely analyzed by LCMS to investigate the known and unknown 
lipids in a sample.  
 Obtaining exact and accurate mass information on metabolites and lipids is 
currently a somewhat trivial task, determining the structure of those mass features is 
much more difficult, especially by the very commonly employed method of electrospray 
ionization mass spectrometry (ESI-MS). ESI is a soft ionization source that does not 
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typically induce fragmentation of analytes being introduced to the mass spectrometer. 
This of benefit in LC-ESI-MS experiments since the identity of the intact analytes are 
detected and identified by their exact mass and retention time against a library of 
analytical standards subjected to the same chromatographic method. This however does 
not allow the analyst to differentiate between compounds of the same exact mass and 
retention profile that have slight structural differences form on another. This issue can be 
resolved by using a hard-ionization source such as electron impact (EI) to produce 
structurally characteristic fragments.; however, EI is not a compatible ionization source 
under atmospheric pressures due to the negative effect on the source filaments. It would 
be useful if there was a way to shift the mass of structural isomers from each other so 
that they may be detected independently. In the second chapter of this dissertation, an 
isotope tracing experiment was devised to do just this in microbial systems. This was 
accomplished by feeding microbes a deuterated isolipid building block, isovaleric acid, 
which would be catabolized by the organisms to produce isotopically labeled compounds 
featuring a terminal isopropyl unit; thusly permitting simultaneous detection of 
structurally isomeric lipids with the isolipids shifted higher in mass than their straight-
chain isomers.  
 The analysis of biological systems through mass spectrometry has allowed for 
scientists to make substantiated conclusions about the influence of small molecules on 
the overall function of an organism. There are many examples of biologically derived 
molecules that have potent activities toward pathogens and dysfunctional cells, such as 
the antibiotic compound penicillin and the anti-cancer compound taxol. These molecules 
were discovered serendipitously to have beneficial properties in treating disease, but 
their isolation and identification is what allowed for the chemical production of these 
compounds for use in medicine. Natural product chemistry is a field in which molecules 
with interesting properties are isolated and characterized to not only inform the scientific 
community of their structure and function, but to potentially be synthetic targets for 
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chemists to produce in order to exploit their useful properties. There is not always a need 
for biologically derived molecules to be isolated and characterized to find a purpose 
outside the realm of scientific knowledge. One such case is in the understanding of 
nutrient uptake and cycling in marine microbes, where low concentrations of organic and 
inorganic compounds present in the environment pressure the organisms to develop 
chemical mechanisms to sustain life and thrive in these situations. In particular, the low 
abundance and bioavailability of iron in these environments coerces the production of 
small organic molecules with a high-affinity for iron, called siderophores. These iron-
binding compounds are not produced by all marine microbes but can be found in most 
marine environments including surface waters, as dissolved organic compounds, on 
water-suspended particles, and on the ocean floor.8 The preliminary isolation and mass 
spectrometric analyses of an unknown siderophore produced by a poorly studied 
Roseobacter isolate is described in the third and final chapter of this dissertation. 
Determining the structure of this unknown iron-binding compound would not only 
contribute to the scientific literature but depending on potential antimicrobial activity 
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1.1 – Abstract 
 Glucocorticoids (GCs) have been a mainstay in medicine for the treatment of 
autoimmune-mediated conditions, certain cancers, and to manage immune response in 
organ transplantation. GCs are steroid molecules that have many modes of action, usually 
acting as transcription factors that regulate pro-inflammatory gene expression. The 





Figure 1.1.1 – Human glucocorticoid receptor 5NFP 
 Crystal structure of the ligand binding domain of the human GR complex with 
ligand (budesonide) and protein crystallization additives removed. The ligand binding 
pocket is circled in pink.  
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in mammalian tissues, rendering agonistic molecules as valuable therapeutic agents for a 
variety of conditions requiring the regulation of inflammation in some capacity. Previously 
reported 1-(4-fluorophenyl)pyrazole-based GC analogues have been shown to reduce 
interleukin-6 (IL-6) induced inflammation (transrepression), but were accompanied by an 
undesired upregulation of  pro-inflammatory genes associated with GC-induced diabetes, 
muscle wasting, and osteoporosis (transactivation).9 Development of an anti-
inflammatory GC with a therapeutic profile that minimizes transactivation could greatly 
influence the prevention and treatment of inflammation induced type-1 diabetes mellitus 
(T1DM).10 In this study, an unexplored series of 1-(4-substituted phenyl)pyrazole-based 
GC analogues were synthesized and screened for structure-activity relationships that lead 
to the desired therapeutic profile. Compounds 11aa and 11ab (Figure 1.1.2) were found 
to have improved properties, including anti-inflammatory efficacy comparable to 
dexamethasone, as well as reduced ability to suppress pancreatic β-cell insulin secretion. 
Repression of IL-1β-induced inflammation by molecules 11aa and 11ab at 1 µM were 
comparable to dexamethasone at 10 nM, while also having similar GRE activation. 
Compound 11aa reduced insulin secretion at levels compared to the control, 
dimethylsulfoxide (DMSO), while dexamethasone reduced insulin secretion ~6-fold. 
Results from the biological testing of these compounds suggest this molecular scaffold to 





Figure 1.1.2 – Top dissociated GC therapy candidates from this study 




1.2 – Introduction 
1.2.1 – Glucocorticoids as anti-inflammatory drugs 
 Non-steroidal drugs such as salicylic acid have been used since ancient times, with 
records recalling the use of extracts of myrtle and willow tree bark for the management 
of inflammation.11 It was not until the late 19th century that chemists finally made 
modifications to these salicylate-containing remedies with the synthesis of acetylsalicylic 
acid (aspirin) by chemists Felix Hoffmann and Arthur Eichengrün.12 During the time period 
between 1930 and 1950, corticosteroids were isolated and structure-activity 
relationships for their anti-inflammatory action were investigated. From these studies on 
cortisol and other steroid molecules it was found that steroid drugs bearing a hydroxyl-
group on C11 (Figure 1.2.1) imparted an effect on immune-regulated inflammatory 
response but also gluconeogenesis.13  
 
 
Figure 1.2.1  – Natural vs. synthetic GC ring system 
 The positioning of the C11 hydroxyl group in traditional steroid molecules is 
important for glucocorticoid receptor specificity.14 Carbon atom numbering kept 
consistent to show structural similarities in terms of scaffold functionalization. 
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 The mechanism of action for aspirin eluded scientists until 1971, finding that it is 
a potent inhibitor of a family of enzymes called cyclooxygenases (COX-1 and COX-2), 
which are essential for the formation of prostaglandins that have a variety of downstream 
effects in vivo.15 Notably, certain prostaglandins stimulate the production of mucous that 
protects our gastrointestinal system from the actions of pepsin and acids produced in the 
stomach. During treatment with aspirin, this mucous production is halted, and can lead 
to the formation of ulcers in the stomach and intestines and lead to internal bleeding.16 
Indicating a need to not rely on these therapies for all instances of inflammation, 
especially in chronic inflammatory conditions. Throughout the following years synthetic 
anti-inflammatory drugs with greater specificities were developed, but to this day there 
has been little effort towards developing a non-steroidal anti-inflammatory drug (NSAID) 
that does not affect the production of insulin. 
 GCs are steroid hormones, possessing both anti-inflammatory and metabolism 
altering effects, synthesized endogenously in the adrenal glands. GCs operate by acting 
as a ligand for the glucocorticoid receptor (GR), located in the cellular cytoplasm bound 
to chaperone proteins. The GR is expressed by nearly all cell types, including pancreatic 
β-cells, and is the product of a single gene, NR3C1, that is post-translationally modified to 
produce functionally distinct subtypes of the GR.5 These functionally differentiable GR 
subtypes are one of the greatest contributors to the numerous side-effects of NSAID 
therapy and why developing drug candidates with specific activities is so challenging. 
Post-translational modifications to proteins are something that is not encoded by the 
genome and are very difficult to characterize the various modified forms of the GR, and 
thusly their individual influence on transcription. The GR has at least six modes of 
activation at the cellular level. The ligand-bound GR (GR-GC) can translocate to the 
nucleus, whereby it can bind to a glucocorticoid-response element (GRE) to (1) induce or 
(2) suppress gene expression; additionally, while in the nucleus the GR-GC can (3) 
facilitate or (4) hinder the actions of other transcription factors. Alternatively, the GR-GC 
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can remain in the cytoplasm and (5) increase, or (6) decrease, the activity of proximal 
proteins.17 Due to the anti-inflammatory and metabolic-altering effects of GCs, along with 
the ubiquity of the GR, GC-based therapies have been successfully applied to treating a 
wide range of inflammatory, auto-immune disorders, and cancers as well aiding in organ 
and tissue transplantation.17-18 
1.2.2 – Synthetic glucocorticoids with specific bioactivity 
 Application of synthetic GCs as a possible anti-inflammatory drug for type 1 
diabetes mellitus (T1DM) and immunosuppressive agent for organ transplants is 
attractive for a variety of reasons. Diabetes is the seventh leading cause of death in the 
United States, affecting at least 7.2% of the U.S. population in 2015; 3.3% of these cases 
are juvenile type 1 diabetes mellitus (T1DM) in children and adolescents ≤ 20 years of 
age.19 Early onset T1DM is now thought to be partially caused by inflammation.6, 20 
Application of synthetic GCs as possible therapeutics for the inflammatory component of 
T1DM and as immunosuppressive agents for organ transplants is attractive; however, 
these compounds, pose a long list of serious side effects including Cushing's disease, 
metabolic syndrome, osteoporosis, and the most common cause of drug-induced 
diabetes is clinical administration of GCs.3 T1DM is an autoimmune disorder characterized 
by inflammation and subsequent autoimmune-mediated destruction of the insulin-
producing β-cells.21 One manner of autoimmune β-cell death commonly associated with 
T1DM occurs through insulitis, a process by which β-cell damage and death occur via 
infiltration by macrophages and T-cells due to an accumulation of pro-inflammatory 
cytokines such as IL-1β, IFN-γ, and TNF-α.4, 22-23 Cytokine-mediated inflammation of β-cells 
causes the expression of chemokines CXCL9 and CXCL10, which through binding to 
integral membrane protein CXCR3 signal the recruitment of T-cells followed by infiltration 
and cell death.7, 22, 24 The ideal GC-based T1DM therapeutic would suppress the 
autoimmune response, which ultimately destroys the β-cells. Moreover, synthetic GCs 
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are designed to exhibit a "dissociated profile”, possessing enhanced anti-inflammatory 
activity with reduced side effects. 
 Two of the six modes of activation for the GR are often focused on as being the 
major contributors of the deleterious and salutary effects. One being the translocation of 
the GR-GC to the nucleus to increase transcription of pro-inflammatory genes, termed 
transactivation. The metabolic dysregulation caused by the direct binding of the GR-GC 
to GREs is thought to cause several side effects including those already mentioned, as well 
as hypertension and hyperglycemia. The other significant mode of GR activation results 
in translocation of the GR-GC to the nucleus to inhibit the action of pro-inflammatory 
cytokines, such as IL-1β, NF-κB, or AP-1, termed transrepression. The repression of 
various pro-inflammatory genes through the direct binding of the GR-GC to transcription 
factors are thought to be responsible for the observed anti-inflammatory effects of GCs 
scaffolds resembling 11, 12, and 13 (Figure 1.2.2).25-27 
 Different GREs differentially affect GR-GC binding conformation which implies that 
a GR-GC that cannot bind one GRE may be able to bind another GRE based on the specific 
target gene. Furthermore, different types and ratios of transcriptional cofactors are 
dependent on the cell or tissue type, and interactions with the GR-GC and other 
transcription factors contribute to the activity and dissociative properties of the GR-GC in 
terms of tissue type.18, 28-30 Synthetic GCs have been shown to improve β-cell 
development and suppress inflammation induced by IL-1β; However, they have also been 
shown to reduce adult β-cell mass.31-32 In this study, a series of novel non-steroidal 1-(4-
substituted phenyl)pyrazole-based GC analogues were synthesized and subjected to ex-
vivo assays measuring transactivation and transrepression. The top candidates from these 
assays were further assayed to determine how insulin production was affected. 
1.2.3 – Molecular modeling to inform structure-activity relationships 
 When developing a drug therapy, biological assays are used to determine their 





Figure 1.2.2 – Synthetic route toward 1-(4-substitued phenyl)pyrazolyl glucocorticoid 
analogues 
Synthetic procedure adapted from the work of Ali and coworkers.9 
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intended to affect. Knowing the structures of the molecules used as therapeutic agents 
and the results from these assays provide key information as to how the structures affect 
the observed activity, but this usually does not describe what interactions are occurring 
within the ligand-receptor complex, which are contributing to the change in activity. 
Changes in ligand size, electron accepting/donating capability, hydrogen-bonding, π-π 
interactions, and dipolar interactions all play a part in how a molecule binds to the target 
receptor. Computational methods, known collectively as molecular modeling, assist 
chemists in understanding the physical interactions between a drug and its target 
receptor. Modeling these interactions inform the chemist of what structural features 
enhance or diminish the desired bioactivity and guide the logic of creating more effective 
medications. 
 The most typically employed methods of molecular modeling are docking 
experiments between a ligand and a rigid receptor.33 In these calculations, electrostatic 
interactions between two bodies are evaluated in a number of physical orientations until 
the lowest-energy system is achieved, which would be representative of the most likely 
scenario that the ligand would bind to the receptor. The interacting bodies in this case 
are a ligand with all allowable rotations (torsions) and a non-moving (rigid) receptor. 
Receptor proteins are typically modeled in the conformation determined by x-ray 
crystallography and do not permit allowable torsions within the receptor. It is possible to 
produce a dynamic protein model; However, modeling an entire protein as a flexible 
molecule would be computationally exhaustive. These types of calculations need either a 
powerful processor or a lot of time, usually requiring a super-computer to perform these 
calculations in a reasonable timeframe. Even calculating the real-time molecular 
dynamics of a single small protein over the course of 10 microseconds (µs) took 3 months 
of supercomputing time for Dr. Kalus Schulten’s computational biophysics laboratory at 
the University of Illinois at Urbana-Champaign.34 Although this 11-year old example 
exaggerates the time requirements for these calculations on modern computing systems, 
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the computational cost of these molecular dynamic calculations for large-body protein 
systems are still very costly in terms of time and processing power. 
 There are higher levels of modeling methods than simple docking calculations that 
go beyond electrostatic interactions, such as DFT and symmetry adapted perturbation 
theory (SAPT) calculations, which take quantum-level electron density probabilities into 
account. These methods are also more computationally cumbersome, so simple docking 
experiments are typically acceptable when determining what residues are involved in the 
biding of the drug candidates to the target receptor, and how those interactions are 
playing a role in the bioactivity of the tested compounds. 
1.3 – Synthesis and purification of glucocorticoid analogues 
1.3.1 – Synthetic route and characterization 
 The total synthesis of all 1-(4-substituted phenyl)pyrazole-based GC analogues 
tested in this study were prepared by a previously described synthesis for a series of GC 
analogues9 with a few modifications made to synthetic procedure and substrate scope 
from Merck’s published method (Figure 1.3.1).9 A simple change of reagent is employed 
in the conversion of secondary alcohol 11 to ketone 12, accomplished using a standard 
PCC (pyridinium chlorochromate) oxidation in place of the costly oxidation with 
tetrapropylammonium perruthenate (TPAP) using N-methylmorpholine-N-oxide (NMO) 
as a sacrificial oxidant. The molecules investigated by Ali and coworkers (Merck 2004) 
focused on alterations to the R2 moiety while leaving the 4-fluorophenyl R1 group as a 
constant. Changing the identity of R1 was realized through the addition of the appropriate 
phenylhydrazine to β-ketoaldehyde 6, thereby installing the desired R1-arylpyrazole 
moiety (termed “headgroup”). Additionally, to further enhance the scope of 
functionalities examined in our biological evaluation was included a cyanomethylene unit 





Figure 1.3.1 - Synthetic modifications to previously published work 
Above are shown our synthetic modifications to the previously published synthetic route 
toward 1-(4-fluorophenyl)pyrazole-based glucocorticoid analogues. Additionally, is 
shown the scope of target structures between the two studies.9 
Ali et. al. (2004) 
Kennedy et. al. (2019) 
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 Briefly, the total synthesis of the steroid core begins with a Robinson annulation of 
compounds 1 and 2 to form intermediate trione 3, which upon asymmetric intramolecular 
cyclization gives Wieland-Miescher ketone 4. Selective ethylene glycol protection of 
compound 4 leaves the α-β-unsaturated ketone available for enolate formation and 
subsequent addition to ethyl formate, giving β-ketoaldehyde 6. Addition of the 
appropriate phenylhydrazine to 6 completes the core structure of the 1-(4-substituted 
phenyl)pyrazole-based GCs as compounds 7. The acid-catalyzed deprotection of acetal 7 
provided synthon 8, which was formylated via Wittig reaction to afford aldehyde 10, the 
essential intermediate for the divergent synthesis of all analogues presented in this study. 
Separation of starting material from the product of the one-pot Wittig/hydrolysis 
sequence from ketone 8 to aldehyde 10 was futile. In order to obtain aldehyde 10 in high 
purity, the intermediate enol-ether 9 was isolated from the Wittig reaction, purified via 
flash chromatography to remove any unreacted starting material, and subsequently 
subjected to hydrolysis conditions to afford compound 10 in sufficient purity to proceed 
with the next reaction.   
 Insertion of the sidegroup (R2) into the GC scaffold was achieved through 
generation of the appropriate alkyl lithium reagent followed by addition of aldehyde 10, 
resulting in a series of 2˚ alcohols (11) that were subjected to biological testing. 
Intermediate ketone 12 was obtained through a PCC oxidation of 11, and after purification 
was treated with MeLi to afford a series of 3˚ alcohols (13), which were also assayed. 
Synthesis of undesired byproducts 11ag and 13ag were attempted using the reaction 
conditions for generating compounds 11, 12, and 13. Persistent 1H-NMR impurities of 
purified target compounds 11ad, 11ae, and 11af prompted the need to synthesize a t-
butyl analogue of compound 11. Addition of t-BuLi to aldehyde 10a was achieved using 
reaction conditions described in generating the GC analogues in question - with 
consideration to the overall polarity of the reaction solvent system. The reaction to make 
11ag would not proceed if the volume of polar organic solvent was ≤ 50% of the total 
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solvent volume. Even though t-BuLi is generally a poor nucleophile for additions to 
carbonyl compounds, the reaction of t-BuLi with aldehyde 10 produced a pure yield ~25% 
suggesting a non-negligible amount of 11ag is being produced in the reactions affording 
11ad, 11ae, and 11af. Compound 13ag could not be synthesized under the reaction 
conditions used for generating the other compound 13 analogues, ketone 12ag was 
recovered from a reaction with 10 equivalents of MeLi with minimal evidence of 13ag 
being synthesized – this was verified by performing an HPLC analysis of crude recovered 
material where 12ag was detected as the major component, and 13ag was essentially 
detected as instrumental noise (Figure 1.3.2; appendix 1.8.8). 
1.3.2 – Optimization of flash chromatography 
 Throughout the synthetic procedure are purification steps requiring silica-based 
flash chromatography. TLC analysis was primarily done using a 25% solution of EtOAc in 
hexanes. Visualization of resolved compounds using short-wave UV light reveals 
separations that do not seem challenging, but when applied to a flash column by routine 
methods result in poor separation.  The best chromatographic resolution was obtained 
using a silica stationary phase and a low-polarity mixture of EtOAc in hexanes as the 
mobile phase. Other mobile phases such as PetEt/Et2O, Et2O/pentane, MeOH/DCM, or 
THF/hexanes proved to be less effective toward the isolation of the target compounds. 
Dissolution of the compounds in halogenated solvents allow for wet-loading concentrated 
solutions to the top of the column but will create unwanted band-broadening. All the 
compounds purified in this synthesis would dissolve mostly in polar solvents that would 
obscure the chromatography and result in poor separation. It was found that the best 
chromatographic resolution can be obtained by loading compounds onto silica, wet-
packing the silica column, carefully placing a thin layer of sand to maintain column 
integrity during compound loading, and finally loading the vacuum-dried compound-
adsorbed silica on top of the sand layer. This procedure mimics that of a typical TLC 






Figure 1.3.2 – Extracted ion chromatograms of compounds 11ag and 13ag 
LCMS analysis of crude 3˚-OH 13ag after oxidation of 2˚-OH 11ag and attempted 
methylation of ketone 12ag compared to a sample of compound 11ag. Virtually no 13ag 





the solvent is allowed to evaporate, and then the whole chromatographic system is 
subjected to the desired mobile phase composition. 
1H-NMR analysis of the purified intermediates revealed the presence of low 
intensity and low ppm “impurities” that were attributable to the presence of structural 
isomers of the desired intermediates and final products. This issue was likely avoided in 
the previous work of Ali et al. who used preparative chiral HPLC to achieve enantiomeric 
purity at each intermediate step of the synthesis of their series of N-arylpyrazolo[3,2-c]-
based glucocorticoid analogues.9 Preparative HPLC was not an accessible technology in 
the synthesis of the target compounds, and therefore isomers of intermediates were 
carried though the entire synthesis of the glucocorticoid analogues reported in this study. 
It should be noted that these spectral anomalies were fairly consistent across all tested 
compounds and should not be a significant factor in the responses observed in the 
biological assays reported. 
 The compounds subjected to biological testing in this preliminary study have a 
purity ~80% by 1H-NMR analysis, which is due in part to subtle differential intramolecular 
relaxation effects, as well as the presence of diastereomers of the final compounds. For 
compounds bearing R2 = 2,3-diflouoroanisolyl, 3-thiophenyl, and cyanomethyl - a single 
byproduct could not be removed by the chromatographic methods employed throughout 
the synthesis of the target compounds. The byproduct in question originates from the 
conversion of 10 to 11, where freshly generated organolithium species using t-BuLi are 
added to aldehydes 10. Being that lithium-halogen exchange reactions are an equilibrium 
process based on the comparative stability between the exchanging species, these 
reactions will generate a small amount of the undesired “t-butyl adduct”, which was 
synthesized and subjected to the same bioassays as all other compounds to determine 
how the presence of this undesired byproduct affected the observed activities of the 
screened GC analogues. All intermediates were only carried forward if TLC analysis 
revealed the purified compound as a single spot by UV visualization and/or TLC staining. 
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Although the synthetic GCs subjected to ex-vivo biological testing were not pure single 
molecules, the fact that these “impurities” were found in nearly all the compounds 
assayed should indicate that the observed activities for the compounds tested are directly 
related to the desired synthetic GC analogue. The isolation of pure compounds was quite 
challenging, and since this study is a first-pass screening of biological activity, further 
efforts in the absolute isolation of the desired compounds was deemed impractical. For 
future explorations of compounds similar in structure and synthesis – it should be noted 
that these molecules require rigorous purification strategies for silica-based flash 
chromatography such as low polarity mobile phase (5-10% EtOAc in hexanes) and several 
large columns (column dimensions ~ 50 x 4 cm) for single-gram quantities 
1.3.3 – Synthetic methods 
 Procedures for obtaining compound 6 were followed from a previously reported 
synthesis of N-arylpyrazolo[3,2-c]-based GC derivatives. The same general procedure can 
be followed for obtaining both tolyl- and anisolyl- (R1 = 1(4-methylphenyl); 1-(4-
methoxyphenyl)) GC analogue series starting from compound 6, the point of synthetic 
originality for this study. Synthetic procedures, chromatographic methods, and 
characterization data for intermediates and previously reported GC analogues will not be 
shown (namely the fluorophenyl series of GC analogues) except for GC analogues which 
were subjected to biological testing. Chemical reagents were purchased commercially and 
used without further purification, except for methyl vinyl ketone, which was purified by 
distillation immediately prior to use. Dry ethereal solvents were obtained by distillation 
from a potassium-benzophenone ketyl still, all other dry solvents were obtained via 
distillation over CaH2(s). Thin-layer chromatography (TLC) was carried out using Sorbent 
Technologies silica G w/UV254 TLC plates. All purified compounds of interest were 
visualized as single spots using short-wave UV light; more permanent staining of TLC spots 
was achieved using vanillin, p-anisaldehyde, or ceric ammonium molybdate (Hannesian’s) 
TLC staining solutions.  
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 1H-NMR spectra were obtained on an Oxford 300 Mhz or Varian InNova 500 MHz 
instruments in solutions of CDCl3. All 13C-NMR spectra were recorded on a Varian InNova 
500 MHz instrument in solutions of CDCl3. High resolution mass spectrometry (HRMS) was 
performed using either a JEOL direct analysis in real-time (DART) source in positive ion 
mode coupled to a JEOL AccuTOF JMS-T100LC mass spectrometer, or an Applied 
Biosystems QStar Elite mass spectrometer equipped with a Sciex Turboionspray 
electrospray ionization (ESI) source in positive ionization mode. Optical rotation was 
measured using a Perkin-Elmer 241 polarimeter equipped with a sodium source lamp. IR 
spectra were collected using a Nicolet iS5 spectrophotometer as a dry film on single 
NaCl(s) plates. LCMS analysis was conducted on a Dionex Ultimate3000 UHPLC system 
coupled to a Thermo Exactive Plus™ Orbitrap mass spectrometer with an ESI source 
operating in positive ionization mode (Thermo Scientific; Pittsburgh, PA). All annotated 
characterization data as well as tabulated bioassay data, NMR spectra of final compounds, 






General procedure for GC headgroup installation - compound series 7: To a solution of 6 
(5.0 g, 20 mmol) in glacial acetic acid (50 mL) was added the appropriate phenylhydrazine 
HCl salt (23 mmol) and sodium acetate (1.88 g, 23 mmol) and allowed to stir at room 
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temperature for 2 h. The reaction mixture was then slowly and carefully poured into a 
cold (0-5 ˚C) and actively stirred solution of saturated aqueous NaHCO3. The neutralized 
solution was then extracted with EtOAc (5x100 mL), washed with brine, dried with 
anhydrous MgSO4, filtered, and concentrated in vacuo. Purification of the crude product 
was accomplished using flash chromatography (20% EtOAc in hexanes) to give a viscous 
orange oil.  
4a-methyl-1-(p-tolyl)-1,4,4a,6,7,8-hexahydrospiro-[benzo[f]indazole-5,2'-
[1,3]dioxolane] (7b): From 6 using p-tolylphenylhydrazine HCl. Yield = 44%. TLC Rf = 0.28 
(30% EtOAc/hexanes). 1H-NMR (CDCl3, 499.73 MHz) δ 1.21 (s, 3H), 1.65-1.83 (m, 4H), 2.28 
(dt, 2H), 2.4 (s, 3H), 2.51 (d, 1H), 3.16 (d, 1H), 3.99-4.08 (m, 4H), 6.23 (s, 1H), 7.24-7.26 (d, 
2H), 7.35-7.37 (d, 2H), 7.43 (s, 1H). 
1-(4-methoxyphenyl)-4a-methyl-1,4,4a,6,7,8-hexahydrospiro[benzo[f]indazole-5,2'-
[1,3]dioxolane] (7c): From 6 using p-methoxyphenylhydrazine HCl. Yield = 38%. TLC Rf = 
0.27 (50% EtOAc/hexanes). 1H-NMR (CDCl3, 499.73 MHz) δ 1.22 (s, 3H), 1.68-1.83 (m, 3H), 
2.30-2.31 (d, 1H), 2.51-2.54 (d, 2H), 3.15-3.18 (d, 2H), 3.85 (s, 3H), 4.01-4.13 (m, 4H), 6.17 





Acetal deprotection for preparation of ketone 8: To a solution of 7 (5.9 mmol) in THF (50 
mL) was added 6 M HCl (3.9 mL, 23.6 mmol) and subjected to reflux for 3.5 h. The reaction 
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mixture was then neutralized by the slow addition of saturated aqueous NaHCO3 and 
extracted with ethyl acetate (4x100 mL). The pooled organic layer was washed with brine, 
dried with anhydrous MgSO4, and concentrated in vacuo. Purification of the crude product 
was accomplished using flash chromatography (20% EtOAc in hexanes)  to give a dull 
orange solid.  
4a-methyl-1-(p-tolyl)-1,4,4a,6,7,8-hexahydro-5H-benzo[f]indazol-5-one (8b): From 7b. 
Flash column mobile phase - 15% EtOAc/hexanes. Yield = 72%. TLC Rf = 0.34 (30% 
EtOAc/hexanes). 1H-NMR (CDCl3, 499.73 MHz) δ 1.25 (s, 3H), 1.62-1.71 (m, 1H), 2.06-2.11 
(m, 1H), 2.40 (s, 3H), 2.51-2.57 (m, 2H), 2.60-2.67 (m, 2H), 2.90 (s, 2H), 6.33 (s, 1H), 7.26-
7.28 (d, 2H), 7.35-7.38 (d, 2H), 7.48 (s, 1H). 
1-(4-methoxyphenyl)-4a-methyl-1,4,4a,6,7,8-hexahydro-5H-benzo[f]indazol-5-one (8c): 
From 7c. Flash column mobile phase - 20% EtOAc/hexanes. Yield = 77%. TLC Rf = 0.28 (40% 
EtOAc/hexanes). 1H-NMR (CDCl3, 499.73 MHz) δ 1.24 (s, 3H), 1.60-1.73 (m, 1H), 2.04-2.11 





General Procedure for the synthesis of aldehydes 10: A commercially available solution 
of potassium bis(trimethylsilyl)amide in toluene (0.5 M, 33.12 mL, 16.5 mmol) was added 
dropwise with a syringe to an actively stirred suspension of 
methoxymethyltriphenylphosphonium chloride (6.81 g, 19.8 mmol) in THF (65 mL) cooled 
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to -40 °C. The solution was warmed to 0 °C and stirred at that temperature for 15 min and 
a color change from pale yellow to dark red was observed. A solution of the appropriate 
ketone precursor 8 (6.6 mmol) in THF (16 mL) was transferred dropwise via canula to the 
chilled ylide. After stirring for 24 h, the reaction was quenched by the addition of 1:1 
THF/MeOH (16 mL), diluted with three reaction volumes of EtOAc, washed with water and 
brine, dried over MgSO4, filtered, concentrated in vacuo and subjected to flash 
chromatography (15% EtOAc/hexanes). Fractions containing enol either 9 were collected, 
concentrated in a round bottom flask, and dissolved in THF. To the prepared solution of 9 
in THF was added 4 M HCl and was allowed to stir at room temperature for 36 h. The 
reaction mixture was afterward diluted with EtOAc - washed with water, saturated 
aqueous NaHCO3, and brine. The organic layer was dried over MgSO4, filtered, and 
concentrated in vacuo to give crude aldehyde 10 as a beige solid. Purification of the crude 
product was accomplished using flash chromatography (15% EtOAc/hexanes). 
4a-methyl-1-(p-tolyl)-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazole-5-carbaldehyde 
(10b): Yield = 40.0 %. TLC Rf = 0.31 (25% EtOAc/hexanes). 1H-NMR (CDCl3, 300.08 MHz) δ 
1.12 (s, 3H), 1.30-1.40 (m, 2H) 1.70-1.78 (m, 2H), 1.90-1.96 (m, 1H), 2.32-2.44 (m, 2H), 
2.40 (s, 3H), 2.91 (d, 1H), 3.10 (d, 1H), 6.21 (s, 1H), 7.26-7.28 (d, 2H), 7.35-7.37 (d, 2H), 
7.44 (s, 1H), 9.90 (s, 1H) 
1-(4-methoxyphenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazole-5-
carbaldehyde (10c): Yield = 45.0 %. TLC Rf = 0.28 (25% EtOAc/hexanes). 1H-NMR (CDCl3, 
499.73 MHz) δ 1.11 (s, 3H), 1.39-1.43 (m, 1H), 1.72-1.75 (m, 1H), 1.90-1.96 (m, 2H), 2.33-
2.44 (m, 3H), 2.89-2.92 (d, 1H), 3.08-3.11 (d, 1H), 3.85-3.86 (s, 3H), 6.15 (s, 1H), 6.95-7.42 







General Procedure for R2 = methyl 2˚OH analogues: A commercially available solution of 
1.6 M MeLi in Et2O (312 µL, 0.5 mmol) was transferred via syringe to a round bottom flask 
containing diethyl ether (5 mL) and cooled to -78 °C. A solution of the appropriate 
aldehyde 10 (0.05 mmol) in THF (5 mL) was added dropwise via canula, and the reaction 
was stirred at -78 °C for 45 min. The reaction was quenched with isopropyl alcohol (IPA), 
poured into a separatory funnel containing saturated aqueous NH4Cl, and extracted three 
times with EtOAc. The organic phase was washed with once each with water and brine, 
dried over anhydrous MgSO4, filtered, and concentrated in vacuo. Purification of the crude 
product was accomplished using flash chromatography (15% EtOAc/hexanes) to give a 
white solid 
1-(1-(4-fluorophenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-
yl)ethan-1-ol (11aa): 1H-NMR (CDCl3, 499.73 MHz) δ 1.14 (s, 3H), 1.26-1.28 (d, 3H), 1.41-
.147 (dd, 2H), 1.63-1.68 (dd, 1H), 1.73-1.80 (m, 1H), 1.90-1.97 (m, 1H), 2.31-2.43 (m, 2H), 
2.46-2.52 (d, 1H), 2.98-3.03 (d, 1H), 4.25 (s, 1H), 6.10 (s, 1H), 7.11-7.19 (m, 2H), 7.41-7.47 
(m, 3H). 
1-(4a-methyl-1-(p-tolyl)-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl)ethan-1-ol 
(11ba): From 10b using MeLi (1.6 M solution in Et2O). Yield = 50%. Flash column mobile 
phase – 15% EtOAc in hexanes. TLC Rf = 0.16 (30% EtOAc/hexanes). HRMS (DART-RTOF) 
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m/z: [M+H]+ Calcd for C21H27N2O, 323.21179; found 323.21001. 1H-NMR (CDCl3, 499.73 
MHz): δ 1.13 (s, 3H), 1.23-1.29 (m, 3H), 1.34-1.45 (m, 2H), 1.56-1.62 (m, 2H), 1.72-1.78 
(m, 1H), 1.90-1.94 (m, 1H), 2.27-2.30 (m, 1H), 2.32-2.37 (m, 4H) 2.47-2.50 (d, 1H), 2.97-
3.00 (d, 1H), 6.14 (s, 1H), 7.23-7.26 (d, 2H), 7.34-7.36 (d, 2H), 7.40 (s, 1H) 
1-(1-(4-methoxyphenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-
yl)ethan-1-ol (11ca): From 10c using MeLi (1.6 M solution in Et2O). Yield = 58%. Flash 
column mobile phase – 30% EtOAc/hexanes. TLC Rf = 0.11 (25% EtOAc/hexanes). HRMS 
(DART-RTOF) m/z: [M+H]+ Calcd for C21H27N2O2, 339.20670; found 339.20344. 1H-NMR 
(CDCl3, 499.73 MHz): δ 1.13 (s, 3H), 1.23-1.29 (m, 4H), 1.34-1.45 (m, 3H), 1.74-1.78 (d, 
1H),1.88-1.95 (d, 1H), 2.28-2.31 (d, 1H), 2.35-2.39 (m, 1H), 2.47-2.51 (d, 1H), 2.98-3.01 (d, 





General Procedure for R2 = phenyl 2˚OH analogues: A commercially available solution of 
1.9 M PhLi in di-n-butyl ether (3.42 mL, 6.5 mmol) was transferred to a round bottom flask 
containing a small portion of dry Et2O and was cooled to -78 °C. A solution of 10 (0.65 
mmol) in THF (2 mL) was added dropwise via canula, and the reaction was stirred at -78 
°C for 45 min. The reaction was quenched with IPA, poured into a separatory funnel 
containing saturated aqueous NH4Cl, and extracted three times with EtOAc. The organic 
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phase was washed with once each with water and brine, dried over anhydrous MgSO4, 
filtered, and concentrated in vacuo. Purification of the crude product was accomplished 
using flash chromatography. 
(1-(4-fluorophenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-
yl)(phenyl)methanol (11ab): 1H-NMR (CDCl3, 499.73 MHz) δ 1.18 (s, 3H), 1.52-1.58 (m, 
2H), 1.60-1.63 (dd, 1H), 1.70-1.74 (m, 2H), 2.17-2.21 (m, 1H), 2.28-2.36 (m, 1H), 2.66-2.69 
(d, 1H), 3.08-3.11 (d, 1H), 5.10 (d, 1H), 6.02 (s, 1H), 7.04-7.08 (m, 2H), 7.16-7.18 (m, 1H), 
7.27-7.29 (m, 4H), 7.35-7.38 (m, 3H). 
(4a-methyl-1-(p-tolyl)-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-
yl)(phenyl)methanol (11bb): From 10b using PhLi (1.9 M solution in di-n-butyl ether). 
Flash column mobile phase – 15% EtOAc/hexanes, to give a white solid. Yield = 28%. TLC 
Rf = 0.20 (30% EtOAc/hexanes). HRMS (DART-RTOF) m/z: [M+H]+ Calcd for C26H29N2O, 
385.22744; found 385.22612. 1H-NMR (CDCl3, 499.73 MHz): δ 1.26 (s, 3H), 1.60-1.81 (m, 
5H), 2.23-2.28 (d, 1H), 2.36-2.43 (m, 4H), 2.74-2.77 (d, 1H) 3.15-3.18 (d, 1H), 5.17 (s, 1H), 
6.15 (s, 1H), 7.23-7.27 (d, 3H), 7.34-7.38 (m, 6H), 7.41 (s, 1H). 
(1-(4-methoxyphenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-
yl)(phenyl)methanol (11cb): From 10c using PhLi (1.9 M solution in di-n-butyl ether). 
Flash column mobile phase – 20% EtOAc/hexanes, to give a beige solid. Yield = 73 %. TLC 
Rf = 0.11 (30% EtOAc/hexanes). HRMS (DART-RTOF) m/z: [M+H]+ Calcd for C26H29N2O2, 
401.22235; found 401.21952. 1H-NMR (CDCl3, 499.73 MHz): δ 1.27 (s, 3H), 1.56-1.81 (m, 
6H), 2.24-2.27 (d, 1H), 2.36-2.44 (m, 1H), 2.75-2.78 (d, 1H), 3.17-3.20 (d, 1H), 3.85 (s, 3H), 







General Procedure for R2 = 4-fluorophenyl 2˚OH analogues: A commercially available 
solution of 2.0 M 4-fluorophenylmagnesium bromide in diethyl ether was transferred to 
a round bottom flask and cooled to -78 °C. A solution of 8 R1 = Me in THF was added 
dropwise via canula, and the reaction was stirred at -78 °C for 45 min. The reaction was 
quenched with IPA, poured into a separatory funnel containing saturated aqueous NH4Cl, 
and extracted three times with EtOAc. The organic phase was washed with once each with 
water and brine, dried over anhydrous MgSO4, filtered, and concentrated in vacuo. 
Purification of the crude product was accomplished using flash chromatography (10% 
EtOAc in to give a white solid. 
(4-fluorophenyl)(1-(4-fluorophenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-
benzo[f]indazol-5-yl)methanol (11ac): 1H-NMR (CDCl3, 300.08 MHz) δ1.26 (s, 3H), 1.65-
1.69 (m, 3H), 1.77-1.86 (m, 1H), 2.26-2.41 (m, 2H), 2.72-2.77 (d, 1H), 3.17-3.22 (d, 1H), 
5.19-5.22 (s, 1H), 6.12 (s, 1H), 7.02-7.08 (t, 2H), 7.13-7.19 (t, 2H), 7.30-7.34 (dd, 2H), 7.44-
7.48 (m, 3H). 
(4-fluorophenyl)(4a-methyl-1-(p-tolyl)-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-
yl)methanol (11bc): From 10b using 4-fluorophenylmagnesium bromide (2.0 M in Et2O). 
Flash column mobile phase – 10% EtOAc/hexanes. Yield = 11.5 %. TLC Rf = 0.24 (25% 
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EtOAc/hexanes). HRMS (DART-RTOF) m/z: [M+H]+ Calcd for C26H28FN2O, 403.21802; found 
403.21649. 1H-NMR (CDCl3, 499.73 MHz): δ 1.26 (s, 3H), 1.50-1.61 (m, 3H), 1.67-1.71 (m, 
2H), 1.79-1.82 (d, 1H), 2.25-2.28 (d, 1H), 2.39 (s, 3H), 2.74-2.77 (d, 1H), 3.16-3.20 (d, 1H), 
5.19 (s, 1H), 6.16 (s, 1H), 7.02-7.46 (m, 9). 
(4-fluorophenyl)(1-(4-methoxyphenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-
benzo[f]indazol-5-yl)methanol (11cc): From 10c using 4-
fluorophenylmagnesiumbromide (2.0M in Et2O). Flash column mobile phase - 15% 
EtOAc/hexanes. Yield = 69%. TLC Rf = 0.26 (30% EtOAc/hexanes). HRMS (DART-RTOF) m/z: 
[M+H]+ Calcd for C26H28FN2O2, 419.21293; found 419.20660. 1H-NMR (CDCl3, 499.73 
MHz): δ 1.26 (s, 3H), 1.56-1.58 (m, 2H), 1.66-1.70 (m, 2H), 1.79-1.82 (m, 1H), 2.25-2.28 
(m, 1H), 2.37-2.40 (m, 1H), 2.73-2.76 (d, 1H), 3.17-3.20 (d, 1H), 3.85 (s, 3H), 5.20 (d, 1H), 





General Procedure for R2 = 2,3-difluoroanisolyl 2˚OH analogues: A solution of 5-Bromo-
2,3-difluoroanisole (4.6 mmol) in THF (10 mL) was cooled to -78 °C, to which a 
commercially available solution of 1.9 M t-BuLi in pentanes (4.6 mmol, 2.9 mL) was added 
dropwise via syringe. The reaction was stirred for 20 min at -78 °C, raised to 0 °C for 5-10 
min until the solution transitioned from pale yellow to dark yellow-green, and then was 
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immediately cooled back to -78 °C for 5 min. A solution of 10 (0.46 mmol) in THF (2 mL) 
was added dropwise via canula, and the reaction was stirred at -78 °C for 1 h. The reaction 
was quenched with IPA, poured into a separatory funnel containing saturated aqueous 
NH4Cl, and extracted three times with EtOAc. The organic phase was washed with water 
and brine, dried over anhydrous MgSO4, filtered, and concentrated in vacuo. Purification 
of the crude product was accomplished using flash chromatography to give a white solid. 
(3,4-difluoro-5-methoxyphenyl)(1-(4-fluorophenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-
1H-benzo[f]indazol-5-yl)methanol (11ad): From 10a using commercially available 5-
bromo-2,3-difluoroanisole. Flash column mobile phase – 30% EtOAc/hexanes. Yield = 61.9 
%. TLC Rf = 0.26 (25% EtOAc/hexanes). 1H-NMR (CDCl3, 300.08 MHz) δ 1.26 (s, 3H), 1.54-
1.57 (m, 1H), 1.64-1.72 (m, 1H), 1.82-1.86 (m, 2H), 2,28-2.46 (m, 3H), 2.72-2.77 (d, 1H), 
3.17-3.22 (d, 1H), 3.92 (s, 3H), 5.12 (s, 1H), 6.12 (s, 1H), 6.72-6.80 (m, 2H), 7.15-7.21 (m, 
2H), 7.45-7.54 (m, 3H). 
(3,4-difluoro-5-methoxyphenyl)(4a-methyl-1-(p-tolyl)-4,4a,5,6,7,8-hexahydro-1H-
benzo[f]indazol-5-yl)methanol (11bd): From 10b using commercially available 5-bromo-
2,3-difluoroanisole. Flash column mobile phase - 10% EtOAc/hexanes. Yield = 76.7 %. TLC 
Rf = 0.22 (25% EtOAc/hexanes). HRMS (DART-RTOF) m/z: [M+H]+ Calcd for C27H29F2N2O2, 
451.21916; found 451.21790. 1H-NMR (CDCl3, 499.73 MHz) δ 1.25 (m, 3H), 1.37-1.50 (m, 
2H), 1.54-1.65 (m, 2H), 1.76-1.79 (d, 1H), 2.04 (s, 3H), 2.26-2.29 (d, 1H), 2.72-2.75 (d, 1H), 
3.14-3.17 (d, 1H), 3.88 (s, 3H), 5.10 (s, 1H), 6.16 (s, 1H), 6.72-6.78 (m, 2H), 7.24-7.46 (m, 
6H). 
(3,4-difluoro-5-methoxyphenyl)(1-(4-methoxyphenyl)-4a-methyl-4,4a,5,6,7,8-
hexahydro-1H-benzo[f]indazol-5-yl)methanol (11cd): From 10c using commercially 
available 5-bromo-2,3-difluoroanisole. Flash column mobile phase - 15% EtOAc/hexanes. 
Yield = 71.4 %. TLC Rf = 0.16 (30% EtOAc/hexanes). HRMS (DART-RTOF) m/z: [M+H]+ Calcd 
for C27H29F2N2O3, 467.21408; found 467.21488. 1H-NMR (CDCl3, 499.73 MHz) δ 1.26 (s, 
3H), 1.52-1.56 (m, 2H), 1.66-1.69 (m, 2H), 1.80-1.84 (m, 2H), 2.26-2.29 (m, 1H), 2.73-2.76 
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(d, 1H), 3.15-3.18 (d, 1H), 3.85 (s, 3H), 3.91 (s, 3H), 5.12 (s, 1H), 6.11 (s, 1H), 6.72-6.79 (m, 





General Procedure for R2 = thiophenyl 2˚OH analogues: A solution of 3-bromothiophene 
(0.6 mL, 6.4 mmol) in THF (10 mL) was cooled to -78 °C, to which a commercially available 
solution of 1.9 M t-BuLi in pentanes (6.8 mL, 12.8 mmol) was added dropwise via syringe. 
After the reaction stirred for 30 min at -78 °C, a solution of 10 (6.4 mmol) in THF (2 mL) 
was added dropwise via canula, and the reaction was allowed to gradually warm to room 
temperature over the course of 1.5 h. After returning the reaction to -78 °C, the reaction 
was quenched with IPA, poured into a separatory funnel containing saturated aqueous 
NH4Cl, and extracted three times with EtOAc. The organic phase was washed with water 
and brine, dried over anhydrous MgSO4, filtered, and concentrated in vacuo. Purification 
of the crude product was accomplished using flash chromatography (10% EtOAc/hexanes) 
to give a white solid. 
(1-(4-fluorophenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-
yl)(thiophen-3-yl)methanol (11ae): From 10a using commercially available 3-
bromothiophene. Flash column mobile phase – 10% EtOAc/hexanes. Yield = 35.8%. TLC Rf 
= 0.26 (25% EtOAc/hexanes). 1H-NMR (CDCl3, 499.73 MHz) δ 1.24 (s, 3H), 1.65-1.93 (m, 
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5H), 2.27-2.48 (m, 2H), 2.67-2.72 (d, 1H), 3.08-3.15 (d, 1H), 5.24 (s, 1H), 6.12 (s, 1H), 6.94-
6.99 (m, 1H), 7.12-7.24 (m, 3H), 7.30-7.33 (m, 1H), 7.43-7.48 (m, 3H). 
(4a-methyl-1-(p-tolyl)-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl)(thiophen-3-
yl)methanol (11be): From 10b using commercially available 3-bromothiophene. Flash 
column mobile phase – 10% EtOAc/hexanes. Yield = 35.8%. TLC Rf = 0.26 (25% 
EtOAc/hexanes). HRMS (DART-RTOF) m/z: [M+H]+ Calcd for C24H27N2OS, 391.18386; found 
391.13976. 1H-NMR (CDCl3, 499.73 MHz) δ 1.23 (s, 3H), 1.62-1.91 (m, 6H), 2.26-2.31 (m, 
1H), 2.40 (s, 3H), 2.67-2.72 (m, 1H), 3.06-3.14 (m, 1H), 5.39 (s, 1H), 6.16 (s, 1H), 6.95-7.43 
(m, 8H). 
(1-(4-methoxyphenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-
yl)(thiophen-3-yl)methanol (11ce): From 10c using commercially available 3-
bromothiophene. Flash column mobile phase – 15% EtOAc/hexanes. Yield = 79.5%. TLC Rf 
= 0.17 (30% EtOAc/hexanes). HRMS (ESI-RTOF) m/z: [M+H]+ Calcd for C24H27N2O2S, 
407.1787; found 407.1720. 1H-NMR (CDCl3, 499.73 MHz) δ 1.26 (m, 4H), 1.62-1.72 (m, 
2H), 1.77-1.85 (m, 2H), 2.27-2.41 (m, 2H), 2.69-2.72 (d, 1H), 3.12-3.15 (d, 1H), 3.85 (s, 3H), 






hydroxypropanenitrile (11af): A commercially available solution of 1.7 M t-BuLi in 
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pentanes (0.9 mL, 1.53 mmol) was transferred to a round bottom flask containing THF (2 
mL) and cooled to -78 °C. A solution of ACN (80 µL) in THF (2 mL) was added dropwise at 
-78 °C. Following addition, a solution of 10a (400 mg, 1.3 mmol) in THF (2 mL) was added 
dropwise via canula, and the reaction was stirred at -78 °C for 1 h. The reaction was 
quenched with saturated aqueous NH4Cl, acidified to a pH of 7 via dropwise addition of 
0.5 M HCl, and extracted three times with diethyl ether. The organic phase was washed 
with water and brine, dried over anhydrous MgSO4, filtered, and concentrated in vacuo. 
Purification of the crude product was accomplished using flash chromatography (25% 
EtOAc/hexanes) to give a white solid. Yield = 45.5%. TLC Rf = 0.14 (25% EtOAc/hexanes). 
HRMS (DART-RTOF) m/z: [M+H]+ Calcd for C21H23FN3O, 352.18197; found 352.18293. 1H-
NMR (CDCl3, 499.73 MHz) δ 1.04-1.13 (s, 3H), 1.25-1.46 (m, 2H), 1.61-1.71 (m, 2H), 1.78-
1.97 (m, 2H), 2.30-2.42 (m, 2H), 2.47-2.72 (m, 3H), 2.93-3.21 (d, 1H), 4.16-4.40 (m, 1H), 





General procedure for the synthesis of intermediate 12: A solution of the appropriate 2˚-
OH precursor (11) in dichloromethane was transferred dropwise via canula to a 
suspension of pyridinium chlorochromate (1.5 molar equivalents to compound being 
oxidized) and freshly activated 4 Å molecular sieves (an equivalent weight to compound 
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being oxidized) in dichloromethane. The reaction was stirred at room temperature until 
complete conversion was observed by TLC analysis (reaction times varied from 1-7 h). 
Upon complete conversion, the reaction mixture was immediately loaded onto a prepared 
florisil column (packed DCM slurry) and subjected to purification via flash chromatography 
(100% DCM flush) to give ketone 12 in sufficient purity to move forward with the 
synthesis. 
3-(1-(4-fluorophenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl)-3-
hydroxybutanenitrile (12af): White solid obtained from 11af with PCC as the oxidizing 
agent. Yield = 16%. TLC Rf = 0.11 (30% EtOAc/hexanes). HRMS (DART-RTOF) m/z: [M+H]+ 
Calcd for C21H21FN3O, 350.16632; found 350.16529. 1H-NMR (CDCl3, 499.73 MHz) δ 1.20 
(s, 3H), 1.45-1.49 (m, 2H), 1.82-1.87 (t, 2H), 1.93-1.97 (d, 1H), 2.32-2.44 (m, 3H), 2.74-2.77 





General procedure for the synthesis of compound 13 analogues: The appropriate ketone 
precursor (12) was dissolved in diethyl ether and cooled to -40 °C, and a commercially 
available soluion of MeLi (1.9 M, 10 equivalents to ketone starting material) was added 
dropwise via syringe. The reaction was stirred under argon at -40° for 45 min. The reaction 
was quenched with IPA (10 equivalents to MeLi added), poured into a separatory funnel 
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containing saturated aqueous NH4Cl, and extracted with EtOAc. The organic phase was 
washed with water and brine, dried over anhydrous MgSO4, filtered, and concentrated in 
vacuo. Purification was accomplished using flash chromatography (see each entry for 
respective column conditions). 
2-(1-(4-fluorophenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-
yl)propan-2-ol (13aa): 1H-NMR (CDCl3, 300.08 MHz) δ 1.14 (s, 3H), 1.26-1.28 (d, 3H), 1.35-
1.47 (m, 2H), 1.58 (s, 3H), 1.63-1.68 (dd, 1H), 1.73-1.80 (m, 1H), 1.89-1.98 (m, 1H), 2.26-
2.42 (m, 2H), 2.46-2.52 (d, 1H), 2.98-3.03 (d, 1H), 6.10 (s, 1H), 7.12-7.18 (m, 2H), 7.41-7.47 
(m, 3H). 
2-((4aR)-4a-methyl-1-(p-tolyl)-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl)propan-
2-ol (13ba): From appropriate ketone 12 using commercially available MeLi (1.9 M in Et2O) 
to give a white solid in 55% yield. Flash column mobile phase - 20% EtOAc/hexanes. TLC 
Rf = 0.17 (25% EtOAc/hexanes). HRMS (ESI-RTOF) m/z: [M+H]+ Calcd for C22H29N2O, 
337.2274; found 337.2200. 1H-NMR (CDCl3, 499.73 MHz) δ 1.19 (s, 3H), 1.33-1.37 (s, 8H), 
1.38-1.39 (d, 1H), 1.66-1.69 (d, 1H), 1.77-1.80 (dt, 1H), 1.84-1.87 (dt, 1H), 2.31 (m, 1H), 
2.39 (s, 3H), 2.73-2.76 (d, 1H), 3.53-3.57 (d, 1H), 6.16 (s, 1H) 7.24-7.25 (d, 2H), 7.35-7.38 
(d, 2H), 7.40 (s, 1H). 
1-((4aR)-4a-methyl-1-(p-tolyl)-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl)-1-
phenylethan-1-ol (13bb): From appropriate ketone 12 using commercially available MeLi 
(1.9 M in Et2O) to give a white solid in 82% yield. Flash column mobile phase - 15% 
EtOAc/hexanes. TLC Rf = 0.27 (30% EtOAc/hexanes). HRMS (ESI-RTOF) m/z: [M+H]+ Calcd 
for C27H31N2O, 399.2430; found 399.2368. ); 1H-NMR (CDCl3, 499.73 MHz) δ 1.27 (s, 3H), 
1.62-1.66 (m, 2H), 1.68 (s, 3H), 1.74-1.79 (m, 2H), 2.04-2.07 (d, 1H), 2.24-2.28 (d, 1H), 
2.33-2.40 (m, 4H), 2.60-2.63 (d, 1H), 3.10-3.13 (d, 1H), 6.14 (s, 1H), 7.23-7.29 (m, 4H), 
7.33-7.36 (m, 4H), 7.49-7.52 (m, 2H). 
1-(4-fluorophenyl)-1-((4aR)-4a-methyl-1-(p-tolyl)-4,4a,5,6,7,8-hexahydro-1H-
benzo[f]indazol-5-yl)ethan-1-ol (13bc): From appropriate ketone 12 using commercially 
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available MeLi (1.9 M in Et2O) to give a white solid in 80% yield. Flash column mobile phase 
- 15% EtOAc/hexanes. TLC Rf = 0.25 (30% EtOAc/hexanes). HRMS (DART-RTOF) m/z: 
[M+H]+ Calcd for C27H30FN2O, 417.23367; found 417.23232. 1H-NMR (CDCl3, 499.73 MHz) 
δ 1.26 (s, 3H), 1.60-1.63 (m, 3H), 1.66 (s, 3H), 1.75-1.79 (d, 1H), 1.99-2.02 (d, 1H), 2.24-
2.27 (d, 1H), 2.39 (s, 3H), 2.60-2.63 (d, 1H), 3.12-3.15 (d, 1H), 5.30 (s, 1H), 6.14 (s, 1H), 
7.01-7.48 (m, 9H). 
1-(3,4-difluoro-5-methoxyphenyl)-1-((4aR)-4a-methyl-1-(p-tolyl)-4,4a,5,6,7,8-
hexahydro-1H-benzo[f]indazol-5-yl)ethan-1-ol (13bd): From appropriate ketone 12 using 
commercially available MeLi (1.9 M in Et2O) to give a white solid in 94% yield. Flash column 
mobile phase - 10% EtOAc/hexanes. TLC Rf = 0.19 (30% EtOAc/hexanes). HRMS (ESI-RTOF) 
m/z: [M+H]+ Calcd for C28H31F2N2O2, 465.2348; found 465.2283. 1H-NMR (CDCl3, 499.73 
MHz) δ 1.22-1.35 (m, 6H), 1.58-1.62 (m, 4H), 1.79-1.83 (d, 1H), 1.96-1.99 (d, 1H), 2.25-
2.28 (d, 1H), 2.34-2.44 (s, 3H), 2.57-2.61 (d, 1H), 3.05-3.08 (d, 1H), 3.91-3.96 (s, 3H), 6.15 
(s, 1H), 6.87-6.92 (m, 2H), 7.23-7.30 (m, 4H), 7.36 (s, 1H). 
1-((4aR)-4a-methyl-1-(p-tolyl)-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl)-1-
(thiophen-2-yl)ethan-1-ol (13be): From appropriate ketone 12 using commercially 
available MeLi (1.9 M in Et2O) to give a white solid in 76% yield. Flash column mobile phase 
- 10% EtOAc/hexanes. TLC Rf = 0.28 (25% EtOAc/hexanes). HRMS (ESI-RTOF) m/z: [M+H]+ 
Calcd for C25H29N2OS, 405.1995; found 405.1899. 1H-NMR (CDCl3, 499.73 MHz) δ 1.25 (s, 
3H), 1.40-1.41 (d, 1H), 1.57-1.59 (d, 1H), 1.65 (s, 3H), 1.69-1.70 (d, 2H), 1.76-1.78 (d, 1H), 
2.03-2.06 (d, 1H), 2.26-2.28 (d, 1H), 2.39 (s, 3H), 2.66-2.69 (d, 1H), 3.22-3.25 (d, 1H), 6.15 
(s, 1H), 7.12-7.37 (m, 8H). 
2-((4aR)-1-(4-methoxyphenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-
yl)propan-2-ol (13ca): From appropriate ketone 12 using commercially available MeLi (1.9 
M in Et2O) to give a white solid in 58% yield. Flash column mobile phase - 25% 
EtOAc/hexanes. TLC Rf = 0.08 (30% EtOAc/hexanes). HRMS (ESI-RTOF) m/z: [M+H]+ Calcd 
for C22H29N2O2, 353.2223; found 353.2184. 1H-NMR (CDCl3, 499.73 MHz) δ 1.19 (s, 3H) 
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1.30-1.38 (d, 6H), 1.48-1.55 (m, 1H), 1.66-1.69 (d, 1H), 1.76-1.87 (dd, 2H), 2.27-2.37 (m, 
3H), 2.73-2.76 (d, 1H), 3.53-3.57 (d, 1H), 3.85 (s, 3H), 6.11 (s, 1H) 6.95-7.41 (m, 5H). 
1-((4aR)-1-(4-methoxyphenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-
yl)-1-phenylethan-1-ol (13cb):  From appropriate ketone 12 using commercially available 
MeLi (1.9 M in Et2O) to give a beige solid in 100% yield. Flash column mobile phase - 10% 
EtOAc/hexanes. TLC Rf = 0.20 (30% EtOAc/hexanes). HRMS (DART-RTOF) m/z: [M+H]+ 
Calcd for C27H31N2O2, 415.23800; found 415.23680. 1H-NMR (CDCl3, 499.73 MHz) δ 1.27 
(s, 3H), 1.55-1.63 (m, 3H), 1.68 (s, 3H), 1.75-1.77 (m, 1H), 2.04-2.07 (m, 1H), 2.23-2.26 (m, 
1H), 2.33-2.38 (m, 1H), 2.60-2.63 (d, 1H), 3.10-3.13 (d, 1H), 3.84 (s, 3H), 6.08 (s, 1H), 6.95-
7.51 (m, 10H). 
1-(4-fluorophenyl)-1-((4aR)-1-(4-methoxyphenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-
1H-benzo[f]indazol-5-yl)ethan-1-ol (13cc): From appropriate ketone 12 using 
commercially available MeLi (1.9 M in Et2O) to give a white solid in 49% yield. Flash column 
mobile phase - 20% EtOAc/hexanes. TLC Rf = 0.28 (30% EtOAc/hexanes). HRMS (DART-
RTOF) m/z: [M+H]+ Calcd for C27H30FN2O2, 433.22858; found 433.22897. 1H-NMR (CDCl3, 
300.08 MHz) δ 1.25 (s, 3H), 1.53-1.62 (m, 2H), 1.67 (s, 3H), 1.73-1.78 (m, 1H), 1.99-2.02 
(d, 1H), 2.24-2.36 (m, 3H), 2.60-2.63 (d, 1H), 3.12-3.15 (d, 1H), 3.85 (s, 3H), 6.09 (s, 1H), 
6.95-7.49 (m, 9H). 
1-(3,4-difluoro-5-methoxyphenyl)-1-((4aR)-1-(4-methoxyphenyl)-4a-methyl-
4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl)ethan-1-ol (13cd): From appropriate 
ketone 12 using commercially available MeLi (1.9 M in Et2O) to give a white solid in 65% 
yield. Flash column mobile phase - 15% EtOAc/hexanes. TLC Rf = 0.13 (30% 
EtOAc/hexanes). HRMS (DART-RTOF) m/z: [M+H]+ Calcd for C27H30FN2O2, 433.22858; 
found 433.22897. 1H-NMR (CDCl3, 499.73 MHz) δ 1.26 (s, 3H), 1.60-1.67 (m, 6H) 1.79-
1.82(d, 1H), 1.96-1.99 (d, 1H), 2.24-2.39 (m, 2H), 2.57-2.60 (d, 1H), 3.05-3.08 (d, 1H), 3.85 




yl)-1-(thiophen-2-yl)ethan-1-ol (13ce): From appropriate ketone 12 using commercially 
available MeLi (1.9 M in Et2O) to give a white solid in 48% yield. Flash column mobile phase 
- 15% EtOAc/hexanes. TLC Rf = 0.16 (30% EtOAc/hexanes). HRMS (ESI-RTOF) m/z: [M+H]+ 
Calcd for C25H29N2O2S, 421.1944; found 421.1907. 1H-NMR (CDCl3, 499.73 MHz) δ1.25 
(s, 3H), 1.59-1.65 (m, 2H), 1.68 (s, 3H), 1.73-1.78 (m, 2H), 2.03-2.06 (d, 1H), 2.25-2.36 (m, 
2H), 2.65-2.69 (d, 1H), 3.22-3.25 (d, 1H), 3.84 (s, 3H), 6.10 (s, 1H), 6.94-7.40 (m, 8H). 
1.4 – Molecular modeling 
1.4.1 – Structure activity relationships 
 Structure-activity relationships are considered when designing drug candidates for 
specific biological activities. It is well understood that with most drug therapies, there is a 
target receptor and/or tissue the drug is designed to interact with. Receptors in the 
biological and chemical sense are pockets within an individual protein or a large multi-
protein complex. These receptors have a specific shape, and a complex and dynamic 
electrostatic surface that can be targeted for doing a number of biologically important 
functions. Some of these functions include up/down-regulating the production of 
transcription factors that alter cellular production of proteins and/or enzymes, 
enhancing/blocking the action of cellular machinery such as proton pumps or cation 
channels, or simply by altering the circulating levels of hormones or other signaling 
molecules. Modeling the interactions between a receptors and ligands with known 
biological response can help tailor the design of molecules with more precise biological 
activity. 
To better understand the results from the data obtained from bioassays, ligand-
receptor interactions were modeled between the  synthesized molecules subjected to ex-
vivo testing and the human glucocorticoid receptor (PDB ID: 5NFP).35 Ligand models were 
prepared in Chem3D (PerkinElmer) to generate a structure in the lowest-energy 
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conformation to be used in the docking experiment. Docking was performed between the 
rigid 5NFP GR and the flexible ligands generated from Chem3D using AutoDock Vina (The 
Scripps Research Institute).36 The resulting docking conformations were viewed in 3D with 
PyMol (Schrödinger)37 and 2D ligand-residue interaction figures were generated with 
LigPlot+ (European Molecular Biology Laboratory)(Figure 1.4.1; appendix 1.8.9).38 Four 
characteristic binding orientations were observed in most AutoDock Vina output files 
(Figure 1.4.2). Orientation within the pocket may be an important factor to contributing 
to the observed effects of these compounds. 2D and 3D representations of the modeled 
interactions as well as calculated binding affinities (AutoDock Vina) can be found in the 
appendix of chapter 1 (section 1.8.7). Ligand-residue interactions obtained from analysis 
using LigPlot+ were tabulated and further processed in R to create an interaction map 
(Figure 1.4.3). Most of the top binding orientations for the modeled compounds are in 
“orientation 1” with six exceptions: dexamethasone, 11ab, 11ae, 11af, 11be, and 13ca. 
1.4.2 – Modeling and visualization software 
 There are a number of programs available for free to visualize molecular 
structures for modeling purposes in 3D. AutoDock Tools is a visualization program from 
The Scripps Research Institute that allows you not only to view structures but also lets 
you manage the physical parameters of the structures to prepare them for docking 
experiments. These parameters - such as allowable bond rotations, defining an area of a 
protein docking will be performed within, or bonding capabilities of atoms – are set prior 
to a docking experiment that is performed with a related program, AutoDock Vina. A 
traditional docking experiment calculates the lowest energy orientation that a submitted 
ligand can exist as within a predefined volume of space in a protein crystal structure. The 
output of these calculations is a structure file with the (X, Y, Z) coordinates of each atom 
in Cartesian space relative to the spatial coordinates of the protein the ligand was 




Figure 1.4.1 – Ligand-receptor docking 
A truncated process map where first, the flexible ligand and target receptor are prepared 
in AutoDock for docking simulations (A). Once calculations are performed, the docking 
conformations can be viewed in PyMol in a number of ways (B). Secondary programs like 






















Figure 1.4.2 – Ligand orientation within 5NFP binding pocket 
Autodock calculations revealed that there are four relative orientations for ligands within 
the GC receptor pocket, shown above. All molecules are shown stacked upon each other 
in the 5NFP binding pocket (top), as well as in each of the representative orientations 




Figure 1.4.3 – Ligand-residue interaction map and therapeutic index scores 
Ligand-residue interaction map (left) displaying hydrophilic (red) and hydrophobic (blue) interactions, as well as non-interacting 
residues (grey) with the respective compound in the human glucocorticoid receptor (5NFP) binding pocket. Compounds in 
interaction map are organized by therapeutic index (right). Residue interactions shown are of the ligands in their highest 
binding-affinity orientations (denoted by parenthetical numbers beside compound codes).
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free software package called PyMol, which allows the user to label atoms, set color 
schemes, and view protein residues and/or tertiary structure. 
 With PyMol you can move the structures around to see what residues are close in 
space to the ligand and make educated assumptions about the most significant molecular 
interactions that are contributing to the simulated binding. There is another cost-free 
software for visualizing the interactions that are most significant called LigPlot+ out of the 
European Molecular Biology Laboratory that takes the output from AutoDock Vina and 
maps the interactions between ligand and protein in 2D, differentiating hydrophobic from 
hydrophilic interactions. This program also calculates donor-acceptor distances for the 
hydrophilic interactions, which is a nice feature. By using the combination of PyMol and 
LigPlot+, one can begin to make conclusions about the specific interactions that may be 
large contributors to the ligands observed bioactivity. The combined visualizations of 
ligand-residue interactions for all the tested compounds from this study can be found in 
chapter 1 appendix section 1.8.6. 
For density functional theory-based calculations (DFT) performed by the research 
group of Dr. Konstantinos Vogiatzis at the University of Tennessee, Knoxville; the 
following procedures were followed for ligand-receptor interaction calculations on a 
truncated receptor pocket: Calculation were performed on all synthetic GCs subjected to 
biological testing, which molecular models were prepared by the author. This was done 
by generating a minimized energy model of the ligands in Chem3D (Perkin Elmer) and 
converting this file to the appropriate .pdbqt file-type by AutoDock Tools. The receptor 
pocket was modeled by including all main group atoms within 6 Å of the co-crystalized 
ligand (budesonide) within the 5NFP structure obtained from PDB with solvent molecules 
removed. All valences were capped with appropriate atoms based on geometry of the 
included fragments. Calculations were performed with the TURBOMOLE 7.2 quantum 
chemical software package using DFT.39 Constrained geometry optimizations were 
performed on docking output orientations by relaxing all hydrogen atoms and the full 
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glucocorticoid molecule within the pocket with atoms of the pocket frozen during 
convergence. The BP86 density functional, comprised of the Becke 1988 exchange and 
the Perdew 1986 correlation functionals, was employed along with Grimme’s D3 
dispersion correction with the Becke-Johnson damping function (D3(BJ)) and the def2-
SVP basis set for all atoms.40-44 The resolution of identity (ri) approximation was used for 
rapid integral evaluation.45 In addition to the optimized structures at the riBP86-
D3(BJ)/def2-SVP level, single-point calculations were performed using the riB3LYP-
D3(BJ)/def2-TZVPP level for higher accuracy.46-48 Interaction energies between the GCs 
and the pocket will be calculated by subtracting the energy of the empty pocket and the 
GC from the pocket-GC supersystem. 
1.5 – In-vitro studies with synthetic glucocorticoids 
1.5.1 – Assessing therapeutic profile 
 Inflammation can be assessed by a number of assays measuring the expression of 
inflammatory cytokines such as IL-1β, NF-κB, or AP-1. For this study, the %-maximal IL-1β 
response is used to determine the extent of transrepression in the ex-vivo assays. The 
amount of IL-1β transcribed was measured as a percentage compared to the IL-1β 
response toward the drug vehicle, DMSO, which was quantified by a luminometer as in a 
typical luciferase assay. For the quantitative assessment of the production of this pro-
inflammatory cytokine, modified cells with a luciferase-reporter inserted before the gene 
responsible for the production of chemokine C-C motif ligand 2 (CCL2)(Figure 1.5.1A). In 
this way, as IL-1β was transcribed, so was an equivalent amount of luciferase. Upon 
treating the culture with luciferin, the resulting fluorescence is measured and is 
quantitatively representative of the production of IL-1β. The second inflammatory assay 
(3xGRE) that was used in this study was another luciferase assay measuring 
transactivation, or the transcription of pro-inflammatory chemokines by activation of the 






1.5.1 – Truncated results from assays measuring inflammation and insulin secretion 
Bioassay data for compounds exhibiting desired directionality of therapy. (A) CCL2-
promoter-luciferase-promoter activity assay; x-axis: log concentration (molar); y-axis: %-
maximal IL-1β response (relative promoter activity). (B) 3xGRE-promoter-luciferase-
promoter activity assay; x-axis: log concentration (molar); y-axis: fold over control. (C) 





of immune cells, subsequent inflammation, and autoimmune-mediated damage to 
pancreatic β-cells. This assay was a means of measuring the amount of transactivation, 
which minimizing was a goal of this study with respect to the synthetic GCs employed 
(Figure 1.5.1B). Once the synthetic GCs were assayed for their therapeutic profile in terms 
of anti-inflammatory action, the top performing drug candidates were subjected to an 
assay measuring glucose-stimulated insulin secretion (GSIS). One of the primary goals of 
investigating these 1(4-substituted phenyl)arylpyrazolyl GCs is to see how they compare 
to established GC therapeutics in terms of their influence on insulin production in vivo. 
Saturating concentrations (100 nM) of synthetic GCs were dissolved in DMSO and added 
to isolated human islets (pancreatic β-cells) to which known concentrations of glucose 
were added to stimulate the production of insulin. An enzyme-linked immunosorbent 
assay (ELISA) was performed on the GSIS samples to determine the concentration of 
insulin produced. 
1.5.2 – Cell culture and assay parameters 
 Methods for the culture of 832/13 cells and measurements of insulin secretion 
have been described previously.49 Six-point dose-response curves were used to generate 
EC50 and saturating concentrations of each steroid compound. For glucose-stimulated 
insulin secretion (GSIS), saturating concentrations (100 nM) of each commercial steroid or 
1-(4-substituted phenyl)arylpyrazolyl based GC analogues were used (Figure 1.5.1C). 
Insulin secretion was measured with ELISA as previously described, using a kit from 
Mercodia (Uppsala, Sweden). Measurements for the 3xGRE luciferase assay were 
performed as described in the literature.7 Briefly, 832/13 cells were grown in 24 well plates 
to 50% confluence and then transiently transfected with 25 ng of indicated plasmid per 
well using TransFectin Lipid Reagent (Bio-Rad; Hercules, CA) following the manufacturer’s 
directions. Cell lysis, luciferase assays, and normalization to total protein content were 
also carried out as described previously.7 Quantification of CCL2 secreted into the cell 
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media was carried out using a rat Quantikine ELISA kit from R&D Systems, Inc 
(Minneapolis, MN). 
1.6 – Results 
1.6.1 – Inflammatory action of synthetic glucocorticoids 
 Synthetic GC analogues were assayed for their ability to reduced inflammation 
through modulating transrepression and transactivation. Three different sets of GC 
analogues with respect to the installed headgroup (R1) were tested for biological activity, 
and the 4-fluorophenyl series (compounds 11a, 12a, and 13a) was observed to have the 
greatest dissociated profile. Levels of transrepression were measured by a CCL2-
luciferase-reporter assay determining the %-maximal response to pro-inflammatory 
cytokine IL-1β. Levels of transactivation was monitored through a 3xGRE-luciferase-
reporter assay measuring the transcriptional activation toward the production of pro-
inflammatory cytokines. The desired dissociated profile of the administered drug would 
reduce transrepression while also minimizing the transcription of cytokines known to be 
involved with an inflammatory response (transactivation). It was apparent from the CCL2 
and 3xGRE assay data that the R1 = 4-fluorophenyl series gave more desirable bioactivity 
than the R1 = 4-methoxyphenyl or R1 = 4-methylphenyl compounds. This may be a function 
of the bioavailability of the fluorinated analogues, which are known to be more permeable 
toward cell membranes and stable towards metabolism of the drug itself.50 
 Compounds 11aa, 11ab, 13aa, and 13ab were found to have the desired reduction 
in IL-1β response. Transrepression commenced at nM and µM concentrations with ~70% 
reduction in relative promoter activity for the higher concentrations of fluorophenyl GCs 
(~1 µM). Compounds with the greatest observed transrepression were those whose 
sidegroup (R2) possesses a delocalized system of π-electrons (R2 = phenyl, 4-fluorophenyl, 
1,2-difluoroanisolyl, and 3-thiophenyl). The observed activity is likely a function of 
hydrophobic interactions between GC and bound GR. GCs with R2 moieties of smaller 
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(methyl-), and larger (cyanomethyl-) steric bulk that do not bear any delocalized π-
electrons show a fairly pronounced reduction in desired activity, suggesting that size of 
the R2 group has little influence on biological response with respect to transrepression – 
but rather that electronic interactions between GC and GR are more impactful. 
 The observed trend with transactivation was an increase in transcription of pro-
inflammatory chemokine CCL2 with analogues bearing an R2 moiety having delocalized 
system of π-electrons. Transactivation is observed at GC concentrations ranging from nM 
to µM, where there is differential activity between molecule sets 11 and 13 having the 
same sidegroup. The additional steric bulk around the alcohol introduced by a methyl 
group in compound series 13 seems to enhance transrepression but also has a significant 
upregulating influence on transactivation, which makes series 13 less therapeutically 
valuable than the series 11 analogues. The intermediate ketone series 12aa-12ag was 
tested for biological activity, but was found to enhance transactivation more than 
transrepression, indicating the alcohol group of series 11 and 13 analogues being 
important in influencing transrepressive activity of these molecules. It seems that 
coordination of the alcohol and/or an electron rich aromatic R2 group in the GR binding 
pocket elicit a dissociated profile, unlike with the ketone intermediate; Therefore, 
intermediate series 12 (excluding analogues 12aa-12ag) were not subjected to biological 
testing. 
1.6.2 – Effect on insulin secretion in top-performing GC analogues 
 Glucose-stimulated insulin secretion was measured for the synthetic GCs that 
conferred the most dissociated therapeutic profile, meaning that the drug suppressed 
inflammatory response and did not also incite the production of immunostimulating 
chemokines. Compounds 11aa, 11ab, 13aa, and 13bb were chosen as the molecules with 
the most desirable combination of bioactivities and were subjected to an immunoassay 
to quantify the amount of insulin produced in response to a concentration of glucose, as 
indicated in the figure legend (Figure 1.4B). It was found that the 1-(4-substituted 
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phenyl)arylpyrazolyl based GC analogues had a range of effects on insulin production with 
11aa (R2 = methyl) being a compound that did not hinder the production of insulin and 
compound 11ab (R2 = phenyl) , which had only a slight impact on insulin secretion.  
 There are not enough data points in terms of GSIS assays to make assumptions of 
what effect the identity of the R2 moiety had on insulin production, but from what was 
performed, one could assume that larger and more electron-dense sidegroups may have 
a positively correlating factor in this assay. One other feature of the synthetic 
glucocorticoids that alludes to steric bulk around the R2 moiety is that the compound 13 
analogues 13aa and 13ab both had a significant impact on insulin secretion. This made 
compound 13 analogue therapeutically less valuable than their compound 11 series 
counterparts. From the data describing the ligand-residue interactions, there was no 
apparent residue interaction that was consistently present or not present in compounds 
13 versus compounds 11, suggesting that binding features were not the major drivers of 
the activity, but rather that the conformation of the GC-GR complex acting as a 
transcription factor played a more pivotal role. This will have to be investigated in the 
future in order to pin-point the underlying mechanisms associated with the 
downregulation of insulin production in response to these compounds. 
1.6.3 – Structure-activity relationship of dissociated therapeutic profile 
 Considering the results from the CCL2, 3xGRE, and GSIS assays and comparing the 
results from the molecular docking experiment, there is not much to say about the 
simulated ligand binding scenarios. The binding profiles for all the compounds subjected 
to biological testing were all very similar, with only a few indications of hypothetically 
important residues involved in binding to have an influence on the observed activity. 
Hydrophilic interactions with residue Ala605 seemed to be a primary indicator of 
beneficial activity in conjunction with missing interactions toward Met639 and Cys643, 
but compounds with a much lower therapeutic index also featured this binding pattern. 
If anything should be taken from the ligand-residue interaction docking experiments, it’s 
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that these molecules have similar binding features, but range in structure and electronic 
properties that may be affecting the structure of the GC-GR complex, which must have a 
powerful effect on DNA transcription specificity. Although this is something that could be 
modeled, it would require a computer with huge processing power to calculate the 
resulting GC-GR complex structure from a flexible ligand/receptor simulation and then 
compute interactions between the GC-GR complex against relevant DNA loci toward 
insulin function and inflammatory response. The data that is currently being collected 
from the higher-order DFT calculations on a truncated receptor pocket with the flexible 
ligands does point to a trend where orientation of the GC within the pocket leads to the 
desired therapeutic profile. There are four orientations that were considered where the 
GC was either flipped horizontally, vertically, and both horizontally and vertically with 
respect to the original orientation. Drug-residue interactions are currently being 
investigated by Justin K. Kirkland whom is a graduate research student in the 
computational chemistry research group of Dr. Konstatinos Vogiatzis at the University of 
Tennessee, Knoxville. 
 Without taking the docking experiments into consideration, the apparent 
effectors of biological activity of the synthetic GCs is their range of structural, chemical, 
and electronic properties that confer the observed bioactivities. As stated before, 
compounds with an R2 group that can participate in π-π interactions or could act as a 
hydrogen bond-acceptor seemed to increase the incidence of transactivation, but also 
enhanced transrepression. From this, it could be stated that smaller more electronically 
incapable sidegroups such as R2 = methyl would be moving toward a scaffold with the 
desired activity. 
1.7 – Conclusion 
 Synthetic GCs were tested for their ability to reduce IL-1β-induced inflammation 
(CCL2 assay - transrepression), and their propensity for enhancing transcription of a 
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synthetic GRE-containing promoter luciferase reporter gene (3xGRE assay - 
transactivation). Compounds providing the desired dissociated profile reduce 
inflammation with reduced transactivation compared to dexamethasone. Unfortunately 
for most of the compounds that exhibit transrepression, they also enhance transactivation 
presumably through dimerization of the GR-GC complex. It has been previously shown 
that dimerization of the GR-GC complex prior to binding to the nuclear GREs enhance the 
side effects of these drug therapies by enhancing the transcription of pro-inflammatory 
cytokines. At a SAR-level, this increase in transactivation seems to be influenced by GCs 
whose sidegroup can participate in π-π interactions with a bound GR. Only two of the 
compounds synthesized and screened for their therapeutic profile showed the desired 
activity (Figure 1.5.1 A/B) and were further assayed to determine their effect on insulin 
secretion. The GSIS assay for these compounds concluded that the 2’-OH compound 11 
series did not hinder insulin secretion. A simple change in series 11 to the 3’-OH 
compound 13 series proved to begin impacting the function of β-cells and were thusly 
determined to be less therapeutically valuable in this study. CCL2 and 3xGRE assay data 
for all tested compounds can be found in appendix for chapter 1.  
 Both 1-(4-methoxyphenyl) and 1-(4-methylphenyl) headgroup analogues did not 
show a significant decrease in transrepression or an increase in transactivation, except for 
compounds whose R2 moiety contains delocalized π-electrons. For those compounds, 
appreciable transrepression was observed at concentrations in the µM-range, and an 
increase in transactivation was also observed at high GC concentrations (≥µM). This 
difference in activity compared to the 4-fluorophenyl headgroup series may be 
attributable to differential solubility between the analogues, being that fluorinated drugs 
are known for their increased lipid-solubility making them more easily transported 
throughout the cell.51 Data from the inflammatory assays portend that compared to the 
R1 = 1-(4-methoxyphenyl)- / 1-(4-methylphenyl)-GCs, the R1 = 1-(4-fluorophenyl) series 
would appear to have a greater affinity for the hGR, or may just be more easily transported 
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throughout the cell due to solubility properties compared to the other GC analogues. 
Binding affinity calculations (Chapter I Appendix 1.8.7) for all tested compounds reveal 
similar affinities to the hGR (5NFP) with an average binding affinity of -9.5 ±1.75 kcal/mol. 
These calculations are not a very precise view of the true binding affinities for the 
compounds within the GR binding pocket, as the calculations were performed on a rigid 
receptor model. Ongoing work is being finished for the final publication of this study that 
features DFT calculations of a dynamic truncated GR-pocket and the interactions of the 
synthetic GCs within this pocket. As previously stated, orientation seems to be an 
important feature in the bioactivity of these compounds. This has been corroborated by 
preliminary data obtained from these DFT calculations as three of four possible 
orientations within the pocket had a positive correlation with the observed therapeutic 
index of these compounds as a function of increasing binding affinity. The remaining 
orientation displays a positive correlation of therapeutic index as a function of decreasing 
binding affinity. So future work with designing compounds with the desired dissociated 
therapeutic profile will have to take these orientation considerations into account for 
targeting specific drug-residue interactions that dissuade the negative effects that GCs can 
have. 
 An increase in transactivation is an undesired effect of these drug candidates, and 
this activity is enhanced in compounds containing an aromatic sidegroup (R2); Although, 
the modeled binding patterns within the hGR between the R2 analogues are similar, the 
aromatic sidegroups may generate strong π-π interactions not accounted for with a non-
flexible receptor model, which may be an important factor in enhancing transactivation. 
These aromatic sidegroups may be decreasing the binding affinity for the compounds in 
the correct orientation, or rather, they may be increasing the affinity for binding the 
receptor pocket in the orientation that decreases the therapeutic index score as a function 
increasing binding affinity. There is also an observable trend in which series 13 compounds 
have a higher average affinity for the hGR than series 11. This increase in binding affinity 
56 
 
may be strongly associated with the transactivating orientation, but these observations 
have not yet been made with the DFT studies. Compounds 11 may have more freedom in 
the ways they may bind in the receptor pocket due to a greater degree of accessibility, 
which may explain why compounds 12 and 13 exhibit stronger transactivating activity 
when compared to 2˚OH series 11. The differential activity observed between compounds 
bearing different R1 headgroups as suggested before may be attributable to differences in 
bioavailability, but when considering the binding features in the R1 = 1-(4-fluorophenyl) 
series, there is a hydrophilic interaction with residue Ala605 in nearly all instances, 
especially among the molecules conferring the desired therapeutic profile. This may 
suggest some of the observed differences in biological activity for the R1 = 1-(4-
fluorophenyl) series as being a function of bioavailability, or more likely the resultant 
shape of the GR-GC complex specific to each GC compound. Determining the precise 
structure of these complexes would either require crystallizing each GR-GC complex and 
determining a crystal structure to be compared with DNA binding domains, or by powerful 
computational calculations, both of which would be exhausting bodies of work – 
especially the former.  
The work presented here on synthetic GCs with the desired anti-inflammatory 
profile without disturbing insulin production shows promise for future work in tailoring a 
structure with optimal activity. This study focuses on the structure-activity relationship of 
these synthetic compounds on inflammation with the added observation that of the 
compounds assayed for their effects on insulin secretion show little to no ability to 
diminish β-cell function. Compounds 11aa and 11ab were found to be most efficacious in 
this regard. Their ex vivo efficacy has been demonstrated, but their efficacy in vivo will 
need to be determined to validate these findings.  
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 1.8 – Chapter I appendix 
























































[1,3]dioxolane] (7a): 1H-NMR (CDCl3, 500 MHz) δ 1.21 (s, 3H), 1.65-1.82 (m, 4H), 2.27-2.30 
(d, 1H), 2.42-2.52 (m, 2H), 3.14-3.17 (d, 1H), 3.97-4.10 (m, 4H), 6.20 (s, 1H), 7.14 (m, 2H), 
7.41-7.44 (m, 3H). 
 
1-(4-fluorophenyl)-4a-methyl-1,4,4a,6,7,8-hexahydro-5H-benzo[f]indazol-5-one (8a): 1H-
NMR (CDCl3, 500 MHz) δ 1.25 (s, 3H), 1.63-1.72 (m, 1H), 2.06-2.12 (m, 1H), 2.51-2.57 (m, 
2H), 2.60-2.69 (m, 2H), 2.87-2.91 (s, 2H), 6.29 (s, 1H), 7.15-7.18 (t, 2H), 7.44-7.47 (m, 2H), 
7.48 (s, 1H). 
 
1-(4-fluorophenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazole-5-
carbaldehyde (10a): 1H-NMR (CDCl3, 500 MHz) δ 1.25 (s, 3H), 1.35-1.45 (m, 2H), 1.68-1.77 
(m, 1H), 1.89-1.95 (m, 2H), 2.32-2.42 (m, 3H), 2.87-2.90 (d, 1H), 3.07-3.10 (d, 1H), 6.18 (s, 
1H), 7.12-7.16 (t, 2H), 7.41-7.44 (m, 3H), 9.93 (s, 1H). 
 
1-(1-(4-fluorophenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl)ethan-
1-ol (11aa): 1H-NMR (CDCl3, 500 MHz) δ 1.14 (s, 3H), 1.26-1.28 (d, 3H), 1.41-.147 (dd, 2H), 
1.63-1.68 (dd, 1H), 1.73-1.80 (m, 1H), 1.90-1.97 (m, 1H), 2.31-2.43 (m, 2H), 2.46-2.52 (d, 
1H), 2.98-3.03 (d, 1H), 4.25 (s, 1H), 6.10 (s, 1H), 7.11-7.19 (m, 2H), 7.41-7.47 (m, 3H). 
 
2-(1-(4-fluorophenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-
yl)propan-2-ol (13aa): 1H-NMR (CDCl3, 300 MHz) δ 1.14 (s, 3H), 1.26-1.28 (d, 3H), 1.35-
1.47 (m, 2H), 1.58 (s, 3H), 1.63-1.68 (dd, 1H), 1.73-1.80 (m, 1H), 1.89-1.98 (m, 1H), 2.26-
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yl)(phenyl)methanol (11ab): 1H-NMR (CDCl3, 500 MHz) δ 1.18 (s, 3H), 1.52-1.58 (m, 2H), 
1.60-1.63 (dd, 1H), 1.70-1.74 (m, 2H), 2.17-2.21 (m, 1H), 2.28-2.36 (m, 1H), 2.66-2.69 (d, 
1H), 3.08-3.11 (d, 1H), 5.10 (d, 1H), 6.02 (s, 1H), 7.04-7.08 (m, 2H), 7.16-7.18 (m, 1H), 7.27-
7.29 (m, 4H), 7.35-7.38 (m, 3H). 
 
1-(1-(4-fluorophenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl)-1-
phenylethan-1-ol (13ab): 1H-NMR (CDCl3, 500 MHz) δ 1.27 (s, 3H), 1.56-1.65 (m, 2H), 1.67 
(s, 3H), 1.74-1.80 (m, 1H), 2.02-2.08 (dd, 1H), 2.23-2.44 (m, 2H), 2.58-2.64 (d, 1H), 3.12-
3.17 (d, 1H), 6.09 (s, 1H), 7.10-7.16 (t, 2H), 7.27-7.52 (m, 8H). 
 
 (4-fluorophenyl)(1-(4-fluorophenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-
benzo[f]indazol-5-yl)methanol (11ac): 1H-NMR (CDCl3, 300 MHz) δ1.26 (s, 3H), 1.65-1.69 
(m, 3H), 1.77-1.86 (m, 1H), 2.26-2.41 (m, 2H), 2.72-2.77 (d, 1H), 3.17-3.22 (d, 1H), 5.19-




benzo[f]indazol-5-yl)ethan-1-ol (13ac): 1H-NMR (CDCl3, 500 MHz) δ 1.25 (s, 3H), 1.51-1.62 
(m, 2H), 1.66 (s, 3H), 1.72-1.81 (m, 2H), 1.95-2.05 (m, 1H), 2.21-2.40 (m, 2H), 2.58-2.64 (d, 
1H), 3.14-3.20 (d, 1H), 6.09 (s, 1H), 7.00-7.06 (t, 2H), 7.11-7.17 (t, 2H), 7.25-7.28 (m, 1H), 





1H-benzo[f]indazol-5-yl)methanol (11ad): 1H-NMR (CDCl3, 300 MHz) δ 1.26 (s, 3H), 1.54-
1.57 (m, 1H), 1.64-1.72 (m, 1H), 1.82-1.86 (m, 2H), 2,28-2.46 (m, 3H), 2.72-2.77 (d, 1H), 
3.17-3.22 (d, 1H), 3.92 (s, 3H), 5.12 (s, 1H), 6.12 (s, 1H), 6.72-6.80 (m, 2H), 7.15-7.21 (m, 
2H), 7.45-7.54 (m, 3H). 
 
1-(3,4-difluoro-5-methoxyphenyl)-1-(1-(4-fluorophenyl)-4a-methyl-4,4a,5,6,7,8-
hexahydro-1H-benzo[f]indazol-5-yl)ethan-1-ol (13ad): 1H-NMR (CDCl3, 500 MHz) δ 1.26 
(s, 3H), 1.54-1.60 (m, 2H), 1.62 (s, 3H), 1.64-1.66 (m, 1H), 1.80-1.85 (m, 1H), 1.96-1.99 (dd, 
1H), 2.24-2.30 (m, 1H), 2.34-2.42 (m, 1H), 2.57-2.60 (d, 1H), 3.07-3.11 (d, 1H), 3.91 (s, 3H), 
6.10 (s, 1H), 6.87-6.91 (m, 2H), 7.12-7.16 (t, 2H), 7.28 (s, 1H), 7.42-7.45 (m, 2H). 
 
 (1-(4-fluorophenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-
yl)(thiophen-3-yl)methanol (11ae): 1H-NMR (CDCl3, 500 MHz) δ 1.24 (s, 3H), 1.65-1.93 (m, 
5H), 2.27-2.48 (m, 2H), 2.67-2.72 (d, 1H), 3.08-3.15 (d, 1H), 5.24 (s, 1H), 6.12 (s, 1H), 6.94-
6.99 (m, 1H), 7.12-7.24 (m, 3H), 7.30-7.33 (m, 1H), 7.43-7.48 (m, 3H). 
 
1-(1-(4-fluorophenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl)-1-
(thiophen-3-yl)ethan-1-ol (13ae): 1H-NMR (CDCl3, 500 MHz) δ 1.27 (s, 3H), 1.52-1.62 (m, 
3H), 1.68 (s, 3H), 2.01-2.06 (m, 1H), 2.24-2.43 (m, 3H), 2.64-2.69 (d, 1H), 3.24-3.30 (d, 1H), 
6.10 (s, 1H), 7.14-7.17 (m, 3H), 7.27-7.30 (m, 1H), 7.33 (s, 1H), 7.42-7.47 (m, 3H). 
 
3-(1-(4-fluorophenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl)-3-
hydroxypropanenitrile (11af): white solid obtained in 46% yield; mp 121-123.8 ˚C; TLC 
(Silica G w/UV254) 25% EtOAc in hexanes, Rf = 0.14; [α]D20 = +60 (c 1.0, MeOH); 1H-NMR 
(CDCl3, 500 MHz) δ 1.04-1.13 (s, 3H), 1.25-1.46 (m, 2H), 1.61-1.71 (m, 2H), 1.78-1.97 (m, 
2H), 2.30-2.42 (m, 2H), 2.47-2.72 (m, 3H), 2.93-3.21 (d, 1H), 4.16-4.40 (m, 1H), 6.12 (s, 
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1H), 7.14-7.44 (m, 5H); 13C-NMR (CDCl3, 500 MHz) δ 19.32, 20.91, 25.37, 26.20, 32.98, 
33.19, 34.64, 52.82, 66.62, 109.76, 115.96, 116.14, 125.32, 137.86; IR (NaCl, thin film) νmax 
(cm-1): 3335 (OH), 3030 (w), 2934, 2867, 2249 (CN), 1619, 1518, 1225, 840; HRMS (DART-
RTOF) m/z: [M+H]+ Calcd for C21H23FN3O, 352.18197; found 352.18293. 
 
3-(1-(4-fluorophenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl)-3-
hydroxybutanenitrile (12af):  white solid obtained in 16% yield; mp 192-194 ˚C; TLC (Silica 
G w/UV254) 30% EtOAc in hexanes, Rf = 0.11; [α]D20 = +60 (c 1.0, CHCl3); 1H-NMR (CDCl3, 
500 MHz) δ 1.20 (s, 3H), 1.45-1.49 (m, 2H), 1.82-1.87 (t, 2H), 1.93-1.97 (d, 1H), 2.32-2.44 
(m, 3H), 2.74-2.77 (d, 1H), 2.82-2.88 (m, 2H), 3.53-3.61 (s, 2H), 6.15 (s, 1H), 7.14-7.44 (m, 
5H); 13C-NMR (CDCl3, 500 MHz) δ 18.53, 25.21, 25.61, 31.72, 33.85, 34.75, 41.16, 59.60, 
110.18, 112.91, 113.49, 116.00, 135.61, 136.29, 137.72, 146.60, 160.56, 162.53, 199.38; 
IR (NaCl, thin film) νmax (cm-1) 2955, 2920, 2850, 1723 (m), 1514 (m), 1462, 1377, 1222; 
HRMS (DART-RTOF) m/z: [M+H]+ Calcd for C21H21FN3O, 350.16632; found 350.16529. 
 
1-(1-(4-fluorophenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl)-2,2-
dimethylpropan-1-ol (11ag): 1H-NMR (CDCl3, 500 MHz) δ 0.97 (s, 9H), 1.08 (s, 3H), 1.38-
1.45 (m, 1H), 1.59-1.67 (m, 1H) 1.72-1.79 (m, 2H), 1.83-1.87 (m, 1H), 2.30-2.35 (m, 1H), 
2.36-2.44 (m, 1H), 2.45-2.48 (d, 1H), 2.82-2.85 (d, 1H), 3.50 (s, 1H), 6.13 (s, 1H), 7.13-7.17 
(t, 2H), 7.41 (s, 1H), 7.43-7.47 (m, 2H). 
 
2-(1-(4-fluorophenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl)-3,3-
dimethylbutan-2-ol (12ag): beige solid obtained in 14% yield; mp 192-194 ˚C; TLC (Silica 
G w/UV254) 30% EtOAc in hexanes, Rf = 0.54; [α]D20 = +8.7 (c 1.0, MeOH); 1H-NMR (CDCl3, 
499.73 MHz) δ 1.19 (s, 9H), 1.33 (s, 3H), 1.40-1.50 (m, 1H), 1.55 (s, 1H), 1.70-1.74 (dd, 1H), 
2.27-2.33 (m, 1H), 2.42-2.53 (m, 1H), 2.56-2.68 (m, 2H), 3.08-3.13 (m, 1H), 6.11 (s, 1H), 
7.12-7.18 (t, 2H), 7.36 (s, 1H), 7.42-7.46 (dd, 2H); 13C-NMR (CDCl3, 125.66 MHz) δ 19.22, 
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26.03, 27.02, 27.50, 31.99, 34.63, 41.82, 45.42, 53.04, 109.06, 113.60, 115.92, 119.70, 
125.32, 135.81, 136.61, 137.77, 149.32, 160.46, 162.43, 218.05; IR (NaCl, thin film) νmax 
(cm-1) 2927, 2855, 1699, 1516, 1479, 1464, 1375, 1366, 1292, 1224, 1176, 1152, 1134, 





(7b): 1H-NMR (CDCl3, 300 MHz) δ 1.14 (s, 3H), 1.56-1.79 (m, 5H), 2.19-2.22 (m, 1H), 2.32 
(s, 3H), 2.42-2.45 (d, 1H), 3.08-3.11 (d, 1H), 3.92-4.01 (m, 4H), 6.18 (s, 1H), 7.17-7.19 (m, 
2H), 7.27-7.29 (m, 2H), 7.33 (s, 1H). 
 
4a-methyl-1-(p-tolyl)-1,4,4a,6,7,8-hexahydro-5H-benzo[f]indazol-5-one (8b): 1H-NMR 
(CDCl3, 300 MHz) δ 1.24 (s, 3H), 1.59-1.79 (m, 2H), 2.03-2.13 (m, 1H), 2.40 (s, 3H), 2.49-
2.70 (m, 3H), 2.90 (s, 2H), 6.32 (s, 1H), 7.26-7.28 (m, 2H), 7.35-7.38 (m, 2H), 7.47 (s, 1H). 
4a-methyl-1-(p-tolyl)-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazole-5-carbaldehyde (10b): 
1H-NMR (CDCl3, 300 MHz) δ 1.12 (s, 3H), 1.33-1.50 (m, 1H), 1.67-1.76 (m, 1H), 1.81-1.98 
(m, 2H), 2.34-2.46 (m, 6H), 2.88-2.94 (d, 1H), 3.08-3.13 (d, 1H), 6.21 (s, 1H), 7.25-7.28 (m, 
2H), 7.34-7.37 (m, 2H), 7.43 (s, 1H), 9.91 (s, 1H). 
 
1-(4a-methyl-1-(p-tolyl)-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl)ethan-1-ol 
(11ba): white solid obtained in 50% yield; mp 178.1-181.0 ˚C; TLC (Silica G w/UV254) 30% 
EtOAc in hexanes, Rf = 0.16; [α]D20 = -16 (c 1.0, MeOH); 1H-NMR (CDCl3, 500 MHz) δ 1.13 
(s, 3H), 1.23-1.29 (m, 3H), 1.34-1.45 (m, 2H), 1.56-1.62 (m, 2H), 1.72-1.78 (m, 1H), 1.90-
1.94 (m, 1H), 2.27-2.30 (m, 1H), 2.32-2.37 (m, 4H) 2.47-2.50 (d, 1H), 2.97-3.00 (d, 1H), 
6.14 (s, 1H), 7.23-7.26 (d, 2H), 7.34-7.36 (d, 2H), 7.40 (s, 1H); 13C-NMR (CDCl3, 500 MHz) δ 
19.21, 20.81, 24.34, 25.85, 33.32, 34.67, 41.14, 54.89, 56.00, 66.11, 109.50, 113.47, 
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123.47, 129.65, 136.81, 137.28, 137.60, 149.57; IR (NaCl, thin film) νmax (cm-1): 3315 (OH), 
3043 (w), 2962, 2936, 2862, 1620, 1518 (w), 1425, 1132, 820; HRMS (DART-RTOF) m/z: 
[M+H]+ Calcd for C21H27N2O, 323.21179; found 323.21001. 
 
2-((4aR)-4a-methyl-1-(p-tolyl)-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl)propan-2-
ol (13ba): white solid obtained in 55% yield; mp 173-176 ˚C; TLC (Silica G w/UV254) 25% 
EtOAc in hexanes, Rf = 0.17; [α]D20 = -75 (c 1.0, MeOH); 1H-NMR (CDCl3, 500 MHz) δ 1.19 
(s, 3H), 1.33-1.37 (s, 8H), 1.38-1.39 (d, 1H), 1.66-1.69 (d, 1H), 1.77-1.80 (dt, 1H), 1.84-1.87 
(dt, 1H), 2.31 (m, 1H), 2.39 (s, 3H), 2.73-2.76 (d, 1H), 3.53-3.57 (d, 1H), 6.16 (s, 1H) 7.24-
7.25 (d, 2H), 7.35-7.38 (d, 2H), 7.40 (s, 1H); 13C-NMR (CDCl3, 500 MHz) δ 19.65, 26.38, 
27.48, 29.70, 33.91, 34.52, 36.19, 43.57, 57.61, 75.52, 109.76, 115.22, 123.26, 129.63, 
136.59, 137.38, 150.95; IR (NaCl, thin film) νmax (cm-1): 3395 (OH), 2928, 2855, 1611 (w), 
1519 (m); HRMS (ESI-RTOF) m/z: [M+H]+ Calcd for C22H29N2O, 337.2274; found 337.2200. 
 
(4a-methyl-1-(p-tolyl)-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl)(phenyl)methanol 
(11bb): white solid obtained in 28% yield; mp 184-187 ˚C; TLC (Silica G w/UV254) 30% 
EtOAc in hexanes, Rf = 0.20; [α]D20 = -12 (c 1.0, MeOH); 1H-NMR (CDCl3, 500 MHz) δ 1.26 
(s, 3H), 1.60-1.81 (m, 5H), 2.23-2.28 (d, 1H), 2.36-2.43 (m, 4H), 2.74-2.77 (d, 1H) 3.15-3.18 
(d, 1H), 5.17 (s, 1H), 6.15 (s, 1H), 7.23-7.27 (d, 3H), 7.34-7.38 (m, 6H), 7.41 (s, 1H); 13C-
NMR (CDCl3, 500 MHz) δ 19.90, 21.05, 25.79, 41.28, 56.66, 71.95, 109.51, 113.67, 123.52, 
125.38, 126.78, 128.16, 129.68, 137.60, 145.70, 149.77; IR (NaCl, thin film) νmax (cm-1): 
3319 (OH), 3039 (w), 2929, 2868, 1610 (w), 1519 (m), 821; HRMS (DART-RTOF) m/z: 
[M+H]+ Calcd for C26H29N2O, 385.22744; found 385.22612. 
 
1-((4aR)-4a-methyl-1-(p-tolyl)-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl)-1-
phenylethan-1-ol (13bb): white solid obtained in 82% yield; mp 172-174.5 ˚C; TLC (Silica 
G w/UV254) 30% EtOAc in hexanes, Rf = 0.27; [α]D20 = -26 (c 1.0, MeOH); 1H-NMR (CDCl3, 
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500 MHz) δ 1.27 (s, 3H), 1.62-1.66 (m, 2H), 1.68 (s, 3H), 1.74-1.79 (m, 2H), 2.04-2.07 (d, 
1H), 2.24-2.28 (d, 1H), 2.33-2.40 (m, 4H), 2.60-2.63 (d, 1H), 3.10-3.13 (d, 1H), 6.14 (s, 1H), 
7.23-7.29 (m, 4H), 7.33-7.36 (m, 4H), 7.49-7.52 (m, 2H); 13C-NMR (CDCl3, 500 MHz) δ 
20.41, 21.02, 25.82, 26.11, 28.40, 29.68, 34.20, 35.90, 44.00, 56.78, 78.79, 109.52, 115.37, 
123.26, 125.56, 126.74, 128.02, 129.62, 136.05, 136.53, 137.41, 137.72, 151.03; IR (NaCl, 
thin film) νmax (cm-1): 3365 (OH), 3054 (w), 2928, 2858, 1610 (w), 1519 (m), 821; HRMS 
(ESI-RTOF) m/z: [M+H]+ Calcd for C27H31N2O, 399.2430; found 399.2368. 
 
(4-fluorophenyl)(4a-methyl-1-(p-tolyl)-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-
yl)methanol (11bc): white solid obtained in 11.5% yield; mp 188-191 ˚C; TLC (Silica G 
w/UV254) 25% EtOAc in hexanes, Rf = 0.24; [α]D20 = -24 (c 1.0, MeOH); 1H-NMR (CDCl3, 
500 MHz) δ 1.26 (s, 3H), 1.50-1.61 (m, 3H), 1.67-1.71 (m, 2H), 1.79-1.82 (d, 1H), 2.25-2.28 
(d, 1H), 2.39 (s, 3H), 2.74-2.77 (d, 1H), 3.16-3.20 (d, 1H), 5.19 (s, 1H), 6.16 (s, 1H), 7.02-
7.46 (m, 9); 13C-NMR (CDCl3, 500 MHz) δ19.19, 21.04, 25.74. 33.25, 35.24, 41.24, 56.75, 
71.47, 109.62, 113.54, 114.58, 123.50, 126.92, 129.69, 136.68, 136.90, 137.23, 137.58, 
141.26, 149.48, 160.71, 162.66; IR (NaCl, thin film) νmax (cm-1): 3312 (OH), 3041 (w), 2931, 
2867, 2830, 1898, 1603, 1518, 1219, 819; HRMS (DART-RTOF) m/z: [M+H]+ Calcd for 
C26H28FN2O, 403.21802; found 403.21649. 
 
1-(4-fluorophenyl)-1-((4aR)-4a-methyl-1-(p-tolyl)-4,4a,5,6,7,8-hexahydro-1H-
benzo[f]indazol-5-yl)ethan-1-ol (13bc): white solid obtained in 80% yield; mp 188.5-191 
˚C; TLC (Silica G w/UV254) 30% EtOAc in hexanes, Rf = 0.25; [α]D20 = -9 (c 1.0, MeOH); 1H-
NMR (CDCl3, 500 MHz) δ 1.26 (s, 3H), 1.60-1.63 (m, 3H), 1.66 (s, 3H), 1.75-1.79 (d, 1H), 
1.99-2.02 (d, 1H), 2.24-2.27 (d, 1H), 2.39 (s, 3H), 2.60-2.63 (d, 1H), 3.12-3.15 (d, 1H), 5.30 
(s, 1H), 6.14 (s, 1H), 7.01-7.48 (m, 9H); 13C-NMR (CDCl3, 500 MHz) δ 20.40, 21.02, 25.83, 
26.16, 28.41, 34.15, 36.03, 43.98, 56.89, 78.55, 109.60, 114.59, 115.25, 123.26, 127.24, 
129.63, 136.58, 137.69, 150.94; IR (NaCl, thin film) νmax (cm-1): 3315 (OH), 3020 (w), 2928, 
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2860, 1600, 1519, 1222; HRMS (DART-RTOF) m/z: [M+H]+ Calcd for C27H30FN2O, 
417.23367; found 417.23232. 
 
(3,4-difluoro-5-methoxyphenyl)(4a-methyl-1-(p-tolyl)-4,4a,5,6,7,8-hexahydro-1H-
benzo[f]indazol-5-yl)methanol (11bd): white solid obtained in 76% yield; mp 97-101 ˚C; 
TLC (Silica G w/UV254) 25% EtOAc in hexanes, Rf = 0.22; [α]D20 = +31 (c 1.0, MeOH); 1H-
NMR (CDCl3, 500 MHz) δ 1.25 (m, 3H), 1.37-1.50 (m, 2H), 1.54-1.65 (m, 2H), 1.76-1.79 (d, 
1H), 2.04 (s, 3H), 2.26-2.29 (d, 1H), 2.72-2.75 (d, 1H), 3.14-3.17 (d, 1H), 3.88 (s, 3H), 5.10 
(s, 1H), 6.16 (s, 1H), 6.72-6.78 (m, 2H), 7.24-7.46 (m, 6H); 13C-NMR (CDCl3, 500 MHz) δ 
14.18, 19.94, 21.04, 25.70, 33.17, 35.31, 41.20, 56.71, 60.38, 71.28, 105.52, 106.04, 
109.70, 113.35, 123.36, 129.66, 136.67, 136.99, 137.17, 137.55, 149.25; IR (NaCl, thin 
film) νmax (cm-1): 3387 (OH), 3050 (w), 2927, 2850, 1623, 1522, 1454, 1426, 1339, 1226, 




1H-benzo[f]indazol-5-yl)ethan-1-ol (13bd): white solid obtained in 94% yield, mp 181-183 
˚C; TLC (Silica G w/UV254) 30% EtOAc in hexanes, Rf = 0.19; [α]D20 = +13 (c 3.0, MeOH); 
1H-NMR (CDCl3, 500 MHz) δ 1.22-1.35 (m, 6H), 1.58-1.62 (m, 4H), 1.79-1.83 (d, 1H), 1.96-
1.99 (d, 1H), 2.25-2.28 (d, 1H), 2.34-2.44 (s, 3H), 2.57-2.61 (d, 1H), 3.05-3.08 (d, 1H), 3.91-
3.96 (s, 3H), 6.15 (s, 1H), 6.87-6.92 (m, 2H), 7.23-7.30 (m, 4H), 7.36 (s, 1H); 13C-NMR 
(CDCl3, 500 MHz) δ 20.53, 25.64, 26.24, 28.90, 33.96, 35.77, 44.02, 56.34, 123.27, 129.65, 
136.66; IR (NaCl, thin film) νmax (cm-1): 3348 (OH), 2927, 2853, 1622, 1520, 1451, 1420, 






yl)methanol (11be): white solid obtained in 36% yield; mp 109-114 ˚C; TLC (Silica G 
w/UV254) 25% EtOAc in hexanes, Rf = 0.26; [α]D20 = -17 (c 1.0, MeOH); 1H-NMR (CDCl3, 
500 MHz) δ 1.23 (s, 3H), 1.62-1.91 (m, 6H), 2.26-2.31 (m, 1H), 2.40 (s, 3H), 2.67-2.72 (m, 
1H), 3.06-3.14 (m, 1H), 5.39 (s, 1H), 6.16 (s, 1H), 6.95-7.43 (m, 8H); 13C-NMR (CDCl3, 500 
MHz) δ 19.07, 21.03, 21.64, 23.60, 24.35, 25.83, 33.32, 33.51, 34.67, 35.08, 40.64, 41.13, 
54.89, 56.02, 66.12, 67.89, 109.57, 114.13, 123.42, 129.65, 136.46, 137.59, 149.61; IR 
(NaCl, thin film) νmax (cm-1): 3319 (OH), 3106 (w), 3045 (w), 2928, 2856, 2836, 1611, 1540 
(m); HRMS (DART-RTOF) m/z: [M+H]+ Calcd for C24H27N2OS, 391.18386; found 391.13976. 
 
1-((4aR)-4a-methyl-1-(p-tolyl)-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl)-1-
(thiophen-2-yl)ethan-1-ol (13be): white solid obtained in 76% yield; mp 90-95 ˚C; TLC 
(Silica G w/UV254) 25% EtOAc in hexanes, Rf = 0.28; [α]D20 = -12 (c 3.0, MeOH); 1H-NMR 
(CDCl3, 500 MHz) δ 1.25 (s, 3H), 1.40-1.41 (d, 1H), 1.57-1.59 (d, 1H), 1.65 (s, 3H), 1.69-1.70 
(d, 2H), 1.76-1.78 (d, 1H), 2.03-2.06 (d, 1H), 2.26-2.28 (d, 1H), 2.39 (s, 3H), 2.66-2.69 (d, 
1H), 3.22-3.25 (d, 1H), 6.15 (s, 1H), 7.12-7.37 (m, 8H); 13C-NMR (CDCl3, 500 MHz) δ 20.13, 
21.02, 26.16, 28.19, 29.68, 34.31, 35.80, 43.88, 56.70, 109.66, 115.39, 119.69, 123.26, 
125.64, 126.49, 129.63, 136.56, 137.73, 150.91; IR (NaCl, thin film) νmax (cm-1): 3381 (OH), 
3105 (w), 3042 (w), 2928, 2859, 1611, 1518 (m), 821; HRMS (DART-RTOF) m/z: [M+H]+ 





[1,3]dioxolane] (7c): 1H-NMR (CDCl3, 300 MHz) δ 1.21 (s, 3H), 1.64 (m, 2H), 1.84 (m, 2H), 
2.24-2.30 (m, 1H), 2.38-2.45 (m, 1H), 2.48-2.53 (d, 1H), 3.13-3.19 (d, 1H), 3.86 (s, 3H), 




1H-NMR (CDCl3, 300 MHz) δ 1.24 (s, 3H), 1.59-1.79 (m, 2H), 2.03-2.13 (m, 1H), 2.40 (s, 3H), 




carbaldehyde (10c): 1H-NMR (CDCl3, 300 MHz) δ 1.11 (s, 3H), 1.33-1.48 (m, 1H), 1.65-1.80 
(m, 1H), 1.88-1.96 (m, 2H), 2.32-2.45 (m, 3H), 2.85-2.92 (d, 1H), 3.06-3.11 (d, 1H), 3.84 (s, 
3H), 6.16 (s, 1H), 6.96-6.99 (m, 2H), 7.36-7.40 (m, 3H), 9.89 (s, 1H). 
 
1-(1-(4-methoxyphenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-
yl)ethan-1-ol (11ca): white solid obtained in 58% yield; mp 156-159 ˚C; TLC (Silica G 
w/UV254) 25% EtOAc in hexanes, Rf = 0.11; [α]D20 = +25 (c 1.0, MeOH); 1H-NMR (CDCl3, 
500 MHz) δ 1.13 (s, 3H), 1.23-1.29 (m, 4H), 1.34-1.45 (m, 3H), 1.74-1.78 (d, 1H),1.88-1.95 
(d, 1H), 2.28-2.31 (d, 1H), 2.35-2.39 (m, 1H), 2.47-2.51 (d, 1H), 2.98-3.01 (d, 1H), 3.84-3.87 
(s, 3H), 6.10 (s, 1H), 6.96-7.40 (m, 5H); 13C-NMR (CDCl3, 500 MHz) δ 19.21, 20.80, 24.36, 
25.85, 33.31, 34.68, 41.16, 54.89, 55.49, 66.10, 109.38, 113.42, 114.25, 133.01, 136.73, 
137.32,149.51, 158.54; IR (NaCl, thin film) νmax (cm-1): 3376 (OH), 3020 (w), 2962, 2931, 
2862, 1612, 1517, 1250, 831; HRMS (DART-RTOF) m/z: [M+H]+ Calcd for C21H27N2O2, 
339.20670; found 339.20344. 
 
2-((4aR)-1-(4-methoxyphenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-
yl)propan-2-ol (13ca): white solid obtained in 58% yield; mp 194-197 ˚C; TLC (Silica G 
w/UV254) 30% EtOAc in hexanes, Rf = 0.08; [α]D20 = -17 (c 1.0, MeOH); 1H-NMR (CDCl3, 
500 MHz) δ 1.19 (s, 3H) 1.30-1.38 (d, 6H), 1.48-1.55 (m, 1H), 1.66-1.69 (d, 1H), 1.76-1.87 
(dd, 2H), 2.27-2.37 (m, 3H), 2.73-2.76 (d, 1H), 3.53-3.57 (d, 1H), 3.85 (s, 3H), 6.11 (s, 1H) 
6.95-7.41 (m, 5H); 13C-NMR (CDCl3, 500 MHz) δ 19.66, 26.38, 27.48, 28.39, 29.68, 33.91, 
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34.51, 36.20, 43.60, 55.52, 57.61, 75.49, 109.57, 114.24, 114.96, 124.86, 133.10, 136.29, 
137.41, 150.90, 158.42; IR (NaCl, thin film) νmax (cm-1): 3349 (OH), 3018, 2928, 2857, 1612, 




yl)(phenyl)methanol (11cb): beige solid obtained in 73% yield; mp 109.3-111.5 ˚C; TLC 
(Silica G w/UV254) 30% EtOAc in hexanes, Rf = 0.11; [α]D20 = -10 (c 1.0, MeOH); 1H-NMR 
(CDCl3, 500 MHz) δ 1.27 (s, 3H), 1.56-1.81 (m, 6H), 2.24-2.27 (d, 1H), 2.36-2.44 (m, 1H), 
2.75-2.78 (d, 1H), 3.17-3.20 (d, 1H), 3.85 (s, 3H), 5.20 (s, 1H), 6.11 (s, 1H), 6.96-7.44 (m, 
9H); 13C-NMR (CDCl3, 500 MHz) δ 19.90, 25.78, 33.28, 35.23, 41.30, 56.65, 72.02, 114.27, 
125.09, 125.36, 126.84, 128.20, 132.99, 145.61, 149.62, 158.58; IR (NaCl, thin film) νmax 
(cm-1): 3307 (OH), 3056 (w), 2932, 2868, 2835, 1611, 1518, 1250, 833; HRMS (DART-RTOF) 
m/z: [M+H]+ Calcd for C26H29N2O2, 401.22235; found 401.21952. 
 
1-((4aR)-1-(4-methoxyphenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-
yl)-1-phenylethan-1-ol (13cb): beige solid obtained in 100% yield, mp 105.1-108 ˚C; TLC 
(Silica G w/UV254) 30% EtOAc in hexanes, Rf = 0.20; [α]D20 = -30 (c 1.0, CHCl3); 1H-NMR 
(CDCl3, 500 MHz) δ 1.27 (s, 3H), 1.55-1.63 (m, 3H), 1.68 (s, 3H), 1.75-1.77 (m, 1H), 2.04-
2.07 (m, 1H), 2.23-2.26 (m, 1H), 2.33-2.38 (m, 1H), 2.60-2.63 (d, 1H), 3.10-3.13 (d, 1H), 
3.84 (s, 3H), 6.08 (s, 1H), 6.95-7.51 (m, 10H); 13C-NMR (CDCl3, 500 MHz) δ 20.43, 25.82, 
26.20, 28.38, 29.68, 34.19, 35.91, 44.03, 55.48, 56.79, 78.80, 109.33, 114.22, 115.10, 
125.55, 128.01, 133.11, 136.12, 137.46, 151.03, 158.39; IR (NaCl, thin film) νmax (cm-1): 
3338 (OH), 3020 (w), 2925, 2854, 1611, 1517, 1250, 833; HRMS (DART-RTOF) m/z: [M+H]+ 





benzo[f]indazol-5-yl)methanol (11cc): white solid obtained in 69% yield; mp 178-182 ˚C; 
TLC (Silica G w/UV254) 30% EtOAc in hexanes, Rf = 0.26; [α]D20 = +4 (c 4.0, MeOH); 1H-
NMR (CDCl3, 500 MHz) δ 1.26 (s, 3H), 1.56-1.58 (m, 2H), 1.66-1.70 (m, 2H), 1.79-1.82 (m, 
1H), 2.25-2.28 (m, 1H), 2.37-2.40 (m, 1H), 2.73-2.76 (d, 1H), 3.17-3.20 (d, 1H), 3.85 (s, 3H), 
5.20 (d, 1H), 6.11 (s, 1H), 6.96-7.06 (m, 4H), 7.30-7.44 (m, 5H); 13C-NMR (CDCl3, 500 MHz) 
δ 19.84, 20.59, 21.04, 25.80, 29.68, 33.28, 35.05, 41.22, 55.69, 69.85, 109.63, 113.56, 
119.81, 123.50, 125.51, 126.00, 129.68, 137.60, 147.31, 149.4; IR (NaCl, thin film) νmax 
(cm-1): 3399 (OH), 2930, 2850, 1602, 1512, 1223, 824; HRMS (DART-RTOF) m/z: [M+H]+ 
Calcd for C26H28FN2O2, 419.21293; found 419.20660. 
 
1-(4-fluorophenyl)-1-((4aR)-1-(4-methoxyphenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-
benzo[f]indazol-5-yl)ethan-1-ol (13cc): white solid obtained in 49% yield; mp 182.1-185 
˚C; TLC (Silica G w/UV254) 30% EtOAc in hexanes, Rf = 0.28; [α]D20 = -51 (c 1.0, MeOH); 1H-
NMR (CDCl3, 300 MHz) δ 1.25 (s, 3H), 1.53-1.62 (m, 2H), 1.67 (s, 3H), 1.73-1.78 (m, 1H), 
1.99-2.02 (d, 1H), 2.24-2.36 (m, 3H), 2.60-2.63 (d, 1H), 3.12-3.15 (d, 1H), 3.85 (s, 3H), 6.09 
(s, 1H), 6.95-7.49 (m, 9H); 13C-NMR (CDCl3, 500 MHz) δ 20.42, 25.82, 26.18, 28.46, 29.69, 
34.14, 36.05, 44.02, 55.53, 56.90, 78.55, 109.48, 114.23, 114.59, 114.76, 124.84, 127.24, 
136.09, 137.48, 151.60; IR (NaCl, thin film) νmax (cm-1): 3363 (OH), 2929, 2840, 1600, 1517, 




hexahydro-1H-benzo[f]indazol-5-yl)methanol (11cd): white solid obtained in 71% yield, 
mp 174.1-177.4 ˚C; TLC (Silica G w/UV254) 30% EtOAc in hexanes, Rf = 0.16; [α]D20 = -50 
(c 1.0, MeOH); 1H-NMR (CDCl3, 500 MHz) δ 1.26 (s, 3H), 1.52-1.56 (m, 2H), 1.66-1.69 (m, 
2H), 1.80-1.84 (m, 2H), 2.26-2.29 (m, 1H), 2.73-2.76 (d, 1H), 3.15-3.18 (d, 1H), 3.85 (s, 3H), 
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3.91 (s, 3H), 5.12 (s, 1H), 6.11 (s, 1H), 6.72-6.79 (m, 2H), 6.96-6.99 (m, 2H), 7.37-7.44 (m, 
3H); 13C-NMR (CDCl3, 500 MHz) δ 20.00, 25.70, 33.15, 35.35, 41.23, 55.54, 56.72, 71.34, 
106.04, 109.62, 113.09, 114.29, 125.09, 136.72, 137.36, 149.14, 158.65; IR (NaCl, thin 
film) νmax (cm-1): 3400 (OH), 2930, 2868, 1611, 1517, 1250, 833; HRMS (DART-RTOF) m/z: 
[M+H]+ Calcd for C27H29F2N2O3, 467.21408; found 467.21488. 
 
1-(3,4-difluoro-5-methoxyphenyl)-1-((4aR)-1-(4-methoxyphenyl)-4a-methyl-4,4a,5,6,7,8-
hexahydro-1H-benzo[f]indazol-5-yl)ethan-1-ol (13cd): white solid obtained in 65% yield, 
mp 184-187 ˚C, TLC (Silica G w/UV254) 30% EtOAc in hexanes, Rf = 0.13; [α]D20 = +55 (c 
1.0, MeOH); 1H-NMR (CDCl3, 500 MHz) δ 1.26 (s, 3H), 1.60-1.67 (m, 6H) 1.79-1.82(d, 1H), 
1.96-1.99 (d, 1H), 2.24-2.39 (m, 2H), 2.57-2.60 (d, 1H), 3.05-3.08 (d, 1H), 3.85 (s, 3H), 3.91 
(s, 3H), 6.10 (s, 1H), 6.87-7.01 (m, 4H), 7.32-7.45 (m, 3H); 13C-NMR (CDCl3, 500 MHz) δ 
20.54, 25.65, 26.24, 28.89, 33.95, 35.79, 44.05, 55.53, 56.35, 56.78, 106.27, 106.78, 
109.50, 114.25, 114.75, 124.85, 133.03, 137.42, 150.81; IR (NaCl, thin film) νmax (cm-1): 
3329 (OH), 2932, 2850, 1622, 1518, 1251, 1100, 834; HRMS (DART-RTOF) m/z: [M+H]+ 
Calcd for C27H30FN2O2, 433.22858; found 433.22897. 
 
(1-(4-methoxyphenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-
yl)(thiophen-2-yl)methanol (11ce): white solid obtained in 79% yield; mp 171-173.6 ˚C; 
TLC (Silica G w/UV254) 30% EtOAc in hexanes, Rf = 0.17; [α]D20 = -6.2 (c 1.0, MeOH); 1H-
NMR (CDCl3, 500 MHz) δ 1.26 (m, 4H), 1.62-1.72 (m, 2H), 1.77-1.85 (m, 2H), 2.27-2.41 (m, 
2H), 2.69-2.72 (d, 1H), 3.12-3.15 (d, 1H), 3.85 (s, 3H), 5.25 (s, 1H), 6.12 (s, 1H), 6.96-7.40 
(m, 8H); 13C-NMR (CDCl3, 500 MHz) δ 19.87, 20.59, 25.80, 33.28, 35.04, 41.26, 55.54, 
55.69, 69.83, 109.44, 113.31, 114.29, 119.82, 125.11, 125.51, 126.00, 137.26, 147.31, 
158.65; IR (NaCl, thin film) νmax (cm-1): 3310 (OH), 3090 (w), 2920, 2860, 1610 (w), 1519, 





yl)-1-(thiophen-2-yl)ethan-1-ol (13ce): white solid obtained in 48% yield; mp 146-148.5 
˚C; TLC (Silica G w/UV254) 30% EtOAc in hexanes, Rf = 0.16; [α]D20 = +12 (c 1.0, MeOH); 
1H-NMR (CDCl3, 500 MHz) δ1.25 (s, 3H), 1.59-1.65 (m, 2H), 1.68 (s, 3H), 1.73-1.78 (m, 2H), 
2.03-2.06 (d, 1H), 2.25-2.36 (m, 2H), 2.65-2.69 (d, 1H), 3.22-3.25 (d, 1H), 3.84 (s, 3H), 6.10 
(s, 1H), 6.94-7.40 (m, 8H); 13C-NMR (CDCl3, 500 MHz) δ 20.16, 26.16, 28.19, 34.31, 35.82, 
43.91, 55.48, 56.71, 77.52, 109.47, 114.23, 115.13, 119.72, 124.88, 126.51, 133.11, 
136.13, 137.47, 150.93, 152.99, 158.40; IR (NaCl, thin film) νmax (cm-1): 3365 (OH), 2930, 
2850, 1610, 1517, 1250, 835; HRMS (ESI-RTOF) m/z: [M+H]+ Calcd for C25H29N2O2S, 
421.1944; found 421.1907. 
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1.8.5 – 1H-NMR and 13C-NMR spectra 
 
 



















1H-NMR for compounds 11ac and 13ac 
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1H-NMR and 13C-NMR for compound 11af 
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1H-NMR and 13C-NMR for compound 11bb 
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1.8.6 – 2D/3D representations of ligand-receptor interactions 
Compounds are shown in the orientation of highest calculated binding affinity, which are 
shown in section 1.8.7. 



















































1.8.7 – Tables of ligand orientations in 5NFP pocket 
1    2       3          4 
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Tables of ligand orientations in 5NFP pocket (continued) 
1    2       3          4 
127 
 
Tables of ligand orientations in 5NFP pocket (continued) 
1    2       3          4 
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Tables of ligand orientations in 5NFP pocket (continued) 
1    2       3          4 
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Tables of ligand orientations in 5NFP pocket (continued) 
 
1    2       3          4 
130 
 
1.8.8 – EICs and LCMS method for analysis of crude product 13ag 
EIC – [M+H]+ 12ag  
 
[M+H]+ calc’d for C23H28FN2O+ = 367.2180 m/z; found – 367.2179 m/z; Δppm = -0.27 
 
RT: 0.00 - 20.52

















































Product12ag_13ag01_180628151209 #1225-1241 RT: 12.50-12.65 AV: 17 NL: 8.71E8
T: FTMS + p ESI Full ms [150.0000-500.0000]














































EIC – [M+H]+ 13ag  
 
Mass spectrum under EIC of 13ag 
 
 
RT: 0.00 - 20.52

















































Product12ag_13ag01_180628151209 #1328 RT: 13.48 AV: 1 NL: 1.17E7
T: FTMS + p ESI Full ms [150.0000-500.0000]



























































Zoomed-in mass spectrum under 13ag peak 
 
 
[M+H]+ calc’d for C24H32FN2O+ = 383.2493 m/z; found – 383.2494 m/z; Δppm = 0.21 
Relative abundance of 13ag to 12ag = 1.55x109 ions 12ag : 5.5x104 ions 13ag
 
Product12ag_13ag01_180628151209 #1328 RT: 13.48 AV: 1 NL: 7.41E5
T: FTMS + p ESI Full ms [150.0000-500.0000]















































Product12ag_13ag01_180628151209 #1328 RT: 13.48 AV: 1 NL: 1.63E5
T: FTMS + p ESI Full ms [150.0000-500.0000]








































SYNTHETIC LIPIDS AS ISOTOPE TRACERS TO DIFFERENTIATE BRANCHED-




Portions of this chapter will be included in a future publication with a working title of: 
Utility of (D3)-isovaleric acid as a stable isotope tracer for differentiating isolipids from 
straight-chain isobars in LC-ESI-MS lipidomic analyses. 
Brandon J. Kennedy, Liz Fozo, Shawn R. Campagna 
 
2.1 – Abstract 
 Absolute identification of individual lipid species is a challenge in lipidomic 
analyses that is often dealt with by clustering groups of lipids by class, chain length, and 
degree of unsaturation (Figure 2.1.1). This is an issue when considering that isobaric lipids 
of the same class may have differing activities in vivo due to the structural differences 
between them. An example of these co-identified lipid species in lipidomic analyses 





Figure 2.1.1 – Lipid Isobars with the same compound abbreviation 
Lipids are typically annotated with a nomenclature that does not specify tail branching or 




are straight-chain lipids with their respective isobaric counterpart containing a terminal 
isopropyl moiety. These isolipids are impossible to differentiate from straight-chain lipids  
since they have the same exact mass and very similar retention profiles in LC separations. 
This type of lipid isobar is easy to identify by routine gas chromatography electron impact 
mass spectrometric (GC-EI-MS) analysis of these compounds for a couple of reasons. Due 
to the higher theoretical plate count in typical gas chromatography versus liquid 
chromatography, there is greater physical separation of these species. Also, by using a 
hard ionization source like EI, the analytes are detected as characteristic fragments that 
illuminate their structural differences.52  
 In order to make many larger lipids and lipid species with bulky headgroups fly in 
a gas chromatograph, they must be derivatized first, either into silyl ethers or into methyl 
esters as with fatty acid methyl ester (FAME) analysis. There are other derivitization 
methods specifically used for isolipid differentiation such as creating dimethyloxazolinyl 
or picolinyl esters (Figure 2.1.2); although these procedures are useful for differentiating 
branched chain lipids from straight-chain lipids, they require chemistries more 
complicated than methylation or silylation and are typically not pursued.53-54 The biggest 
downside to these procedures is the loss of connectivity with head groups, which makes 
it impossible to correlate what higher-order lipids these fatty acid tails were component 
to. Biologically relevant lipid species can be analyzed by mass spectrometry by softer 
ionization sources such as ESI, which keeps the biogenic lipid intact throughout liquid 
chromatographic (LC) separation and subsequent ionization and mass analysis. But this 
lessens the ability of the analyst to differentiate structural isomers of the same exact 
mass. 
 Although instruments that couple LC systems to mass spectrometers with an EI 
source exist, these are not a common instrument to most research facilities due to issues 






Figure 2.1.2 – Fatty acid derivitization methods for GC-EI-MS analysis 
GCMS analysis of lipids usually require sample derivitization to either generate EI spectra 
that give specific structural information such as with nicotinyl esters and oxazolines (A) 





experiment was devised to tag lipids with a stable isotope for LC-ESI-MS analysis (Figure 
2.1.3). The method would permit the biological generation of isotopically labeled isolipids 
from a feedstock of deuterated isovaleric acid (d3-(iso5:0):“D3-iC5”). Through this strategy, 
microbes supplemented with D3-iC5 use the heavy lipid analogue to incorporate into many 
biological molecules that feature a terminal isopropyl unit. In this way, cultures of bacteria 
can be grown on agar that has labeled and unlabeled isovaleric acid, lipids are extracted, 
and analyzed by LCMS instrumentation. The spectral features found in the D3-iC5 
supplemented cultures that contain a population of isotopically labeled analogues not 
seen in the control cultures would indicate the presence of an isolipid. This strategy has 
many implications for LC-ESI-MS analyses of a multitude of biogenic compounds, 





Figure 2.1.3 – iC5-d3 isotope tracer experimental workflow 
Shown above is the experimental workflow for the isotope tracer study. Cells are grown 
normally (A), then cultures are then transferred to new plates doped with either labeled 
or non-labeled isovaleric acid (B). Once enough time has passed for nutrient uptake, cells 
are harvested and extracted for LCMS analysis (C). Cell extracts are separated and 
analyzed by LC-ESI-MS (D), and the data is analyzed for the presence of isotopically 
labeled molecules that correlate to non-labeled molecules in the unlabeled sample (E). 
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2.2 – Introduction 
2.2.1 – Lipidomics and lipid semiochemicals 
 Chemical signals, or semiochemicals, govern microbial life, from guided 
movement of individual cells, to initiating cascades of developmental change within a 
community of cells.55 Understanding these signals may provide insight into how 
unicellular organisms communicate, how individual cells within multicellular organisms 
communicate with each other, and ultimately a greater fundamental understanding of 
cell-cell signaling. Identification and quantification of small molecules in biological 
systems has been of paramount importance to biochemical research, due to the influence 
the small molecule space has on the physiology and function of organisms. Lipids are a 
class of molecules that have important functional role in cell biology, normal and 
dysfunctional physiology, microbial virulence, and disease pathology.56-57 Lipids as 
signaling molecules has been an ongoing paradigm conceived of in the 1950’s concerning 
the function of lipids in cell-cell communication and their role as biomarkers for disease.58-
61 These lipid species can be analyzed by a number of well-established instrumental 
methods such as LCMS, GCMS, MALDI-MS, NMR, and usually fall under the umbrella term 
of metabolomic analysis.  
 Generally, metabolomic studies compare some aspect of the metabolome for 
some control specimen to that of a mutant with some observable phenotypic differences 
to that of the control. By determining relative or absolute concentrations of metabolites 
representative of the system being studied, hypotheses on the functional role of 
metabolites that differ in concentration between the experimental organisms may be 
generated or substantiated. Lipidomics is a sub-class of metabolomics describing the 
analysis of all the detectable lipid species present within a sample. This can include non-
polar compounds such as terpenes, steroids, long-chain fatty acids, and isoprenoids as 
well as polar compounds such as phospholipids, saccharolipids, short-chain fatty acids, 
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and polyketides.62 Several biologically relevant lipid species resemble a similar structure 
where a polar head-group is connected to one, or several, lipid tails of varying length, 
degrees of unsaturation, and functionality. Determining the exact structure of the lipid 
tails in these compounds is often not a trivial task. Characterizing these features require 
isolating the species of interest and performing either 1D/2D NMR experiments or GCMS 
analyses involving some chemical derivatization on the isolated compound(s). These 
derivatized species have much lower vapor pressures (volatilities) making them more 
amenable to analysis by gas chromatography. This gives the analyst the ability to separate 
lipids by chain-length and degree of unsaturation as well as provides fragmentation data 
from the hard ionization source to gather information on molecular structure. 
 Most lipidomic analyses are performed on biological systems with the intent to 
better understand a function or loss of function due to some lipid(s) either being 
present/absent or in higher/lower concentration to that in a biological control specimen. 
Lipids species that are typically targeted and focused on in a lipidomic analysis are those 
that are part of cellular membranes, which vary in composition and structure. Changes to 
membrane lipid content can have a variety of effects on the physical and chemical 
attributes of the cell, such as membrane rigidity/fluidity, temperature tolerance, export 
and import of external and internal compounds, and can affect the binding of proteins 
and small molecules to cell membrane-localized structures.63 These targeted studies 
utilize a library of analytical standards to annotate the data obtained from 
chromatography coupled mass spectrometry to somewhat ambiguously identify the lipids 
present in the system being studied. These libraries consist of several lipid classes that 
are known to exist in cells and cellular compartments; each with a combination of 
previously characterized lipid tails to assist in identifying lipids  
 Often, the goal of microbial lipidomics is to gather information on unknown 
molecule(s) that may have significance in the initiation of a behavioral response in 
microbes, such as the stringent response in the soil bacterium Myxococcus xanthus. 
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Recently, previously uncharacterized lipids with cytotoxic activity that are specifically 
formed during the stringent response of M. xanthus have been reported as containing 
terminal isolipids, which was determined through a combination of MS and NMR 
experiments. Hoffmann and co-workers (ACS Chemical Biology, 2018) isolated the 
cytotoxic lipids (Figure 2.2.1) by semipreparative chromatography of cell extracts of 
nearly 500 plated cultures.64 The inclusion of the NMR experiment was necessary due to 
the limitations of current LCMS techniques in differentiating between straight-chain and 
branched-chain lipids. The amount of work needed to arrive at the same conclusion could 
be minimized by the use of a targeted isotope tracing experiment only requiring the use 





Figure 2.2.1 – Lipids expressed during M. Xanthus stringent-response 
Homospermidine (HS) lipids discovered by Hoffman et. al. to be important for initiating 





2.2.2 – Differentiating isobars in LCMS analyses 
 Structural isomers are a confounding aspect of mass spectrometric analyses. 
Isobaric compounds are a problem often encountered in lipidomic space, where 
structural isomers of lipids obscure the exact knowledge that can be obtained from such 
an analysis. As an example: the position of a methyl group along the length of a lipid tail 
cannot be determined without fragmentation data (Figure 2.2.2). This issue can 
sometimes be resolved under optimal chromatographic conditions to separate the 
isobars, if their retention factors are different enough to allow for such separation; 
However, if the isobars of interest cannot be separated through chromatographic 
techniques prior to introduction into a mass spectrometer, determining relative 
concentrations between these species is practically impossible. The parent mass of these 





Figure 2.2.2 – Isobaric compounds indistinguishable by LC-ESI-MS analysis 




another during mass filtering in instrumental ion optics – such as with a triple-quadrupole 
mass spectrometer. So, even when generating informative fragmentation data on 
mixtures of isobars, it may be very difficult to determine relative concentrations between 
these compounds; Although, there have been successes in differentiating between 
isobaric compounds by LCMS analysis with pre-column derivatization. Marfey’s reagent 
is one such success that is used to modify mixtures of amino acid enantiomers and enforce 
chiral separation on non-chiral stationary phases (Figure 2.2.3).65-66 This allows for 
enantioselective separations to be performed on cheaper and more routinely used HPLC 
columns. Another example of the utility of pre-column derivatization is in the analysis of 
sugars, which have either been phosphorylated or sulfonated that are isobaric in lower-
resolution (<118,000) mass spectrometers. These species can be distinguished from one 
another by using an ion-pairing tripeptide (Lys-Lys-Lys; aka “K3”) to engender 
characteristic fragments that illuminate these functional group differences.67 
 The specific distinction of sulfonation versus phosphorylation or between 
enantiomers are of great importance to biochemical research. These species are 
physiologically and chemically distinguishable by their reactivities and bioactivities, but 
they are indistinguishable in MS-space without the use of a high-resolution instrument 
such as a Fourier transform ion cyclotron resonance (FT-ICR) or Orbitrap mass 
spectrometer. Isobaric compounds that do not contain the exploitable physical and 
chemical properties as just described are simple carbonaceous structural isomers that 
have similar chromatographic properties, which are challenging to distinguish in LCMS 
analyses. These compounds are simple to identify and determine relative concentrations 
of these species in a sample with NMR techniques but require a large amount of fairly 
pure compound in order to make NMR analysis feasible. This is where small molecule 
isotope tracing experiments have an advantage by not having to rely on pre-analysis 
sample derivatization, or unique chemistries induced by instrumental fragmentation. By 







Figure 2.2.3 – Marfey’s reagent for the separation of amino acid enantiomers 
Following derivatization with 1-fluoro-2-4-dinitrophenyl-5-L-alanine amide (Marfey’s 
reagent) of a racemic mixture of amino acids, separation of these enantiomers can be 
achieved using non-chiral stationary phases making these types of analyses more cost-

































to generate metabolites built of the introduced tracer, which would provide a 
distinguishable signal of a multitude of structural isomers. 
2.2.3 – Lipid biosynthesis and isotope tracing 
 Lipids are synthesized biologically by finding and absorbing necessary lipids from 
the environment, or by utilizing small ubiquitous metabolites such as acetate or 
branched-chain amino acids. Straight-chain fatty acids are derived from acetyl-CoA or 
other small straight-chain fatty acids, which undergo a few priming conversions before 
entering the lipid elongation pathway. Branched-chain fatty acids arise from branched-
chain amino acids leucine, isoleucine, and valine or from free branched-chain fatty acids 
such as isovaleric acid acquired from the environment or as byproducts from their own 
metabolism such as the metabolic degradation of leucine (Figure 2.2.4).68-69 It is 
conceivable that these biosynthetic pathways could be taken advantage of by introducing 
a isotopically labeled synthon such as those just described, and allowing the cells to make 
a multitude of isotopically enriched primary and secondary metabolites.  
 Stable isotopes have been used for decades in MS analyses for a number of 
applications, especially in the realm of studying metabolism, or the chemical 
transformations occurring in biological systems.70 Beginning in the 1920’s, the work of 
Francis W. Aston using a primitive mass spectrometer was instrumental in solidifying John 
Dalton’s theory that the existence of many stable isotopes per element was credible. The 
fact that stable isotopes exist and would be detectable from molecules that are not 
isotopically enriched gave scientists an avenue to explore metabolism in vivo. Stable 
isotope-labeled molecules have a number of applications in mass spectrometry such as 
with metabolic flux studies, isotope dilution, internal standardization, and isotope tracing 
experiments. Isotope tracing is the focus of this chapter, more specifically the approach 
of providing an organism an isotopically labeled feed-stock and observing what metabolic 
products are formed. Using this method of introducing a stable isotope into metabolic 





Figure 2.2.4 – Branched-chain and straight-chain lipid biosynthesis 
Branched-chain and straight-chain lipids of varying lengths may be biologically 
synthesized by the elongation of primed branched-chain fatty acids such as isovaleric acid 
and butyric acid (shown above; n=1). 
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the metabolome for structural information about the molecules that adopt an isotopically 
enriched moiety. 
2.2.4 – Isolipid model organism: Myxococcus xanthus  
 The canonical prokaryotic model organism for studying social behavior and cell-
cell signaling is the soil bacterium Myxococcus xanthus; a Gram-negative proteobacteria 
with a large genome that exists as a predatory saprophytic single-species biofilm.55 This 
organism is well suited for studying the effects of chemical signals, due to the nearly 
comprehensive understanding what chemical signals are produced and how colonies of 
these bacteria are affected developmentally by these signals. When a colony of M. 
xanthus faces starvation, vegetative growth ceases and the bacterial colony instead shifts 
all effort to the formation of macroscopic mounds of dormant myxospores, called fruiting 
bodies. This shift in behavior is known as the stringent response and is initiated by amino 
acid limitation. The response promotes the down-regulation of the gene responsible for 
cell growth, SocE, and the simultaneous transcriptional up-regulation of CsgA, which 
produces the inner-membrane protein CsgA - essential for cell aggregation, lipid body 
production, and fruiting body formation.71-72 Although the action of CsgA has been 
determined to be a cardiolipin phospholipase that populates the cell with diacylglycerides 
(DAGs) and diacyl phospholipids that are believed to be essential in fruiting body 
formation.73-74  
Another important feature of the stringent response in M. xanthus is the 
production of homospermidine lipids that are cytotoxic to competing bacteria, a defense 
mechanism that uses lipids available to the organism to produce these compounds. These 
lipids were recently discovered and characterized by Müller and co-workers by a 
combination of LCMS and NMR techniques.64 An alternative strategy to the work that 
went into this discovery could have been the use of a logical isotope tracer to determine 
structural motifs of these lipids. These compounds are easily differentiable since they can 
be identified by their exact mass in a typical LCMS-mediated lipidomic analysis. Using M. 
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xanthus as a model organism for tagging the production of isolipid species via 
supplementation with an isotopically labeled isolipid carbon-source will provide definitive 
proof-of-concept for this isotope tracing method that can be applied to numerous 
microbial systems. 
2.3 – Results and discussion 
2.3.1 – Analysis of M. xanthus lipids 
 In a collaboration with the microbiology lab of Dr. Larry M. Shimkets at the 
University of Georgia, Athens; samples of whole-cell lipid extracts were obtained to 
determine the lipidomic profile of a set of M. xanthus strains that behaved differently 
under nutrient-limitation. Wild-Type sp. DK1622 was used to be the control specimen 
while sp. LS1991 was a strain deficient in the production of branched-chain lipids, which 
did not undergo sporulation under these limiting conditions. It is because this mutant 
(LS1191) lacks a majority of pathways available to M. xanthus to synthesize isovaleryl-CoA 
from leucine. The pathways in question are functions of branched-chain ketoacid 
decarboxylase and a secondary pathway mediated partially by MXAN_4265, a species-
specific glutaconyl-CoA transferase that is part of the melvalonate-dependant isoprenoid 
biosynthetic pathway.75 Specifically, this mutant is restored to normal function by 
supplementation with either exogenous iso15:0 or iso5:0 fatty acids.55 It was shown 
through previous publications that by supplying M. xanthus mutants unable to undergo 
sporulation with lipids extracted from sp. DK1622, the mutant strains were able to 
undergo successful sporulation into viable fruiting bodies.76-77 In order to profile the lipids 
present in M. xanthus whole-cell lipid extracts were subjected to lipidomic analysis by an 
in-house lipidomics method in the Biological Small Molecule Mass Spectrometry Core 
facility (BSMMSC) at the University of Tennessee, Knoxville. Profiling of lipids present 
during vegetative growth would allow for the distinction of the lipids present during this 
growth-phase to be compared to the lipid profile of sp. DK1662 during sporulation. Taking 
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these data into account and comparing them to the profiles of mutant strains, which 
cannot undergo sporulation, could provide evidence of some mass feature not present in 
the mutant strain but readily detectable in the wild-type organism. These detectable 
biomarkers would be the top candidates for either initiating this phenotypic behavior in 
sp. DK1622 and would need to be isolated and structurally characterized by liquid 
chromatography tandem mass spectrometry (LC-MS/MS) with additional structural 
information gathered by NMR analyses of the isolated compound(s). 
 Upon lipidomic analysis of sp. DK1622 and sp. LS1191 it was apparent that the lipid 
profiles between these organisms were similar in terms of detectable lipid species but 
differed in detected concentrations of these lipids between organisms (Figure 2.3.1). It 
could be that there is a necessary quorum of certain lipid species that could be 
contributing to the reason that mutant cells that produced less lipids could not undergo 
fruiting body formation. An alternative and more likely reason for this observation is that 
the structural identity of the lipids present between these organisms may have a greater 
effect on the phenotypic differences between them. Since the esg (E-signal) mutant sp. 
LS1191 is deficient in branched-chain lipid production, the low concentration or absence 
of certain isolipids could be the determining factor in the lack of developmental changes 
when colonies of this mutant face starvation.78-79 If this structural difference in 
semiochemicals is the causal factor for loss of function in sp. LS1191, any of the lipids 
detected between these strains could contain this structural feature as straight-chain 
lipids are indistinguishable from lipids branched-chain lipids of the same chemical formula 
in most LCMS analyses. 
 The BSMMSC list of lipid species cataloged in the in-house lipidomics method 
covers a range of phospholipid species of differing carbon count and degree of 
unsaturation, and the lack of drastic differences between these experimental organisms 
suggests that structural components of these lipids may be contributing to the phenotypic 






Figure 2.3.1 – Lipid composition between M. xanthus strains DK1622 and LS1191 
Lipid species detected in wild-type M. xanthus DK1622 and esg mutant LS1191. This list 




not cataloged in the BSMMSC’s lipidomics library that are contributing to the observed 
differences in these two organisms. The unknown space of LCMS analyses is very complex 
and contain thousands of mass features. In an attempt to curb the complexity of the 
whole-cell lipid extracts, preparative TLC was performed on M. xanthus extracts and a set 
of five distinct bands along the TLC plate revealed restorative activity to sp.LS1191. These 
“bioactive bands” were subjected to lipidomic analysis to determine what unknown 
spectral features in these samples may have contributed to the observed activity. Even 
after performing statistical analyses such as PLSDA and extracting the variable projection 
of importance (VIP) scores of these mass features to determine the features that 
significantly drive statistical separation between samples, the list of statistically impactful 
mass features can still be between hundreds to thousands of significant features (Figure 
2.3.2). With this in mind, being able to spectral features with a specific structural 
component when considering all the detectable masses in a routine lipidomics 
experiment would be notably helpful to the analyst. Including another means of 
determining the compounds in the unknowns to be more relevant to the study of isobaric 
compounds that are structural isomers of each other would reduce the list of important 
features significantly. 
2.3.2 – Isotope tracing in M. xanthus 
 M. xanthus is a well-studied organism and much is known about the behavioral, 
structural, and chemical characteristics that make this organism unique. The lipid 
composition of the cell membrane in M. xanthus has been established to contain an 
unusually high level of 13-methyltetradecanoic acid (iso15:0), which makes up nearly 41% 
of the fatty acid composition of sp. DK1622 cells.81 Taking into consideration the natural 
abundance of isolipids in this organism, it seemed practical to synthesize and supplement 
a deuterated version of the naturally occurring 15-carbon lipid, D6-(iso15:0) – also known 




Figure 2.3.2 – PLSDA and VIP score analysis of unknown spectral features between M. 
xanthus strains DK1622 and LS1191 
Shown above is an example of the complexity of the unknown mass features in an 
untargeted LCMS analysis of M. xanthus strains DK1622 and LS1191. 
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especially during the stringent response. The M. xanthus mutant LS1191 is deficient in 
branched-chain fatty acid synthesis, making it the ideal organism to probe the uptake and 
incorporation of iso-fatty acids into the cell. Developmentally significant lipid species 
containing (iso15:0) can be investigated by presenting sp. LS1191 with synthetic iC15-d6 as 
a component of the media used to grow the cells on. Analysis of the lipids extracted 
fromthe (iC15-d6)-doped LS1191 colonies will demonstrate the uptake and incorporation 
of the synthetic lipid, generating a detectable population of isolipid species that can be 
further targeted for fragmentation studies as putative signaling molecules with a partially 
known structure. 
 The data obtained from this experiment could be used to optimize detection 
methodology in preparation for an untargeted isotope tracing experiment. A critical 
aspect of this project is whether or not M. xanthus will pick up exogenous iC15-d6 and 
incorporate it into higher-order compounds such as phospholipids, cardiolipin, or other 
lipid classes. By adding both synthetic lipids iso15:0 and iC15-d6 to the media of vegetative 
cells and comparing the lipid composition against the lipid extract of wild-type M. xanthus 
cell grown on undoped media, it can be determined if the synthetic lipid was taken up by 
the cells, as well as if the addition of exogenous lipids change the lipid profile of the cells 
themselves. This approach with d6-(iso15:0) was attempted but met with suboptimal 
results. To combat this apparent lack of isotope tracer uptake, a smaller more permeable 
and metabolically useful tracer was considered. Since the primary biologic synthon for 
the biosynthesis of most isolipids in M. xanthus is isovaleryl-CoA, it was obvious that the 
ideal isotope tracer for this study was not iC15-d6, but rather the precursor to isovaleryl-
CoA, isovaleric acid. All synthetic efforts shifted to the generation of the small isotopically 
labeled compound iC5-d3 for the tracing study. After synthesis of this isotope tracer iC5-d3 
and supplementation of the tracer into cultures of DK1622 and the isolipid-deficient 
mutant LS1191, there was a great degree of labeling observed in lipidomic analyses of 
these samples (Appendix 2.6.2). This was not unexpected, as M xanthus synthesizes most 
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of its isolipid components from isovaleryl-CoA, except for the only other smaller 
isobutyrate species. Since these microbes were also supplemented with iC5-d3 during 
amino acid limitation, these microbes should have been producing homospermidine lipids 
as anti-microbial compounds during the stringent response. These molecules were also 
detected in this analysis, and labeled lipids were detected in the samples supplemented 
with iC5-d3, where the degree of labeling corresponds to the number of isolipid tails 
present in the previously identified compounds by Müller and co-workers (section 2.6.3). 
2.3.3 – Synthesis of isotope tracers 
 The synthesis of the preliminary isotope tracer target molecule iC15-d6 was 
adapted from an article published by the Williams group of the University of Melbourne, 
Australia (Figure 2.3.3).82 The synthesis of these long-chain fatty acids starts with the 
commercially available macrocyclic musk 13-methyltetradecanolide and then relies on 
recursive dehomologation to achieve the isolipid of the desired tail-length. Briefly, double 
addition of D3-methyl units, via freshly generated Grignard, to the 15-carbon lactone 1 
provides diol 2. Selective reduction of the tertiary alcohol with a silane reducing agent in 
the presence of BF3•Et2O provides 3 with traces of alkene by-product. After purification 
of the desired product, the residual alkene by-product was reduced by Pd-catalyzed 
hydrogenation, purified, and collected with the rest of the fatty alcohol 3. Recursive 
dehomologation was achieved through a Chugaev reaction with 3, proceeding via 
intramolecular elimination of intermediate xanthate 4 to alkene 5. Oxidation of the 17-
carbon alkene 5 with potassium permanganate giving the 16-carbon iso-fatty acid 6. After 
reduction of 6 by borane-dimethylsulfide, the resultant alcohol 7 was taken through the 
same transformations as molecule 3, yielding the final product iC15-d6 (10). This synthesis 
could have been shortened by a few steps by using cyclotridecanolide as the starting 
material, though this would have been extremely cost-prohibitive due to the fact that 
cyclotridecanolide is ~50,000 times more expensive than 13-methyltetradecanolide. For 
the synthesis of the 5-carbon isotope tracer iC5-d3 , the strategy of attaining this molecule 
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took a similar route at first, but was met with much failure due to self-cyclization of the 
resultant 6- carbon intermediates (Figure 2.3.4). It became quite evident that even 
though this small reactive compound could be isolated, as soon as these intermediates 
came into contact with BF3•Et2O there was enough impetus to allow the terminal 
hydroxyl group to act as a nucleophile and cyclize to 1,1-dimethyltetrahydrofuran. In a 
futile attempt to lessen the ability of this compound to cyclize a bulky protecting group 
was added to one of the terminal hydroxyl group of 2-hydroxy-2-methylpentanediol 
through the use of a bulky protecting group selective for reaction with primary alcohols 





Figure 2.3.3 – Synthetic route toward iC15-d6 
Synthetic procedure of iso-fatty acids adapted from the Williams work to include the 







Figure 2.3.4 – Attempted synthetic routes toward isovaleric acid 
Attempted syntheses of isovaleric acid through the Williams strategy, which was met with 




Even though the reaction conditions of this protection did not result in cyclization, and 
even survived purification via flash chromatography using ammonia-doped silica as the 
stationary phase, efforts to remove the tertiary alcohol all met in failure. Either by using 
similar chemistry to the TBDPS protection to tosylate the remaining alcohol, or under 
reducing conditions with BF3•Et2O, the compound cyclized presumably by some 
nucleophilic mechanism that was not further explored. 
 Alternatively, a new synthetic route was devised after searching the literature for 
reactions allowing the addition of a carbonaceous nucleophile to yield a carboxylic acid 
with a terminal isopropyl group. This approach has been shown to be achievable with a 
number of small strained lactones that gave iso- and anteiso-fatty acids in good yields.83-
84 This synthetic route (Figure 2.3.5) was much simpler, giving small iso-fatty acids directly 
from starting material, and more economical due to the low cost and availability of the 
appropriate synthon for the target molecule, β-butyrolactone (11). The desired 
compound was achieved in a single step by the addition of a D3-methyl unit via a Gilman-
type diorganocuprate, which proceeded through a direct β-carbon fission between the 
isotopically labeled reagent and the lactone 11, giving the product iC5-d3 (12) in a 
reasonable yield. 
2.4 – Methods 
2.4.1 – Synthesis of isotopically labeled tracing lipids 
 The synthetic procedures used to obtain the isotope tracers iC15-d6 and iC5d3 were 
obtained from previously published procedures by Müller and Ito, respectively.82-83 
Deuterium was incorporated into the target compounds by the action of a Grignard 
reagent generated from deuterated methyl iodide (CD3I). Chemical reagents were 
purchased commercially, and most were used without further purification. Carbon 
disulfide, methyl iodide and (D3)-methyl iodide were purified by distillation immediately 







Figure 2.3.5 – Synthetic route toward iC5-d3 
Synthetic procedure for the preparation of deuterated isovaleric acid with proposed 




(Drierite®). All glassware that was used in reactions requiring dry solvents were flame-
Thin-layer chromatography (TLC) was carried out using Sorbent Technologies silica G 
w/UV254 TLC plates. All purified compounds of interest were visualized as single spots 
using short-wave UV light; more permanent staining of TLC spots was achieved using 
vanillin, p-anisaldehyde, bromothymol blue, or KMnO4 TLC staining solutions. 1H-NMR 
spectra were obtained on an Oxford 300 Mhz or Varian InNova 500 MHz instruments in 
solutions of CDCl3. Spectra of isolated compounds are cataloged in the appendix for 
chapter two. High resolution mass spectrometry (HRMS) data was obtained using a 







15-(methyl-d3)hexadecane-16,16,16-d3-1,15-diol (D6-iC17-diol; 2): To a stirring and 
chilled solution (-78 ˚C) of petadecanolide (1, 1.44 g, 6 mmol) in dry THF (40 mL) was 
added freshly generated D3-methlmagnesium iodide in Et2O (1 M, 20 mmol) dropwise via 
cannula. The resulting thick and chunky solution was allowed to warm to room 
temperature and stir for an additional 16 hours. At this time the reaction mixture was 
cooled to 0 ˚C and a saturated solution of NH4Cl was added to the slurry until all 
magnesium salts were dissolved and the pH of the biphasic mixture had reached a slight 
acidity (pH ~6.0). The organic layer was washed with brine (100 mL) and collected while 
the remaining aqueous solution was back-extracted with Et2O (3 x 50 mL). The pooled 
organic extracts were dried over anhydrous MgSO4, filtered, and concentrated in vacuo. 
Crude product was purified recrystallization by dissolution of the crude product in a 
solution of 9:1 [hexanes:EtOAc], and chilled in a -20 ˚C freezer overnight. Yield = 98%. TLC 
Rf = 0.17 (25% EtOAc/hexanes). HRMS (ESI-Orbitrap) m/z: [M+H]+ Calcd for C17H31D6O2, 
279.3165; found 279.3161. 1H-NMR (CDCl3, 300.08 MHz) δ 1.25 (br s, 22H), 1.41 (br s, 2H), 







15-(methyl-d3)hexadecan-16,16,16-d3-1-ol (D6-iC17-ol; 3): To a cool (0 ˚C) solution of 2 
(5.5 g, 20.19 mmol) and Et3SiH (6.45 mL, 40.4 mmmol) in dry DCM (40 mL) was added 
BF3•Et2O (24.93 mL, 202 mmol) in DCM (10 mL) dropwise via a dropping addition funnel. 
Once added, the reaction was allowed to stir for an additional 45 min at 0 ˚C. At this time 
the reaction mixture was diluted with ice-cold water (2 x 40 mL) and extracted with DCM 
(2 x 50 mL) The pooled organic solvent was washed with a saturated solution of NaHCO3. 
The organic layer was dried over anhydrous MgSO4, filtered, and concentrated in vacuo. 
Crude product was purified via normal-phase flash chromatography. Yield = 96%. TLC Rf = 
0.95 (10% Et2O/hexanes). HRMS (ESI-Orbitrap) m/z: [M+H]+ Calcd for C17H31D6O, 
263.3215; found 263.3125. 1H-NMR (CDCl3, 300.08 MHz) δ 1.12-1.16 (m, 2H), 1.26 (br s, 








4): The first step of this one-pot reaction sequence starts with NaH (60% dispersion in 
mineral oil, 1.73 g, 43.33 mmol) being added in one portion to a chilled (0 ˚C) solution of 
3 (4.44 g, 17.33 mmol) in dry THF (60 mL) and allowed to stir for 1 hour at this 
temperature. The next step forms the sodium dithiolate intermediate by slow addition of 
CS2 (1.57 mL, 26 mmol) via syringe to the cool (0 ˚C) reaction solution and is again allowed 
to proceed at this temperature for 1 hour. Formation of the methyldithiolate ester is 
accomplished by the addition of iodomethane (1.62 mL, 26 mmol) to the stirred reaction 
at 0 ˚C, which is then allowed to warm to room temperature naturally over the course of 
5 hours. At this time the reaction is quenched by the addition of a saturated solution of 
NH4Cl (70 mL) and extracted with EtOAc (3 x 100 mL). The organic layer was dried over 
anhydrous MgSO4, filtered, and concentrated in vacuo. The rusty-brown product was 
taken up in enough pentane to drop the viscosity of the oil and passed through a silica 
plug (95:5 [pentane:EtOAc]). The orange solution of product was again concentrated in 
vacuo and residual solvent removed on a strong vacuum manifold to give a bright orange 
oil in quantitative yield of sufficient purity to move forward. HRMS (ESI-Orbitrap) m/z: 
[M+H]+ Calcd for C19H33D6OS2 , 353.2813; found 353.2844. 1H-NMR (CDCl3, 300.08 MHz) 
δ 1.12-1.16 (m, 2H), 1.26 (br s, 20H), 1.38-1.42 (m, 2H), 1.46-1.50 (m, 1H), 1.77-1.83 (p, 







15-(methyl-d3)hexadec-1-ene-16,16,16-d3 (D6-iC17-alkene; 5): This reaction generates 
copious amounts of noxious methanethiol and carbonyl sulfide, which are mostly taken 
care of by way of a bleach-trap. Strong unpleasant odors will be generated throughout 
this procedure and all steps taken are to minimize exposure to these by-products. Caution 
should be taken during intense heating as too much heat can fracture glassware and 
create a considerable fire-risk as the gasses produced by this reaction are extremely 
flammable. 
 A flame-dried flask equipped with a water-cooled Allihn condenser was charged 
with an arbitrary amount of neat 4 and the closed system was evacuated and charged 
with argon several times. The joints of the glassware were wrapped with thick teflon tape 
and the exhaust path of the Schlenk manifold was equipped with a gas-drying bottle filled 
with store-bought bleach before heat was applied to the reaction flask. To begin, a Meker-
Fischer burner was lit, and gently waved under and around the reaction flask to warm the 
glass and prevent cracking during intense heating. Once the glassware was heated 
sufficiently, intense heating was concentrated on the lower portion of the flask to 
generate a reflux (~300 ˚C). Reaction completion is visually monitored by the loss of the 
orange color of 4 in the flask, of which the refluxing vapors adopt a yellow tint. When the 
reaction is finished, the refluxing vapor will be colorless and the neat product in the flask 
will be light yellow in color and charred (30-40 minutes intense heating for 8-10 g of 4). 
Once the flask has cooled enough to touch, the reflux condenser is switched out for a 
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flame-dried short-path distillation head equipped with a round-bottom receiving flask of 
appropriate size to accommodate purified product. The closed system is evacuated and 
charged with argon several times, then the product is distilled by gently heating the 
reaction mixture again with a Meker-Fischer burner to push the alkene to the receiving 
flask. Heating should continue till the remaining liquid in the distilling flask is a thick black 
oil that no longer distills alkene 5. At this time the pungent crude and faint yellow product 
is further purified via normal-phase flash chromatography with 100% pentane to give a 
clear and colorless oil 5 after solvent is removed. Yield = 89%. TLC Rf = 1.0 (100% pentane). 
HRMS (ESI-Orbitrap) m/z: [M-H]- Calcd for C17H27D6, 243.2964; found 243.2986. 1H-NMR 
(CDCl3, 300.08 MHz) δ 1.12-1.16 (m, 2H), 1.26 (br s, 20H), 1.35-1.39 (m, 2H), 1.46-1.49 (t, 





14-(methyl-d3)pentadecanoic-15,15,15-d3 acid (D6-iC16-FA; 6): To a 1 L flask equipped 
with a hefty stir bar is added a solution of 5 (2.0 g, 8.1 mmol) and Bu4NBr (1.92 g, 4.1 
mmol) in DCM and chilled to 0 ˚C with an ice/water bath. In a separate Erlenmeyer flask 
KMnO4 (6.4 g, 40.1 mmol) is fully dissolved in DI H2O (110 mL) and the homogenous 
solution was poured directly into the reaction flask. Finally, glacial acetic acid (23 mL) was 
added to the well-stirred biphasic system and was allowed to warm to room temperature 
and stir for 24 hours. The resultant dark brown sludge was chilled to 0 ˚C and acidified by 
the addition of a cold solution of HCl (5M, 110 mL). A saturated solution of Na2SO3 
(typically >500 mL) was added in small portions to this mixture with vigorous gas evolution 
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until the aqueous portion of the mixture appears slightly cloudy and colorless, with the 
organic layer being a clear pale-yellow solution. The organic layer was separated from the 
mixture, and the aqueous phase extracted with DCM (5 x 50 mL). The pooled organic 
solution was dried over anhydrous MgSO4, filtered, and concentrated in vacuo. Crude 
product was purified via normal-phase flash chromatography. Yield = 93%. TLC Rf = 0.76 
(78:20:2 [pentane:EtOAc:AcOH]). HRMS (ESI-Orbitrap) m/z: [M-H]- Calcd for C16H25D6O2, 
261.2706; found 261.2708. 1H-NMR (CDCl3, 300.08 MHz) δ 1.12-1.16 (m, 2H), 1.25 (br s, 





14-(methyl-d3)pentadecan-15,15,15-d3-1-ol (D6-iC16-ol; 7): A flame-dried round bottom 
flask equipped with a dropping addition funnel was charged with compound 6 (2.71 g, 
10.6 mmol) and 20 mL of dry THF was added to the starting material in the round bottom 
flask and chilled to 0 °C with an ice-water bath. 10 mL of dry THF was loaded into the 
dropping addition funnel along with BH3·SMe2 (1.21 mL, 12.8 mmol), and subsequently 
added dropwise to the chilled solution of 6 under an inert atmosphere. This reaction 
mixture was allowed to stir at this temperature for about 45 minutes, or until the 
cessation of gas evolution was observed. At this time, the reaction was warmed to room 
temperature and was stirred for an additional 12 hours. Once the reaction was complete, 
MeOH was added to the reaction mixture slowly to quench the remaining borane reagent. 
The crude solution was dried over anhydrous MgSO4, filtered, and concentrated in vacuo. 
Crude product was purified via normal-phase flash chromatography. Yield = 78%. TLC Rf = 
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0.95 (10% Et2O/hexanes). HRMS (ESI-Orbitrap) m/z: [M+H]+ Calcd for C16H29D6O, 
249.3059; found 249.3068. 1H-NMR (CDCl3, 300.08 MHz) δ 1.12-1.16 (m, 2H), 1.26 (br s, 





S-methyl O-(14-(methyl-d3)pentadecyl-15,15,15-d3) carbonodithioate (D6-iC16-
xanthate; 8): Refer to the procedure used to generate compound 4 using the same molar 
equivalents of reagents and relative solvent ratios to amount of starting material. The 
rusty-brown product 8 was taken up in enough pentane to drop the viscosity of the oil 
and passed through a silica plug (95:5 [pentane:EtOAc]). The orange solution of product 
was again concentrated in vacuo and residual solvent removed on a strong vacuum 
manifold to give the bright orange oil 8 in quantitative yield of sufficient purity to move 








14-(methyl-d3)pentadec-1-ene-15,15,15-d3 (D6-iC16-alkene; 9): Refer to the procedure 
used to generate compound 5 using the same molar equivalents of reagents and relative 
solvent ratios to amount of starting material. The pungent crude and faint yellow product 
9 is further purified via normal-phase flash chromatography with 100% pentane to give a 
clear and colorless oil 9 after solvent is removed. Yield = 89%. TLC Rf = 1.0 (100% pentane). 
HRMS (ESI-Orbitrap) m/z: [M-H]- Calcd for C16H25D6, 229.2808; found 229.2810. 1H-NMR 
(CDCl3, 300.08 MHz) δ 1.11-115 (m, 2H), 1.25 (br s, 16H), 1.34-1.39 (m, 2H) 1.45-1.49 (t, 




13-(methyl-d3)tetradecanoic-14,14,14-d3 acid (D6-iC15-FA; 10): Refer to the procedure 
used to generate compound 6 using the same molar equivalents and relative solvent 
ratios. Crude product 10 was purified via normal-phase flash chromatography. Yield = 
96%. TLC Rf = 0.68 (78:20:2 [pentane:EtOAc:AcOH]). HRMS (DART) m/z: [M-H]- Calcd for 
C15H23D6O2, 247.2550; found 247.2553. 1H-NMR (CDCl3, 499.73 MHz) δ 1.12-1.17 (m, 2H), 







3-methylbutanoic-4,4,4-d3 acid (D3-iC5-FA; 12): To a 3 L flame-dried 3-neck flask 
equipped with a mechanical stirring rod was added anhydrous copper(I) iodide (32.6 g, 
171 mmol) followed by freshly distilled CS2 (80 mL, 1.32 mol), which was allowed to 
dissolve fully before addition of dry THF (800 mL) all under an inert atmosphere. This clear 
yellow solution was chilled to -78 ˚C and a freshly generated solution of D3MeMgI in Et2O 
(3.4 M, 100 mL) was added dropwise via cannula, which produced a fairly viscous and 
cloudy yellow slurry of the diorganocuprate intermediate. This solution was warmed to -
40 ˚C and allowed to stir for an additional 30 minutes prior to addition of electrophile. At 
this time the reaction was kept at -40˚C during addition of lactone 11 (12.7 mL, 156 mmol), 
which was added dropwise via syringe. During addition of the lactone, the yellow color 
subsided very minimally, and this mixture was allowed to naturally warm to room 
temperature overnight with constant vigorous stirring.  
 Overnight the cloudy solution had turned a gnarly deep brown color with a rancid 
odor of isovaleric acid. The reaction was quenched by the addition of copious amounts of 
a saturated solution of NH4Cl until slightly acidic (pH ~ 6.0), which gave a biphasic system 
consisting of a rusty orange organic phase and a deep blue aqueous phase. The layers 
were separated, the organic phase was filtered first through a paper filter covered with 
sand to remove most of the insoluble Mg/Cu salts, and then filtered again through a plug 
of Celite™ 545 filter aid. The clear organic solution was again washed with NH4Cl to 
remove any residual copper species indicated by the blue Cu-NH4 complex, washed with 
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brine, dried over anhydrous MgSO4, filtered, and concentrated in vacuo. Crude product 
was purified via fractional distillation through a glass bead-packed fractionation column. 
Inseparable by-product of crotonoic acid was reduced to isovaleric acid with Pd/C under 
1 atm of H2 for 3-hours. Yield = 44%. HRMS (ESI-Orbitrap) m/z: [M-H]- Calcd for C5H6D3O2, 
104.0796; found 104.0782. 1H-NMR (CDCl3, 499.73 MHz) δ 0.96-0.98 (d, 3H), 2.05-2.12 (q, 
1H), 2.21-2.23 (d, 2H). 
2.4.2 – Cell culturing and biological incorporation of tracing lipids 
 The procedure for culturing of M. xanthus cells was provided by Dr. Tye O’hara 
Boynton of the Shimkets group and began with growing 20 mL cultures overnight in CYE 
broth (1% casitone, 0.5% yeast extract, 0.1% MgSO4, and 10 mM MOPS) at 32 ˚C. Each 
culture was poured into its own respective 1 L of CYE broth and incubated further until 
the culture reached an optical density (OD) of ~3 x 108 cells/mL. These inoculated broths 
were centrifuged at 10,000 RPM for 10 minutes, then the large cell pellet was 
resuspended in fresh CYE broth until an OD of 5 x 109 cells/mL was reached. At this point 
8 mL of culture was spread onto 500 mL of TPM agar (10mM Tris-HCl, 8mM MgSO4, 1mM 
potassium phosphate buffer @ pH = 7.6, 1.5% agar) and allowed to absorb to dryness, 
then covered and incubated at 32 ˚C for 24 hours. This was the procedure for growing the 
control samples for lipid analysis. For supplemented cultures of M. xanthus synthetic 
lipids or synthetic isotope tracing lipids were introduced during the last step by including 
the lipids in the TPM agar at a fairly high concentration (100 µM) to ensure suitable 
cellular uptake. 
2.4.3 – Lipid extraction, preparative TLC, and sample preparation 
 Lipids were extracted following a method developed and provided by Shimkets 
and co-workers. From the previous culturing procedure (section 2.4.2), cell cultures from 
the TPM plates that had been incubated for 24 hours were harvested into a 50 mL conical 
tube, two 500 mL plates per tube. At this time harvested cells were resuspended in 6 mL 
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of Milli-Q H2O and then 22.5 mL of a [1:2] mixture of CHCl3:MeOH was added to the tube, 
vortexed for three minutes and chilled on ice for 1 hour. After chilling, an additional 6 mL 
of CHCl3 was added and vortexed for 1 minute, then a 6 mL portion of Milli-Q H2O was 
added to the tube and vortexed for another minute. The extraction mixture was then 
centrifuged at 10,000 RPM for 10 minutes to separate the biphasic mixture and the 
organic phase was collected into a separate glass container and the solvent was removed 
under a stream of nitrogen. Dried lipids were re-dissolved in a [1:2] mixture of 
CHCl3:MeOH and quantitatively transferred to a clean and pre-weighed glass vial. Solvent 
was again removed under a stream of nitrogen and the dried lipid samples were weighed 
prior to storage in a -80 ˚C freezer. 
 These whole-cell extracts were further fractionated to isolate the lipid species 
present in the sample from other chloroform-soluble metabolites and proteinaceous cell 
components following a procedure previously published by Hamilton and Comai.85 It 
should be noted that this procedure separated lipids into different lipid classes, but the 
lipid fractions collected at the end of this procedure were pooled and sent to the BSMMSC 
for total lipid analysis. This procedure was also used to isolate partial glycerides for 
preparative TLC, so this procedure served a dual-purpose. Breifly, the lipid fraction of 
whole-cell extracts was achieved using prepacked silica Sep-pak columns (Supelco; 
Supelclean LC-Si SPE; 12 ml; 2 g) by the following procedure. Preparation of a Sep-pac 
column for cell extract fractionation began with washing the column with 16 mL of a 
[96:4] mixture of n-hexane:MTBE followed by 48 mL of n-hexane. A 10 mg portion of 
whole-cell lipid extract was dissolved in 16 mL of a [200:3] n-hexane:MTBE mixture and 
loaded onto the prepared Sep-pak column. Ether lipids were eluted as the first fraction 
by passing 40 mL of [200:3] n-hexane:MTBE through the lipid-loaded column. 
Triglycerides were eluted in the second fraction by passing 48 mL of [96:4] n-
hexane:MTBE through the column. Free fatty acids were eluted in the third fraction by 
first acidifying the loaded column with 40 mL of [100:0.2] n-hexane:AcOH then by passing 
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48 mL of [100:2:0.2] n-hexane:MTBE:AcOH through the column. Monoacyl- and diacyl-
glycerides were eluted in the fourth fraction by passing 48 mL of [100:0.2] MTBE:AcOH 
through the column. The fifth and final fraction eluted from the column contained a 
mixture of phospholipids and xanthene compounds by passing 48 mL of [100:4:1] 
MTBE:methanol:(1 mM NH4OAc). For total lipid analysis these separated lipid fractions 
were pooled and dried under a stream of nitrogen prior to storage at -20 ˚C. 
 Preparative TLC was performed on partial glycerides isolated as fraction four by 
the previous procedure. Normal-phase silica TLC plates were spotted with partial 
glycerides dissolved in [2:1] CHCl3:MeOH and spotted on the TLC plates. Once dry, the 
plates were run with freshly prepared [85:15:5] toluene:CHCl3:MeOH and visualized with 
transient iodine vapor staining. Five lipid fractions (Rf = 0.20, 0.24, 0.29, 0.35, and 0.42) 
from this separation were found to restore fruiting body formation in sp. LS1191 by 
extracellular complementation, were extracted from preparative TLC plate and submitted 
to the BSMMSC for lipidomic analysis. All lipid samples were prepared in the same manner 
prior to lipidomic analysis. For LCMS analysis 10-15 mg of extracted lipid were weighed 
into 1-dram glass vials, resuspended in 300 µL of [9:1] CHCl3:MeOH and sonicated briefly 
to ensure total dissolution. These dissolved lipid samples were centrifuged at 13,000 RPM 
for 5 minutes, quantitatively transferred to autosampler vials and subjected to lipidomic 
analysis.   
2.4.4 – LC-HRMS method 
 The data was collected on an Exactive Plus Orbitrap mass spectrometer with an 
electrospray ionization (ESI) source coupled with an Ultimate3000 ultra high-performance 
liquid chromatography (UHPLC) system (Thermo Fischer Scientific, Pittsburgh, PA). 
Separations were performed on a Kinetex HILIC HPLC column (150×2.1 mm, 2.6 mm) 
(Phenomenex, Torrance, CA, USA) maintained at 25 °C. Mobile phase A was 10 mM 
ammonium formate adjusted with formic acid to pH = 3 and Mobile phase B was 93/7 
(v/v) ACN/10 mM ammonium formate with the aqueous portion of the mixture adjusted 
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with formic acid to pH = 3. The flow rate was 0.2 mL/min and the mobile phase gradient 
used was 0-1 min 100% B, 1-15 min 100-81% B, 15.1-25 min 48% B, 25.1-35 min 100% B. 
The injection volume was 10 μL for each sample, which was kept at 4 °C for the entire 
analysis. The ESI parameters were as follows; scan range 100-1500 m/z, resolution 
140,000, AGC target 3.0 x 106, MaxIT of 200 ms, sheath gas flow rate 25 units, aux gas 
flow rate 10 units, spray voltage ±4.0 kV, and capillary temperature 350 °C. The mass 
spectrometry method was operated in both positive and negative mode using full scan 
analysis for each sample, once per ionization mode, for a total run-time of 1 hour and 10 
minutes per sample. 
2.4.5 – Data analysis 
 Untargeted lipidomics data was analyzed using a MAVEN, which is an open-source 
program used to generate extracted ion chromatograms (EIC) and align samples 
according to retention time. MAVEN is capable of compiling a list of chromatographic 
peaks based on a set of parameters which determine how selective the program is in the 
peaks it extracts from the total ion chromatogram (TIC). This feature is used to gather 
potentially meaningful data within a sample set in an untargeted fashion. A pseudo-
targeted approach to analyzing this data uses a pre-generated list of chemical formulas, 
which provide the program with exact masses to extract chromatographic peaks from the 
data generated by the mass spectrometer. The list used for the targeted method was 
adopted from a previously published study by Dr. Helge B. Bode, which detailed a 
comprehensive list of lipids found in wild-type M. xanthus.80 This exhaustive and 
comprehensive list of lipids and their relative abundance in M. xanthus was used to mine 
the data obtained from this lipidomics study to determine what lipid species were 
significantly different between the experimental groups. 
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2.5 – Conclusion 
 The initial goal of investigating lipids produced during starvation-induced 
sporulation in M. xanthus was to determine what molecule(s) were responsible for the 
initiation of fruiting body formation in this microbial system. Differences in the lipid 
profile between wild-type and mutant cell lines did not provide strong evidence that 
pointed to a single compound or class of compounds that could explain this phenotypic 
difference; Although, it was apparent that the wild-type strain DK1622 was better-able to 
produce larger total quantities of lipids than their mutant counterpart, strain LS1191. The 
relative ratios of detected lipid species were similar between these experimental groups. 
This finding was not sufficient to explain why LS1191 did not produce lipid-bodies under 
nutrient limitation. Being that LS1191 is a strain deficient in the production of branched-
chain lipids, it could be that the structural attributes of the lipids produced in this mutant 
were contributing to the lack of a successful sporulation event. Due to the large 
abundance of isolipid species in M. xanthus, especially isoC15:0, this led to the idea that 
the presence of certain lipid(s) that contained an isopropyl moiety may be the 
determining factor in initiating fruiting body formation; However, these isolipids have 
many isobaric counterparts with differing degrees of tail branching or lack-there-of. The 
isotope tracing experiments devised to mitigate this issue were quite successful in terms 
of allowing for the biological generation of isotopically labeled isolipids in LS1191 to be 
compared against lipids identified in DK1622. In a parallel complementation study headed 
by the lab of Dr. Shimkets, preparative TLC fractions of whole-cell lipid extracts were 
assayed for their ability to restore fruiting body formation in LS1191, but their findings 
showed that several separate TLC fractions were able to restore sporulation behavior in 
the mutant strain. Analysis of these fractions by LCMS again showed that the lipid profiles 
between TLC fractions that did not result in fruiting bodies and the fractions that did 
encourage fruiting body production were very similar in relative ratios of lipids but 
showed different concentrations of lipids being contained within those fractions. It was 
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then thought that the unknown lipid(s) that could be initiators of fruiting body formation 
maybe some previously unobserved lipid species that contained the isolipid structural 
feature, and could be mined from the unannotated LCMS data, or what is referred to as 
the “unknowns”. From here, a lipid tracer study was implemented to make identification 
of these possible unknown compounds much more achievable. 
 The first labeling study attempted to incorporate an isotopically labeled synthetic 
lipid, isoC15-d6, which was intended to be taken up directly by starving M. xanthus cells 
and directly used to make the signaling lipid(s) thought to contain at least one isoC15 tail. 
The uptake of this lipid was not ideal, and lead to a dearth of isotope signal in the wild-
type and mutant cultures. This was likely caused by the innate hydrophobicity of the lipid 
tag, which lead to poor cellular uptake, and ultimately a lack of isotope incorporation into 
biogenic lipids. To get around this issue of poor cellular uptake of the isotope tracer, it 
was postulated that incorporation of a much smaller, more permeable, and 
biosynthetically more useful lipid synthon to the organism could be used. While keeping 
the chemistries of synthesizing the isotopically labeled isopropyl moiety similar to that in 
the strategy of that for isoC15-d6 by using a D3-methyl Grignard reagent, isovaleric acid 
became the synthetic target for the new isotope tracer. LCMS analysis of the lipid fraction 
of whole-cell extracts from M. xanthus strains DK1622 and LS1191 following 
supplementation with iC5-d3 showed a high-level of incorporation of the D3 isotope signal. 
This allowed for the distinction of what mass features contained a terminal isopropyl unit, 
but also made the task of determining the lipids that may initiate sporulation to be a 
daunting task, especially when considering the unknown mass features present in the 
sample. This finding though that the organisms incorporated the isolipids tracer into so 
many things was not unlikely since this organism has been previously shown to survive 
quite well without the ability to make straight-chain lipids. Dr. Helge B. Bode had shown 
that a mutant of M. xanthus that could not build its own straight-chain lipids shifted 
practically all lipid production to that of branched-chain lipids with no observable changes 
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in morphology or behavioral phenotype.81 Because of this, the LS1191 mutant that could 
not make its own branched chain lipids from amino acids proved to be quite effective in 
a proof-of-concept microbe for testing the incorporation of deuterated isovaleric acid into 
the organisms lipidome. 
 A single lipid, or class of lipids, responsible for fruiting body formation was not 
identified by either isotope tracing, or complementation assays of preparative TLC 
fractions. Due to the complexity of lipid fractions that prompted this phenotypic response 
by complementation studies, and the promiscuity of the iC5-d3 isotope tracer, the focus 
of the project quickly shifted toward exploiting iC5-d3 as a means to differentiate straight-
chain lipids from isobars containing a terminal isopropyl unit. This was verified by 
identifying specific labeling of homospermidine lipids produced during fruiting body 
formation, corroborating the findings of Müller and co-workers. 
 The work presented in this chapter describes the utility of isotope tracing in 
lipidomic analyses of complex biological samples using LCMS instrumentation. Through 
this work it has been found that there are clear advantages in using small polar lipids as 
an isotope tracer even when the target lipids species are larger molecules. The author has 
presented an isotope-tracing experiment for detecting compounds in a typical lipidomic 
analysis to differentiate straight-chain lipid species from isobaric congeners containing a 
terminal isopropyl moiety. These isobaric species are difficult to separate 
chromatographically and/or differentiate in the mass-domain without the use of hard-
ionization sources to induce characteristic fragmentation. This method of feeding 
bacterial cultures iC5-d3 has an important application for those undertaking LCMS 
analyses of biological systems, since a large and diverse pool of biogenic lipids can be 
derived from isovaleric acid. The results from an experiment such as this would illuminate 
mass features that contain terminal isopropyl units, while the task of determining the 
exact structure of the parent molecule would still need considerable work in determining 
the precise chemical formula and exact structure of the detected compound.
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2.6 – Chapter II appendix 
Table 2.6.1 – Table of Bode lipidomics data (DK1622 vs LS1191) 
Shown below is a table of detected masses representative of lipid species that are known 
to be present in wild-type M. xanthus DK1622.80 
Potential Compound 
RT Molecular Detected Ion Counts 
p-value 
(min) Species Mass (m/z) DK1622 LS1191 
Cer(d19:0/16:0) 1.6 [M+H]+ 554.5506 4.06E+06 2.35E+07 4.93E-04 
Cer(d19:0/i17:0 2-OH) 1.6 [M+H]+ 584.5613 8.27E+06 7.49E+07 3.36E-04 
Cer(d19:0/i17:0) 1.7 [M+H]+ 568.5665 9.30E+06 1.32E+08 1.04E-04 
CerPI(d19:0/16:0 2-OH) 12.0 [M+H]+ 812.5635 4.14E+06 3.17E+06 4.76E-02 
CerPI(d19:0/16:0) 10.9 [M+H]+ 796.5689 3.05E+06 2.79E+06 6.27E-01 
Cer-PI(D19:0/i17:0 2-OH) 11.9 [M+H]+ 826.5796 1.23E+07 5.66E+06 1.96E-03 
CerPI(D19:0/i17:0) 11.9 [M+H]+ 810.5851 8.41E+06 4.23E+06 4.19E-03 
CL(60:0) 9.7 [M+H]+ 1297.924 4.16E+06 2.45E+06 5.72E-02 
CL(60:1) 9.9 [M+H]+ 1295.906 9.31E+05 9.75E+05 8.12E-01 
CL(60:2) 9.9 [M+H]+ 1293.892 1.22E+05 1.55E+05 4.15E-01 
CL(60:3) - -   - - - 
CL(61:1) 9.5 [M+H]+ 1309.922 1.82E+06 2.82E+06 3.39E-02 
CL(61:2) 9.8 [M+H]+ 1307.909 5.90E+05 7.25E+05 4.48E-02 
CL(61:3) 9.7 [M+H]+ 1305.893 9.12E+04 1.48E+05 1.88E-02 
CL(61:4) - -   - - - 
CL(62:0) 9.8 [M+H]+ 1325.952 1.08E+07 9.36E+06 1.86E-01 
CL(62:1) 9.4 [M+H]+ 1323.938 3.97E+06 6.20E+06 7.98E-04 
CL(62:2) 9.6 [M+H]+ 1321.923 1.62E+06 2.65E+06 6.27E-03 
CL(62:3) 9.3 [M+H]+ 1319.908 3.61E+05 7.60E+05 3.81E-03 
CL(62:4) 9.2 [M+H]+ 1317.893 5.26E+04 9.65E+04 1.33E-01 
CL(62:5) - -   - - - 
CL(63:0) 9.4 [M+H]+ 1339.968 1.06E+07 8.58E+06 1.16E-01 
CL(63:1) 9.6 [M+H]+ 1337.954 6.72E+06 8.58E+06 4.99E-02 
CL(63:2) 9.2 [M+H]+ 1335.939 3.24E+06 5.80E+06 1.53E-03 
CL(63:3) 9.6 [M+H]+ 1333.925 1.21E+06 2.56E+06 7.99E-04 
CL(63:4) 9.5 [M+H]+ 1331.91 2.74E+05 4.69E+05 2.38E-02 
CL(63:5) - -   - - - 
CL(64:0) 9.6 [M+H]+ 1353.98 3.54E+06 5.74E+06 4.27E-03 
CL(64:1) 9.7 [M+H]+ 1351.97 7.28E+06 8.64E+06 8.06E-02 
CL(64:2) 9.4 [M+H]+ 1349.953 4.76E+06 7.90E+06 8.55E-05 
CL(64:3) 9.5 [M+H]+ 1347.94 2.57E+06 5.05E+06 5.59E-04 
CL(64:4) 9.5 [M+H]+ 1345.922 8.10E+05 1.58E+06 2.87E-03 
CL(64:5) 9.5 [M+H]+ 1343.909 1.89E+05 2.63E+05 1.32E-01 
CL(64:6) - -  - - - 
CL(65:1) 9.5 [M+H]+ 1365.982 2.45E+06 5.98E+06 3.94E-04 
CL(65:2) 9.4 [M+H]+ 1363.97 3.65E+06 6.74E+06 9.91E-03 
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Table 2.6.1 (continued) 
Potential Compound 
RT Molecular Detected Ion Counts 
p-value 
(min) Species Mass (m/z) DK1622 LS1191 
CL(65:3) 9.6 [M+H]+ 1361.958 2.98E+06 5.67E+06 6.11E-03 
CL(66:1) 9.8 [M+H]+ 1380.003 9.77E+05 2.87E+06 8.48E-04 
CL(66:2) 9.7 [M+H]+ 1377.988 1.72E+06 4.06E+06 2.12E-04 
DG(30:0) 1.6 [M+NH4]+ 558.5092 3.49E+06 1.90E+06 2.48E-02 
DG(31:1) 1.6 [M+NH4]+ 570.5092 5.31E+05 1.18E+06 1.45E-02 
DG(32:0) 1.7 [M+NH4]+ 586.5405 3.45E+05 1.20E+06 5.77E-05 
DG(32:2) 1.6 [M+NH4]+ 582.5092 4.45E+05 2.67E+06 1.19E-05 
DG(33:0) 1.7 [M+NH4]+ 600.5561 6.45E+05 4.32E+06 2.85E-07 
DG(33:1) 1.6 [M+NH4]+ 598.5405 2.58E+05 4.28E+05 1.40E-02 
DG(33:2) 1.6 [M+NH4]+ 596.5248 2.37E+05 8.81E+05 1.03E-04 
PE(28:0) 9.6 [M+H]+ 636.459 3.89E+07 2.58E+07 5.67E-02 
PE(28:1) 10.0 [M+H]+ 634.4438 8.19E+06 9.56E+06 6.36E-01 
PE(28:2) 9.3 [M+H]+ 632.4258 1.87E+06 1.37E+06 2.09E-01 
PE(29:0) 9.6 [M+H]+ 650.475 1.97E+08 9.36E+07 1.77E-02 
PE(29:1) 9.9 [M+H]+ 648.4591 5.34E+07 5.11E+07 5.33E-01 
PE(29:2) 9.5 [M+H]+ 646.4433 6.62E+06 7.05E+06 6.12E-01 
PE(30:0) 10.0 [M+H]+ 664.4906 3.12E+08 1.51E+08 2.25E-03 
PE(30:1) 8.1 [M+H]+ 662.4734 8.31E+07 1.37E+08 8.19E-04 
PE(30:2) 9.4 [M+H]+ 660.4596 2.49E+07 5.03E+07 7.26E-04 
PE(30:3) 9.6 [M+H]+ 658.4434 3.30E+06 3.65E+06 2.03E-01 
PE(31:0) 9.9 [M+H]+ 678.5056 7.36E+06 7.05E+07 2.11E-03 
PE(31:1) 9.5 [M+H]+ 676.4907 1.20E+08 1.41E+08 1.05E-01 
PE(31:2) 9.7 [M+H]+ 674.4752 7.04E+07 1.09E+08 1.11E-02 
PE(31:3) 9.5 [M+H]+ 672.4574 1.75E+07 2.50E+07 2.56E-02 
PE(31:4) 9.5 [M+H]+ 670.4428 1.14E+06 1.03E+06 2.32E-01 
PE(32:0) 10.0 [M+H]+ 692.5217 2.61E+07 3.15E+07 2.58E-01 
PE(32:1) 9.6 [M+H]+ 690.5069 1.95E+07 7.77E+07 1.16E-03 
PE(32:2) 9.5 [M+H]+ 688.4913 9.11E+07 1.37E+08 3.06E-02 
PE(32:3) 9.6 [M+H]+ 686.4743 5.43E+07 4.92E+07 3.76E-01 
PE(32:4) 9.6 [M+H]+ 684.4586 1.31E+07 7.98E+06 2.92E-02 
PE(33:0) 9.4 [M+H]+ 706.5372 7.85E+05 6.89E+06 2.47E-02 
PE(33:1) 9.6 [M+H]+ 704.5215 1.47E+07 1.54E+07 7.37E-01 
PE(33:2) 8.4 [M+H]+ 702.5044 2.58E+07 1.64E+07 2.22E-03 
PE(33:3) 9.2 [M+H]+ 700.4893 3.40E+07 9.88E+06 2.20E-05 
PE(33:4) 9.2 [M+H]+ 698.4742 1.69E+07 2.76E+06 3.25E-03 
PE(34:0) 9.4 [M+H]+ 720.5526 7.60E+05 1.29E+06 1.20E-01 
PE(34:1) 9.5 [M+H]+ 718.5378 1.92E+06 9.78E+05 3.88E-03 
PE(34:2) 8.2 [M+H]+ 716.5219 4.31E+06 1.66E+06 2.02E-03 
PE(34:3) 9.2 [M+H]+ 714.5054 7.21E+06 1.64E+06 3.77E-03 
PE(34:4) 9.3 [M+H]+ 712.4892 5.08E+06 1.93E+06 4.56E-04 
PE(P-30:0) 9.5 [M+H]+ 648.4957 8.46E+07 2.96E+06 2.54E-02 




Table 2.6.1 (continued) 
Potential Compound 
RT Molecular Detected Ion Counts 
p-value 
(min) Species Mass (m/z) DK1622 LS1191 
PG(29:0) 5.1 [M+H]+ 681.4681 1.73E+06 5.41E+05 2.72E-04 
PG(30:0) 5.6 [M+H]+ 695.4847 2.88E+06 1.50E+06 1.59E-05 
PG(30:1) 5.1 [M+H]+ 693.469 1.49E+06 1.66E+06 5.84E-02 
PG(31:1) 4.2 [M+H]+ 707.4837 2.34E+06 3.64E+06 3.96E-03 
PG(31:2) 4.3 [M+H]+ 705.4707 8.95E+05 9.23E+05 6.87E-01 
PG(32:1) 3.8 [M+H]+ 721.5027 1.46E+06 3.34E+06 7.66E-06 
PG(32:2) 4.4 [M+H]+ 719.4869 2.80E+06 1.70E+06 4.49E-04 
PG(32:3) 5.4 [M+H]+ 717.4675 5.74E+05 2.83E+05 1.02E-02 
PG(33:0) 3.5 [M+H]+ 737.5277 - 3.73E+04 2.01E-01 
PG(33:1) 4.5 [M+H]+ 735.5156 1.48E+06 8.20E+05 7.06E-06 
PG(33:2) 5.0 [M+H]+ 733.4995 6.47E+05 1.70E+05 5.12E-05 
PG(34:0) 5.7 [M+H]+ 751.5456 0.00E+00 3.21E+03 9.15E-02 
PG(34:1) 5.2 [M+H]+ 749.5319 5.72E+04 1.48E+04 3.02E-02 
TG(38:1) 1.6 [M+NH4]+ 782.7232 9.28E+06 2.98E+06 5.10E-02 
TG(39:0) 1.6 [M+NH4]+ 684.6136 7.50E+05 2.68E+05 5.17E-03 
TG(39:1) 1.5 [M+NH4]+ 698.6293 7.11E+05 2.60E+05 2.36E-03 
TG(40:1) 1.5 [M+NH4]+ 696.6136 2.48E+05 2.16E+05 2.49E-01 
TG(40:2) 1.5 [M+NH4]+ 710.6293 4.89E+05 2.89E+05 5.02E-02 
TG(41:1) 1.5 [M+NH4]+ 708.6136 2.13E+05 1.26E+05 7.66E-02 
TG(41:2) 1.5 [M+NH4]+ 724.645 6.32E+05 5.07E+05 3.97E-04 
TG(41:3) 1.5 [M+NH4]+ 722.6293 2.56E+05 2.21E+05 3.59E-01 
TG(42:1) 1.5 [M+NH4]+ 720.6136 5.39E+04 3.66E+04 2.68E-01 
TG(42:2) 1.5 [M+NH4]+ 738.6606 1.47E+06 8.97E+05 3.50E-02 
TG(43:0) 1.5 [M+NH4]+ 736.6449 5.05E+05 4.42E+05 1.95E-01 
TG(43:1) 1.5 [M+NH4]+ 754.6919 5.64E+06 1.54E+06 4.52E-03 
TG(43:2) 1.7 [M+NH4]+ 752.6762 2.35E+06 1.74E+06 6.17E-02 
TG(43:3) 1.5 [M+NH4]+ 750.6606 9.26E+05 8.28E+05 5.46E-02 
TG(44:0) 1.5 [M+NH4]+ 748.6449 2.08E+05 1.97E+05 4.04E-01 
TG(44:1) 1.6 [M+NH4]+ 768.7075 8.04E+06 2.08E+06 2.82E-02 
TG(44:2) 1.5 [M+NH4]+ 766.6919 4.65E+06 2.50E+06 2.82E-03 
TG(44:3) 1.6 [M+NH4]+ 764.6762 2.00E+06 1.53E+06 9.29E-03 
TG(44:4) 1.5 [M+NH4]+ 762.6606 4.45E+05 4.40E+05 8.74E-01 
TG(45:0) 1.5 [M+NH4]+ 760.6449 7.71E+04 7.86E+04 8.88E-01 
TG(45:1) 1.5 [M+NH4]+ 780.7075 5.46E+06 3.82E+06 1.99E-01 
TG(45:2) 1.5 [M+NH4]+ 778.6919 2.77E+06 2.19E+06 2.44E-02 
TG(45:3) 1.6 [M+NH4]+ 776.6762 8.28E+05 6.81E+05 2.38E-02 
TG(45:4) 1.5 [M+NH4]+ 774.6606 1.62E+05 1.38E+05 1.55E-01 
TG(46:0) 1.7 [M+NH4]+ 796.7389 3.41E+06 2.87E+06 3.58E-01 
TG(46:1) 1.6 [M+NH4]+ 794.7232 3.79E+06 3.66E+06 8.64E-01 
TG(46:2) 1.6 [M+NH4]+ 792.7075 3.64E+06 2.33E+06 5.81E-03 
TG(46:3) 1.5 [M+NH4]+ 790.6919 1.17E+06 9.02E+05 1.03E-02 




Table 2.6.1 (continued) 
Potential Compound 
RT Molecular Detected Ion Counts 
p-value 
(min) Species Mass (m/z) DK1622 LS1191 
TG(47:1) 1.5 [M+NH4]+ 808.7388 1.58E+06 2.33E+06 1.69E-01 
TG(47:2) 1.6 [M+NH4]+ 806.7232 2.16E+06 1.65E+06 3.99E-02 
TG(47:3) 1.5 [M+NH4]+ 804.7075 9.57E+05 7.89E+05 5.90E-02 
TG(47:4) 1.5 [M+NH4]+ 802.6919 3.14E+05 2.31E+05 2.35E-02 
TG(48:0) 1.9 [M+NH4]+ 824.7701 9.59E+05 1.46E+06 4.49E-01 
TG(48:1) 1.8 [M+NH4]+ 822.7545 7.00E+05 1.07E+06 7.76E-02 
TG(48:2) 1.6 [M+NH4]+ 820.7388 9.18E+05 8.16E+05 5.95E-01 
TG(48:3) 1.6 [M+NH4]+ 818.7232 6.33E+05 4.37E+05 2.56E-02 
TG(48:4) 1.5 [M+NH4]+ 816.7075 2.49E+05 1.43E+05 4.73E-03 
TG(49:0) 2.2 [M+NH4]+ 838.7858 6.39E+05 6.07E+05 8.82E-01 
TG(49:1) 1.6 [M+NH4]+ 836.7701 2.99E+05 3.63E+05 3.64E-01 
TG(49:2) 1.5 [M+NH4]+ 834.7545 3.47E+05 2.32E+05 1.71E-01 
TG(50:0) 2.2 [M+NH4]+ 852.8014 1.99E+05 1.47E+05 3.63E-01 
TG(50:1) 1.8 [M+NH4]+ 850.7858 1.79E+05 8.81E+04 5.29E-02 
TG(51:0) 2.0 [M+NH4]+ 866.8171 5.91E+04 2.10E+04 1.99E-01 
TG(51:1) 2.0 [M+NH4]+ 864.8014 6.13E+04 9.00E+03 9.61E-02 





Table 2.6.2 – Table of lipidomics data showing incorporation of iC5-d3 
Shown below are the signal intensities for the potential lipid species known to be present 
in M. xanthus DK1622.80 Lipid species that were tagged with the iC5-d3 isotope tracer are 
annotated as detected in the iC5-d3-doped LS1191 sample by a checkmark. Intensities for 
the tagged lipid species are not detailed. 
Potential Compound 
Control IVA Suppl. HIVA Suppl. 2H in LS1191-HIVA 
Ion Counts Ion Counts Ion Counts 
D3 D6 D9 D12 
DK1622 LS1191 DK1622 LS1191 DK1622 LS1191 
Cer(d19:0/16:0) 2.36E+07 1.76E+08 6.50E+06 4.10E+07 1.55E+07 8.17E+06 ✔ ✔ - - 
Cer(d19:0/i17:0 2-OH) 6.08E+07 7.95E+08 1.36E+07 1.14E+08 4.89E+07 9.47E+06 ✔ ✔ - - 
Cer(d19:0/i17:0) 5.44E+07 1.09E+09 1.22E+07 1.33E+08 5.65E+07 9.18E+06 ✔ ✔ - - 
CerPI(d19:0/16:0 2-
OH) 
3.40E+08 4.02E+08 3.01E+08 1.97E+08 1.88E+08 - ✔ ✔ - - 
CerPI(d19:0/16:0) 1.78E+08 2.67E+08 1.58E+08 1.79E+08 1.68E+08 2.97E+07 ✔ ✔ - - 
Cer-PI(D19:0/i17:0 2-
OH) 
8.89E+08 8.84E+08 7.45E+08 6.21E+08 6.52E+08 2.59E+07 ✔ ✔ - - 
CerPI(D19:0/i17:0) 3.09E+08 3.88E+08 2.54E+08 4.06E+08 4.25E+08 1.11E+07 ✔ - - - 
CL(60:0) 4.02E+07 2.13E+07 6.39E+07 6.29E+07 3.75E+07 2.52E+06 ✔ ✔ ✔ ✔ 
CL(60:1) 1.35E+07 1.08E+07 2.61E+07 3.82E+07 1.40E+07 4.32E+05 ✔ ✔ ✔ ✔ 
CL(60:2) 2.27E+06 2.45E+06 5.12E+06 9.13E+06 2.67E+06 1.73E+05 ✔ ✔ ✔ ✔ 
CL(60:3) - - - - - - ✔ ✔ - - 
CL(61:1) 4.85E+07 4.73E+07 6.76E+07 7.50E+07 5.18E+07 3.33E+06 ✔ ✔ ✔ ✔ 
CL(61:2) 1.32E+07 1.95E+07 2.22E+07 2.58E+07 1.50E+07 1.01E+06 ✔ ✔ ✔ ✔ 
CL(61:3) 1.39E+06 2.97E+06 3.82E+06 6.73E+06 1.89E+06 1.71E+05 ✔ ✔ ✔ - 
CL(61:4) - - - - - - ✔ ✔ - - 
CL(62:0) 1.87E+08 1.38E+08 1.84E+08 1.73E+08 2.03E+08 2.07E+07 ✔ ✔ ✔ ✔ 
CL(62:1) 1.16E+08 1.34E+08 1.33E+08 1.15E+08 1.23E+08 8.32E+06 ✔ ✔ ✔ ✔ 
CL(62:2) 4.90E+07 8.01E+07 6.45E+07 6.41E+07 5.15E+07 2.85E+06 ✔ ✔ ✔ ✔ 
CL(62:3) 1.09E+07 2.39E+07 1.82E+07 2.14E+07 1.21E+07 1.38E+06 ✔ ✔ ✔ - 
CL(62:4) 8.42E+05 1.93E+06 2.43E+06 3.81E+06 7.71E+05 1.76E+05 ✔ ✔ - - 
CL(62:5) - - - - - - - ✔ - - 
CL(63:0) 1.71E+08 1.74E+08 1.52E+08 1.44E+08 1.74E+08 3.30E+07 ✔ ✔ ✔ ✔ 
CL(63:1) 1.92E+08 2.35E+08 1.88E+08 1.59E+08 1.97E+08 2.01E+07 ✔ ✔ ✔ ✔ 
CL(63:2) 1.16E+08 1.95E+08 1.29E+08 1.06E+08 1.16E+08 8.35E+06 ✔ ✔ ✔ ✔ 
CL(63:3) 4.11E+07 8.74E+07 5.61E+07 5.17E+07 3.99E+07 3.97E+06 ✔ ✔ ✔ ✔ 
CL(63:4) 7.76E+06 1.65E+07 1.36E+07 1.74E+07 6.93E+06 1.52E+06 ✔ ✔ ✔ - 
CL(63:5) 1.79E+05 5.88E+05 1.07E+06 2.52E+06 2.22E+05 1.08E+05 ✔ ✔ - - 
CL(64:0) 8.17E+07 1.53E+08 6.92E+07 5.77E+07 8.61E+07 4.82E+07 ✔ ✔ ✔ ✔ 
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Table 2.6.2 (continued) 
Potential Compound 
Control IVA Suppl. HIVA Suppl. 2H in LS1191-HIVA 
Ion Counts Ion Counts Ion Counts 
D3 D6 D9 D12 
DK1622 LS1191 DK1622 LS1191 DK1622 LS1191 
CL(64:1) 1.85E+08 2.74E+08 1.70E+08 1.32E+08 1.81E+08 2.42E+07 ✔ ✔ ✔ ✔ 
CL(64:2) 1.79E+08 3.02E+08 1.77E+08 1.45E+08 1.60E+08 1.13E+07 ✔ ✔ ✔ ✔ 
CL(64:3) 9.40E+07 1.89E+08 1.05E+08 9.24E+07 8.12E+07 6.39E+06 ✔ ✔ ✔ ✔ 
CL(64:4) 2.83E+07 5.52E+07 3.73E+07 3.42E+07 2.47E+07 3.50E+06 ✔ ✔ ✔ - 
CL(64:5) 4.24E+06 6.30E+06 7.08E+06 8.49E+06 3.15E+06 1.41E+06 ✔ ✔ - - 
CL(64:6) - - - - - - ✔ ✔ - - 
CL(65:1) 9.12E+07 1.94E+08 7.57E+07 5.84E+07 8.34E+07 2.17E+07 ✔ ✔ ✔ ✔ 
CL(65:2) 1.39E+08 2.71E+08 1.21E+08 9.34E+07 1.17E+08 1.63E+07 ✔ ✔ ✔ ✔ 
CL(65:3) 1.17E+08 2.30E+08 1.16E+08 8.38E+07 9.52E+07 9.00E+06 ✔ ✔ ✔ ✔ 
CL(66:1) 3.59E+07 9.32E+07 2.49E+07 1.61E+07 2.92E+07 1.72E+07 ✔ ✔ ✔ ✔ 
CL(66:2) 6.91E+07 1.50E+08 5.44E+07 3.28E+07 5.52E+07 1.29E+07 ✔ ✔ ✔ ✔ 
DG(30:0) 2.59E+07 1.32E+07 1.27E+07 2.26E+07 5.85E+06 - - ✔ - - 
DG(31:1) 2.66E+06 7.45E+06 2.41E+06 2.29E+06 1.16E+06 - ✔ - - - 
DG(32:0) 5.93E+06 1.40E+07 2.56E+06 4.79E+06 1.84E+06 6.64E+04 - - - - 
DG(32:2) 2.33E+06 1.55E+07 2.84E+06 1.89E+06 8.09E+05 - ✔ ✔ - - 
DG(33:0) 5.18E+06 2.64E+07 1.64E+06 2.80E+06 3.83E+06 6.70E+05 - - - - 
DG(33:1) 1.30E+06 4.92E+06 1.08E+06 9.25E+05 9.60E+05 4.68E+05 ✔ - - - 
DG(33:2) 1.53E+06 7.00E+06 1.88E+06 8.67E+05 1.03E+06 3.15E+05 ✔ ✔ - - 
PE(28:0) 2.90E+08 2.75E+08 4.35E+08 1.91E+08 3.25E+08 2.12E+07 ✔ ✔ - - 
PE(28:1) 4.15E+07 5.09E+07 8.42E+07 9.92E+07 5.19E+07 1.98E+07 ✔ ✔ - - 
PE(28:2) 2.75E+07 2.12E+07 5.50E+07 1.19E+08 2.21E+07 4.94E+07 ✔ ✔ - - 
PE(29:0) 3.72E+09 2.03E+09 4.58E+09 2.84E+09 3.60E+09 9.90E+07 ✔ ✔ - - 
PE(29:1) 1.90E+09 1.27E+09 2.67E+09 3.51E+09 1.83E+09 2.11E+08 ✔ ✔ - - 
PE(29:2) 2.78E+08 3.05E+08 3.94E+08 5.79E+08 3.00E+08 2.08E+08 ✔ ✔ - - 
PE(30:0) 9.81E+09 5.01E+09 1.02E+10 1.40E+10 1.18E+10 1.88E+07 ✔ ✔ - - 
PE(30:1) 4.05E+09 5.00E+09 3.56E+09 2.85E+09 4.05E+09 2.70E+08 ✔ ✔ - - 
PE(30:2) 1.20E+09 2.63E+09 1.34E+09 1.07E+09 1.29E+09 6.06E+08 ✔ ✔ - - 
PE(30:3) 1.66E+08 1.82E+08 2.58E+08 3.70E+08 1.41E+08 2.15E+08 ✔ ✔ - - 
PE(31:0) 2.93E+08 3.40E+09 2.28E+08 1.35E+08 2.89E+08 3.82E+06 ✔ ✔ - - 
PE(31:1) 3.78E+09 5.55E+09 3.08E+09 2.13E+09 3.38E+09 1.03E+08 ✔ ✔ - - 
PE(31:2) 3.53E+09 6.42E+09 3.39E+09 2.51E+09 3.49E+09 6.97E+08 ✔ ✔ - - 
PE(31:3) 8.86E+08 1.26E+09 9.55E+08 8.48E+08 9.06E+08 4.50E+08 ✔ ✔ - - 
PE(31:4) 5.20E+07 4.89E+07 6.73E+07 1.03E+08 4.29E+07 3.00E+07 ✔ ✔ - - 




Table 2.6.2 (continued) 
Potential Compound 
Control IVA Suppl. HIVA Suppl. 2H in LS1191-HIVA 
Ion Counts Ion Counts Ion Counts 
D3 D6 D9 D12 
DK1622 LS1191 DK1622 LS1191 DK1622 LS1191 
PE(32:1) 8.64E+08 3.15E+09 6.38E+08 5.44E+08 8.09E+08 2.51E+06 ✔ ✔ - - 
PE(32:2) 3.94E+09 6.98E+09 3.57E+09 2.05E+09 3.63E+09 8.53E+08 ✔ ✔ - - 
PE(32:3) 2.66E+09 2.79E+09 2.90E+09 2.19E+09 2.04E+09 1.08E+09 ✔ ✔ - - 
PE(32:4) 5.08E+08 3.38E+08 6.78E+08 8.92E+08 2.86E+08 3.71E+08 ✔ ✔ - - 
PE(33:0) 2.61E+07 3.38E+08 1.72E+07 8.01E+06 7.55E+06 - - - - - 
PE(33:1) 5.87E+08 7.22E+08 4.16E+08 2.05E+08 4.20E+08 1.31E+06 ✔ - - - 
PE(33:2) 1.46E+09 9.59E+08 1.30E+09 7.43E+08 1.28E+09 4.34E+06 ✔ ✔ - - 
PE(33:3) 1.74E+09 5.11E+08 1.77E+09 1.43E+09 1.24E+09 7.24E+07 ✔ ✔ - - 
PE(33:4) 6.41E+08 1.28E+08 7.23E+08 8.68E+08 3.40E+08 4.11E+07 ✔ ✔ - - 
PE(34:0) 3.50E+07 6.47E+07 2.39E+07 1.22E+07 1.06E+07 6.89E+05 - - - - 
PE(34:1) 1.18E+08 6.21E+07 8.81E+07 5.80E+07 7.58E+07 - ✔ ✔ - - 
PE(34:2) 2.33E+08 7.89E+07 1.93E+08 1.45E+08 1.61E+08 - ✔ ✔ - - 
PE(34:3) 3.35E+08 7.51E+07 3.05E+08 2.89E+08 2.31E+08 1.52E+07 ✔ ✔ - - 
PE(34:4) 1.96E+08 9.36E+07 1.98E+08 2.10E+08 1.51E+08 5.10E+07 ✔ ✔ - - 
PE(P-30:0) 3.92E+09 1.53E+08 2.60E+09 9.82E+08 2.38E+09 3.32E+07 ✔ ✔ - - 
PE(P-32:0) 7.50E+06 - 3.61E+06 2.06E+05 2.95E+04 - - ✔ - - 
PG(29:0) 8.42E+07 3.36E+07 1.31E+08 1.01E+08 5.52E+07 1.29E+06 ✔ ✔ - - 
PG(30:0) 1.55E+08 1.21E+08 2.07E+08 2.58E+08 1.95E+08 2.91E+06 ✔ ✔ - - 
PG(30:1) 7.56E+07 8.95E+07 8.56E+07 6.02E+07 6.87E+07 2.04E+07 - ✔ - - 
PG(31:1) 1.32E+08 2.22E+08 1.22E+08 8.34E+07 1.98E+08 2.40E+07 ✔ ✔ - - 
PG(31:2) 5.24E+07 5.46E+07 5.26E+07 3.65E+07 6.05E+07 2.28E+07 - ✔ - - 
PG(32:1) 9.97E+07 2.36E+08 7.65E+07 3.48E+07 6.49E+07 1.77E+07 - ✔ - - 
PG(32:2) 1.60E+08 1.12E+08 1.49E+08 1.04E+08 1.35E+08 7.38E+07 - - - - 
PG(32:3) 4.76E+07 2.87E+07 5.53E+07 8.02E+07 5.54E+07 1.82E+07 ✔ - - - 
PG(33:0) - - - - - - - - - - 
PG(33:1) 8.12E+07 4.84E+07 6.89E+07 4.65E+07 5.97E+07 1.92E+06 - ✔ - - 
PG(33:2) 3.64E+07 8.38E+06 3.70E+07 3.53E+07 3.51E+07 3.01E+05 - ✔ - - 
PG(34:0) - - - - - - - - - - 
PG(34:1) 2.02E+06 5.20E+05 2.11E+06 1.73E+06 2.00E+06 2.67E+06 - ✔ - - 
TG(38:1) 1.58E+08 5.03E+07 8.44E+07 2.22E+07 4.01E+07 2.07E+06 - ✔ ✔ - 
TG(39:0) 4.35E+06 1.34E+06 2.13E+06 3.85E+05 4.51E+05 4.29E+05 - - - - 
TG(39:1) 5.20E+06 1.53E+06 5.28E+06 6.15E+05 5.79E+05 5.52E+04 ✔ - - - 
TG(40:1) 1.95E+06 1.39E+06 1.64E+06 3.79E+05 3.13E+05 - - - - - 




Table 2.6.2 (continued) 
Potential Compound 
Control IVA Suppl. HIVA Suppl. 2H in LS1191-HIVA 
Ion Counts Ion Counts Ion Counts 
D3 D6 D9 D12 
DK1622 LS1191 DK1622 LS1191 DK1622 LS1191 
TG(41:1) 1.23E+06 8.08E+05 1.62E+06 2.05E+05 1.72E+05 2.97E+04 ✔ - - - 
TG(41:2) 5.21E+06 4.06E+06 6.27E+06 8.64E+05 1.85E+06 5.79E+05 - - - - 
TG(41:3) 1.54E+06 1.39E+06 2.32E+06 3.55E+05 3.03E+04 - - ✔ - - 
TG(42:1) 2.40E+05 1.87E+05 2.34E+05 9.80E+03 5.38E+04 - ✔ - - - 
TG(42:2) 1.26E+07 7.79E+06 1.31E+07 1.71E+06 2.02E+06 - ✔ - - - 
TG(43:0) 3.49E+06 3.04E+06 4.02E+06 6.20E+05 4.15E+05 5.83E+03 ✔ ✔ ✔ - 
TG(43:1) 6.60E+07 1.87E+07 5.40E+07 6.29E+06 1.14E+07 3.14E+05 ✔ ✔ ✔ - 
TG(43:2) 2.45E+07 1.69E+07 2.33E+07 2.52E+06 5.19E+06 1.79E+05 ✔ - ✔ - 
TG(43:3) 7.24E+06 6.44E+06 8.17E+06 1.09E+06 1.11E+06 3.02E+05 ✔ ✔ ✔ - 
TG(44:0) 1.16E+06 1.02E+06 1.28E+06 8.71E+04 1.78E+05 1.13E+05 ✔ ✔ - - 
TG(44:1) 1.11E+08 3.15E+07 7.82E+07 1.09E+07 1.70E+07 1.53E+05 ✔ ✔ ✔ - 
TG(44:2) 5.35E+07 2.97E+07 4.31E+07 7.39E+06 1.29E+07 - ✔ ✔ ✔ - 
TG(44:3) 1.79E+07 1.33E+07 1.61E+07 3.19E+06 3.62E+06 2.74E+05 ✔ ✔ ✔ - 
TG(44:4) 2.92E+06 2.88E+06 3.30E+06 4.06E+05 4.19E+05 2.88E+05 ✔ ✔ ✔ - 
TG(45:0) 4.00E+05 3.38E+05 4.91E+05 - 5.35E+04 9.05E+04 ✔ ✔ ✔ - 
TG(45:1) 6.49E+07 4.43E+07 4.07E+07 5.43E+06 1.87E+07 4.42E+05 ✔ ✔ ✔ - 
TG(45:2) 2.73E+07 2.13E+07 2.16E+07 1.92E+06 6.27E+06 1.14E+05 ✔ ✔ - - 
TG(45:3) 6.04E+06 4.88E+06 5.70E+06 4.37E+05 7.55E+05 - ✔ ✔ ✔ - 
TG(45:4) 8.40E+05 7.03E+05 9.92E+05 6.22E+04 9.06E+04 - ✔ ✔ ✔ - 
TG(46:0) 6.11E+07 5.40E+07 3.26E+07 3.71E+06 9.28E+06 1.17E+06 ✔ - - - 
TG(46:1) 5.10E+07 4.74E+07 3.11E+07 4.84E+06 2.01E+07 9.40E+05 ✔ ✔ - - 
TG(46:2) 3.79E+07 2.54E+07 2.52E+07 2.59E+06 8.79E+06 2.50E+05 ✔ ✔ - - 
TG(46:3) 9.15E+06 7.47E+06 6.42E+06 4.40E+05 1.40E+06 4.69E+04 ✔ ✔ ✔ - 
TG(47:0) 4.81E+07 4.45E+07 2.40E+07 3.58E+06 7.89E+06 1.71E+06 - - - - 
TG(47:1) 2.77E+07 3.59E+07 1.56E+07 2.22E+06 8.56E+06 1.07E+06 ✔ - - - 
TG(47:2) 2.58E+07 1.96E+07 1.53E+07 1.28E+06 6.92E+06 4.18E+05 ✔ - - - 
TG(47:3) 8.05E+06 6.37E+06 5.01E+06 1.89E+05 1.47E+06 3.28E+05 ✔ ✔ - - 
TG(47:4) 1.83E+06 1.26E+06 1.55E+06 - 1.65E+05 6.38E+05 ✔ ✔ - - 
TG(48:0) 1.40E+07 2.65E+07 5.14E+06 1.66E+05 2.64E+06 1.14E+06 - - ✔ - 
TG(48:1) 1.40E+07 1.98E+07 7.18E+06 9.57E+05 5.33E+06 1.51E+06 - - ✔ - 
TG(48:2) 1.17E+07 1.05E+07 5.96E+06 1.76E+04 2.83E+06 4.54E+05 ✔ - - - 





Table 2.6.2 (continued) 
Potential Compound 
Control IVA Suppl. HIVA Suppl. 2H in LS1191-HIVA 
Ion Counts Ion Counts Ion Counts 
D3 D6 D9 D12 
DK1622 LS1191 DK1622 LS1191 DK1622 LS1191 
TG(48:4) 1.15E+06 6.25E+05 9.09E+05 4.89E+03 1.71E+05 1.46E+04 ✔ ✔ - - 
TG(49:0) 8.37E+06 1.10E+07 2.71E+06 1.02E+05 1.43E+06 4.52E+05 - - - - 
TG(49:1) 5.33E+06 6.15E+06 1.39E+06 - 1.96E+06 7.42E+05 - - - - 
TG(49:2) 4.67E+06 2.72E+06 1.77E+06 1.44E+04 9.34E+05 1.34E+05 - - - - 
TG(50:0) 2.05E+06 2.07E+06 3.78E+05 4.77E+05 6.37E+05 4.10E+05 - - - - 
TG(50:1) 2.25E+06 1.07E+06 4.38E+05 1.87E+04 1.31E+06 9.19E+05 - - - - 
TG(51:0) 6.57E+05 1.15E+05 1.26E+05 1.43E+04 5.79E+02 7.15E+04 - - - - 
TG(51:1) 4.31E+05 2.10E+04 3.83E+03 - 1.04E+05 3.84E+04 - - - - 





2.6.1 – Percent-labeling for detected lipids in M. xanthus DK1622 
Below are a compilation of pie charts describing the populations of labeled lipids observed 
in each of the detected lipids by class as well as by individual species. Since a D3 isolipid 
tracer was used in this experiment, the labels D3, D6, D9, and D12 describe the detected 






































































































2.6.3 – Extracted ion chromatograms of homospermidine lipids and labeled congeners detected in M. xanthus DK1161 and 
LS1191. 




































































2.6.4 – 1H-NMR of synthetic intermediates and isolipid tracers iC15-d6 and iC5-d3 
1H-NMR of compounds iC17-ol and D6-iC17-ol 
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1H-NMR of compounds iC17-xanthate and D6-iC17-xanthate 
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1H-NMR of compounds iC17-alkene and D6-iC17-alkene 
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1H-NMR of compounds iC16-ol and D6-iC16-ol 
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1H-NMR of compounds iC6-diol and TBDPS-iC6-diol 
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ISOLATION AND PRELIMINARY STRUCTURAL ELUCIDATION OF UNKNOWN 
SIDEROPHORE FROM THE MARINE BACTERIUM SULFITOBACTER 




The contents of this chapter are preliminary findings that will be part of a future 
publication titled: 
Isolation, purification, and characterization of a potent siderophore abundantly 
produced by the Roseobacterium Sulfitobacter Loktanella sp. SE62. 
Brandon J. Kennedy, Ashley M. Lato, Gary Lecleir, Shawn R. Campagna, and Stephen 
Wilhelm 
3.1 – Abstract 
 The marine organism Sulfitobacter loktanella sp. SE62 is an α-proteobacterium 
belonging to the large and diverse Rhodobacteraceae genus, Roseobacter. In an 
unpublished study lead by Drs. Steven Wilhelm and Alison Buchan they attempted to 
determine the relative production of iron-binding compounds (siderophores), using 
Roseobacters among other marine microbes, sp. SE62 was found to be very active in the 
production of siderophore-like compounds with unknown structure. The conclusion that 
the apparent siderophore being uncharacterized was determined from thin-layer 
chromatographic (TLC) analyses of extracts from large cultures of microbes known to 
produce these compounds. Strain SE62 produced an iron-binding compound(s) with TLC 
features of different retention factors (Rf), different spot color after staining, and a larger 
spot-area compared to control strains (Figure 3.1.1). This observation of larger spot size 
was presumably due to a higher concentration of siderophore per unit volume of extract. 
This finding parallels the results from plating these microbes on plates of Chrome azurol 
sulfate (CAS)-doped agar (Figure 3.1.2) where the presence of a significantly larger halo 
around the cell culture indicates the microbes are producing an iron-biding compound in 
high amounts. These results lead to the hypothesis that this organism is producing a 
siderophore compound of unknown structure that may have large implications for 







Figure 3.1.1 – TLC analysis of crude siderophore extract from Vib1, DSS3 and SE62 
Shown above is a TLC plate that was developed with iodine-saturated MeOH, and 
subsequently visualized by exposing the plate to a 1% solution of FeCl3 in EtOH. This TLC 
analysis was performed by Sebastien Guilmot whom was a student in the research lab of 








Figure 3.1.2 – Chrome azurol sulfate assay of iron-binding activity 
Image used with permission from Dr. Gary LeCLeir, unpublished data (created 2015). The 
figure shown above was received from Dr. LeCleir, a research scientist in the lab of Dr. 
Steven Wilhelm. The yellow halo around the cell culture indicates the ability of the 




 Efforts toward the absolute isolation of the compound(s) responsible for the high-
affinity for iron in these microbial extracts were undertaken and brought to light some 
important information in identifying the structure of this unknown iron-binding 
compound. Preparative TLC with more selective solvent systems for siderophore 
chromatography were employed, revealing that there are several iron-binding 
compounds present in the crude culture extract. A single highly concentrated fraction 
from sp. SE62 was isolated by preparative TLC and subjected to untargeted UHPLC-MS 
analysis. Two intense masses co-eluted from the LCMS experiment, showing a mass 
pattern indicative of these spectral features being annotated as the iron-bound and iron-
unbound siderophore of interest. A UHPLC-MS/MS experiment to obtain more structural 
information from these putative siderophore masses revealed some unusual 
fragmentation patterns that did not align with typical peptide neutral mass losses, but 
also provided a few fragments indicative of known peptide neutral mass losses. 
 After optimization of TLC conditions for isolating the putative siderophore, both 
normal phase and reverse phase flash chromatography were performed on ~100 mg of 
crude extract in order to isolate a large enough sample of partially purified siderophore 
for NMR studies. Although the amount of compound isolated from flash chromatography 
(~20 mg) was enough to begin seeing single-compound definition in the 1H-NMR 
spectrum and 1H-1H coupling in a 2D-1H-NMR correlation spectrum, but the purified 
sample was still too impure to generate truly meaningful data. The complexity of the 
sample was emphasized by the absence of peaks in the 13C-NMR spectrum of the entire 
isolated sample in a reduced-volume NMR tube. The spectra that were generated 
revealed that the chromatographic methods employed were able to isolate the desired 
compound(s) from the crude mixture, but more material was needed and other 
purification techniques such as semi-preparative HPLC needed to be performed in order 




3.2 – Introduction 
3.2.1 – Siderophores 
 Iron is an essential element to organisms across all animal kingdoms. Its low 
concentration and bioavailability in certain environments provide an evolutionary 
pressure to develop mechanisms to mitigate this issue.86 Iron (III) (Fe3+) species are 
insoluble at biological pH and must therefore must be taken up by mechanisms other than 
diffusion.8, 87 Siderophores are specialized small molecules that allow microbes to leach 
Fe3+ from their surrounding environment through chelation and cellular transport 
mechanisms of the complexed iron into the cell to use in various enzymatic processes.88 
Free iron in the environment is difficult to come by (~1x10-9 – 1x10-18 M Fe3+) as it is 
typically bound in minerals or horded by higher-order organisms where iron is bound to 
functional proteins like hemoglobin or sequestered in specialized storage proteins such 
as ferritins.89-91 
 Bacterial siderophores can have a variety of functions and a variety of structural 
attributes that make this class of compounds diverse and challenging to characterize 
(Figure 3.2.1).92 Microbes in both solid surface and aquatic environments produce these 
compounds to not only aid in the extraction of iron from surrounding sources, but can 
also serve as a defense mechanism. Some bacteria produce anti-microbial siderophores 
that upon being absorbed by rival organisms become toxic and kill off competitors for 
sources of nutrition.93 Many microbes have been shown to produce multiple types of 
siderophore compounds in iron-limited environments.94 This is presumably to mitigate 
the uptake of certain siderophore compounds by competing microbes, and allow for 
species-selective uptake of iron-siderophore complex using compounds that other 




Figure 3.2.1 – Diversity of structure and functionality in siderophores 
There are several types of iron-complexing compounds known as siderophores 
categorized by the functional groups present. What makes these compounds so 
challenging to characterize is that many siderophores belong to more than one class 
known as a mixed-type siderophore.
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 Iron is essential to the function of many enzymes as co-factors for metabolic 
processes and are universally important in the maintenance and synthesis of DNA in all 
organisms. The transport of extracellular iron from the environment into the cell begins 
with the biosynthesis of these compounds within the cytosol of bacterial cells. Once these 
compounds are produced, they are then excreted into the environment by membrane-
bound transport proteins to diffuse into the surrounding environment and scavenge for 
available ferric iron species. to perform redox chemistries and complex with iron bound 
within minerals or to simply complex soluble iron sources. Once these compounds have 
sequestered iron, they may be transported into the cell by specialized membrane-
localized transport proteins and subsequently reduced to release the bound iron and is 
mediated by siderophore complexation. 
3.2.2 – Sulfitobacter loktanella sp. SE62 
 Nearly twenty years ago Dr. Alison Buchan isolated the microbe, Sulfitobacter 
loktanella sp. SE-62 (SE62), from the coastal waters of Sapelo Island, Georgia, which has 
spiked interest in the secondary metabolite(s) it produces that strongly bind iron.96 The 
Roseobacters are a large clade of α-protobacteria that make up ~20% of the microbial 
consortium of coastal marine environments and ~5% of the bacterial population in ocean 
surface waters.97 They are a group of organisms known for their prevalence in marine 
environments, as well as their abundance genes coding for non-ribosomal peptide 
synthetases and polyketide synthases, which are an abundant source of secondary 
metabolites.98 This organism, SE62, when compared to other Roseobacters had shown to 
be a significant producer of iron-binding compounds by an experiment using CAS-doped 
agar plates (Figure 3.1.2). This assay uses an agar that is treated with an equimolar 
combination of CAS and a ferric iron compound (typically FeCl3) that when mixed produce 
a CAS-Iron complex that is blue in color. When there is a compound with a higher affinity 
for iron than that of CAS introduced to the blue agar, the iron is stripped from the CAS 
complex and the blue color is quenched.99 It is apparent by the large halo of uncomplexed 
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CAS appearing around a culture of SE62 that this microbe is either producing a large 
concentration of iron-binding species, or that the compound(s) it produces have a 
significantly higher affinity for iron than the compounds other Roseobacters are 
producing, which also may result in a larger sequestration of iron from the CAS-doped 
agar plate. Identifying this compound, or compounds that this microbe is producing could 
have large implications for marine iron cycling not only in the coastal waters of Sapelo 
Island in Georgia, but if this microbe has a presence in other aquatic environments this 
compound could be used by several organisms to support their own survival. 
3.2.3 – Natural product isolation 
 The isolation of natural products produced by living organisms is a field of 
chemistry that that seeks to purify molecules with potent bioactivities for medical 
purposes such as in the case of the chemotherapeutic agent, taxol. In a review by Otto 
Sticher, it is mentioned that natural products are going to always be a source of potent 
new drugs due to the vast diversity of compounds produced as secondary metabolites in 
living systems that have equally diverse activities in vivo.100 Sources of these medically 
relevant natural products come from innumerable biological sources from all the animal 
kingdoms. This work involves first identifying an organism that produces a compound or 
set of compounds that have bioactivity, gathering the biological matrix that contains the 
compound(s) of interest, extraction of said compounds, absolute isolation of said 
compounds, and finally performing a slew of instrumental and chemical analyses that 
generate data sufficient to determining the structure of the isolated natural product. This 
type of work often provides very small amounts of the target material from a much larger 
sample of raw biological material, which is where chemical synthesis is of great benefit. 
Once the structure of the compound is determined, it is a matter of developing a synthetic 
method that can achieve the desired molecule. Once a potent natural product is 
synthesized, many research groups look to increase the atom economy of the synthetic 
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strategy employed so that sufficient quantities can be made in a cost-effective and timely 
manner. 
3.2.4 – Technologies for small molecule structure elucidation 
 There are several typical means of determining the structure of an unknown 
organic compound from chemical syntheses, where there are quantities of by-product 
that can be isolated from easily scalable reactions. These technologies are also used to 
determine the structure of an unknown compound isolated from nature with interesting 
properties. Tools such as nuclear magnetic resonance (NMR), full-scan and targeted 
tandem mass spectrometry (MS / MS-MS), or spectrophotometric instrumentation (IR, 
UV-Vis, polarimetry) are employed and typically used in conjunction to give enough detail 
to definitively identify a structure. X-ray diffractometry is also another powerful, albeit 
less commonly employed, technique for structural elucidation of small molecules since 
this technique requires very pure crystalline samples. Obtaining samples of pristine purity 
from biological matrices in quantities to grow crystals requires a fairly large amount (≥ 1 
g) of biological material to isolate enough pure compound for appreciable crystal growth. 
Current NMR technologies can acquire reasonably informative spectra (1- and 2-
dimensional homo/heteronuclear experiments) with as little as 100 µg of pure samples.101 
Spectrophotometric analytical methods such as UV-Vis and IR may are routinely used with 
sample quantities in this region, and mass spectrometry is so sensitive that this amount 
of sample would be more than adequate even when coupled to chromatographic 
instrumentation. Although these techniques require a small amount of pure sample, the 
absolute isolation of natural products still may require a considerably larger amount of 
biological material to isolate the compound of interest. As previously mentioned, the 
Pacific Yew tree is a natural source of the powerful anti-cancer drug Paclitaxel (Taxol), but 
the pure compound only makes up on average 7.5 x 10-5 weight-% of the dry bark 
harvested from the tree.102-103 This should emphasize the need for large quantities of raw 
material to isolate single compounds for structural elucidation. 
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3.3 – Results and discussion 
3.3.1 – First-pass screening of culture extracts by UHPLC-UV-MS 
 Samples that were received from the Wilhelm group were siderophore-selective 
extracts of presumably simple composition, which seems to be a common misconception 
that research groups in the biological sciences tend to make. This is not because they do 
not understand the complexity of biological samples, but rather the opposite – they are 
aware that extracts of cells or higher-order tissues are extremely complicated in 
composition, therefore purification methodologies that are well-established are typically 
employed to isolate target compounds. These methodologies are successful in isolating 
target compound classes but are typically laden with numerous molecules of specific 
functional chemistries that behave chromatographically similar or have other comparable 
physical properties that may sometimes be overlooked, which results in numerous 
compounds being isolated alongside target molecules or classes of molecules. In the 
instance of isolating the compound(s) responsible for binding iron toward 
characterization of an unknown siderophore produced by the Sulfitobacter loktanella SE-
62, the use of poorly selective TLC conditions (normal-phase silica and “iodine-saturated” 
MeOH as mobile phase) assumed that there was primarily a single compound isolated by 
the methods employed, which under more scrutinous investigation revealed that this 
single “compound” was in fact a very complicated and diverse sample in and of itself. 
 Before any rigorous cleaning of the samples was employed in the analysis of the 
siderophore selective extracts from Vib1, DSS3, and SE62 obtained from the lab of Dr. 
Steven Wilhelm, it seemed practical to first get an idea of the complexity of the samples 
by means other than TLC. Some type of analysis that could possibly illuminate a set of 
mass features unique to SE62 that may be contributing to the strong ability to leach iron 
from its environment. This was accomplished using ultra high-performance liquid 
chromatography coupled mass spectrometry (UHPLC-MS) to gather preliminary data and 
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compare spectral features between samples. Since these samples were extracted from 
cell cultures, and the overall polarity of the iron-binding compound was not known, but 
it should be quite polar in nature in order to act as a ligand to complex with ionic iron 
species. From this imagining of physical characteristics of the target molecule, it was 
decided to use a HILIC column for analytical separations. There is importance with 
characterizing an unknown molecule to gather as much information you can on a sample, 
this includes spectrophotometric means of obtaining vague insight into the functionality 
of the compounds present in the sample. Information on how these samples respond to 
spectroscopic detection such as with a flow-through photodiode array (PDA) detector 
gave another level of qualitative data to view similarities and differences between the 
samples. As expected, the total ion chromatogram (TIC) (Figure 3.3.1) for the crude 
samples was extremely complex, and had spectral features that were similar, but also 
dissimilar, which is not unexpected. The PDA chromatograms (Figure 3.3.2) from this 
experiment also gave somewhat similar results between samples. It was obvious that the 
samples would have to be purified prior to analysis to give a better idea of which mass 
features were responsible for the iron-binding activity of these extracts. Having this data 
from the crude extracts allows for searching for the extracted ion chromatogram of the 
mass features in the purified samples and lining them up with their respective PDA 
responses at different excitation wavelengths giving a vague idea of functional groups 
that may be present in the detected compounds. 
3.3.2 – Colorimetric analysis and preparative thin-layer chromatography 
 The compound class a siderophore belongs to can be qualitatively determined 
with colorimetric tests such as Arnow’s assay and Atkin’s assay. Arnow’s assay is 
specifically suited for catechol-type siderophore, which upon treatment of the 
siderophore with a nitrous acid, and subsequent treatment with sodium hydroxide gives 
a pink color. Atkin’s assay tests for the presence of a hydroxamate-type siderophore by 




Figure 3.3.1 – Total ion chromatograms from the UHPLC-MS analysis of crude siderophore extracts 




Figure 3.3.2 – Select PDA chromatogram from UHPLC-MS analysis of crude siderophore extract 
Shown above is the PDA chromatogram being collected at 254 nm (bw = 16 nm) for the crude siderophore extracts of Vib1, 
DSS3, and SE62 samples 
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methods are good for non-mixed classes of siderophores that only respond to one or the 
other assay. Developed TLC plates with the crude SE62 sample upon colorimetric analysis 
via assays of Arnow and Atkin did not yield any coloration indicating these isolated 
compounds were neither of a hydroxamate or catecholate type. The approach of this 
experiment was only to identify TLC spots as having an affinity to iron, which was tested 
by selectively staining of the developed TLC plate with a solution of FeCl3. By this method, 
it would be apparent if spots on the TLC plate bound to iron, they would have a 
red/orange color, compared to the rest of the yellow plate. This was also the method of 
choice since it best replicated the TLC analysis performed by the Wilhelm group – using 
normal-phase silica TLC plates as the stationary phase, and iodine-saturated methanol as 
the mobile phase. By replicating their method, using iodine-saturated methanol then 
staining with 5% FeCl3 in MeOH exposed spots that were different in color and retention 
factor (Rf). Vib1 gave spots that were dark grey/blue at Rf = 0.8-0.9, DSS3 gave a faint 
orange spot also around Rf = 0.8, and SE62 gave a large dark merlot spot at Rf = 0.5-0.7 
(Figure 3.1.1). Modifications to the collaborators TLC mobile phase to be less polar and 
chemically reactive (exclusion of iodine in mobile phase) resulted in separations that 
resulted in more selective chromatography than just the iodine saturated MeOH (Figure 
3.3.3A), but only revealed orange spots after staining. Reverse-phase separations were 
also attempted with the crude extract using C18-silica TLC plates and mobile phases of 
varying H2O:ACN ratios, but all separations proved to be poorly selective giving a high Rf 
(≥ 0.95) value for all iron-binding compounds in a single TLC spot. This confirmed that 
normal-phase chromatography would be the best method of isolating these compounds, 
which should be apparent due to the polar nature of these metal chelators.  
 Staining the optimized TLC plate separations with 5% FeCl3 in MeOH revealed that 
there were several spots in the SE62 sample responding to stain containing iron, meaning 





Figure 3.3.3 – Thin layer chromatographic analysis of crude siderophore extracts 
A.) Thin layer chromatography (TLC) optimization for fractionation of crude siderophore 
extracts of vib1(v), DSS3 (d), and SE62 (s), where plate 4 mobile phase conditions were 
found to give the best separation. Plates were stained with an ethanolic solution of FeCl3.  
B.) Differential staining procedures using potassium permanganate, p-anisaldehyde, 
ninhydrin, Hannesian’s, and phosphomolybdic acid to get an idea of functional groups 




 as siderophores, or at least respond/react with ferric iron. To obtain more information 
from this preparative TLC method, several replicate plates were developed and visualized 
with a variety of TLC stains that would reveal more about the chemical identity of 
whatever was being separated on the plate (Figure 3.3.3B). Narrowing down what 
functional groups may be present in the iron-binding fraction versus the other non-iron 
reactive regions of the TLC plate will be useful for determining possible functional groups 
constituent of the unknown compound(s) of interest and how the crude extracts compare 
to each other. Preliminary TLC analyses with an array of TLC stains show an assortment 
of structural features for the iron-binding regions in the SE62 sample due to differential 
staining properties of a variety of possible functional groups. 
 Staining a plate with an alcoholic solution of KMnO4 indicates the presence of 
oxidizable functional groups such as alcohols, amines, alkenes, and alkynes - the resulting 
compounds from the action of KMnO4 stain yellow against a purple plate. Amines and 
amino acids stain brown against a fairly colorless background with a solution of ninhydrin. 
Several general stains were also employed to determine the true complexity of the crude 
samples. From these staining solutions alone, it was determined that the compound of 
interest was likely a peptide due to the brown staining via ninhydrin, and likely contained 
either oxidizable functional groups or itself contained carboxylic acid moiety by the yellow 
staining behavior with KMnO4. Although some TLC staining methods are “universal” they 
do not always stain the same things or with the same intensity. Therefore a few plates 
were treated with Hannesian’s stain (acidic solution of ceric ammonium molybdate) and 
alcoholic solutions of p-anisaldehyde and phosphomolybdic acid which stain compounds 
unselectively giving spots of blue, pink, and green, respectively. These staining procedures 
did not all behave the same with this sample attesting to a diversity of molecule classes 
or functional groups present in the compounds separated by the optimized TLC method. 
 One benefit of preparative TLC is that separations may be done on very small 
amounts of sample and that once the Rf for the compounds of interest have been 
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established, the experimenter may then excise the desired fraction from the TLC plate by 
scraping off the silica. This silica sample has the compound(s) of interest adsorbed to the 
surface of the silica, and can be extracted with small volumes of solvent, and directly 
injected onto an analytical column for LCMS analysis to determine the masses of the 
compounds present in that fraction of the TLC analysis. Using the excised TLC fractions 
between all strains analyzed can assist in pinpointing the mass of the molecules unique 
to the SE62 strain from any other more common cellular compounds that may also be 
present in the other strain extracts.  
3.3.3 – UHPLC-HRMS analysis of Fe-binding TLC fractions 
 Mass spectrometric analysis of the TLC fraction with the strongest staining 
behavior is a starting point towards isolating and identifying the compound(s) responsible 
for binding to iron in this sample. The TLC spots from the preparative TLC experiment with 
SE62 were excised from the plate and extracted with MeOH, filtered, and transferred 
directly to an autosampler vial for injection onto an analytical column for UHPLC-MS 
analysis. Controls to account for metabolites and lipids that may be present in the iron-
binding TLC fraction were used to assist in pinpointing spectral features that were unique 
to the SE62 strain. These controls were prepared by preparative TLC of the extracts from 
Vib1 and DSS3 cell cultures, excising the same Rf region as with the SE62 sample, 
extracting with MeOH, filtering, and transferring the supernatant into autosampler vials 
for analysis.  
 Samples were subjected to UHPLC separation on a Kinetex reverse phase C18 (100 
x 2.1 mm, 2.6 µ, 100 Å) analytical column prior to mass spectrometric analysis. The choice 
of using reverse phase chromatography in this situation was due to the fact that normal 
phase chromatography was already performed on these samples (prep-TLC). This would 
perhaps enforce some separation in lipophilic space if amphiphilic molecules retained 
similarly to the target compounds with this method of sample preparation. Siderophores 
are highly polar compounds, meaning that the compounds of interest in these samples 
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would likely be pushed off a reverse phase column first, leaving behind compounds with 
a degree of hydrophobicity that were likely components of cell membranes. Using an 
electrospray ionization (ESI) source operating in positive mode, the column effluent was 
introduced into the mass spectrometer as positively charged gas-phase ions to be 
detected by an orbitrap mass analyzer. 
 This analysis proved to be quite informative by the identification of co-eluting 
mass features in the total ion chromatogram of the SE62 sample that indicated a 
siderophore-like compound. These detected ions shared similar 13C-isotope peaks, a mass 
pattern indicative of being bound and unbound to iron, and the correct 54/56Fe isotopic 
ratio for the iron-bound ion (Figure 3.3.4). Although the detected ionic species took some 
thought to realize that these were related ions bound and unbound to a ferric ion, and 
not just unrelated masses that co-eluted, the [M+H]+ and [M-2H+Fe3+]+ ions were 
annotated as such, and the detected mass of 671.3230 m/z mass was determined to be a 
strong candidate for the iron-binding behavior of the siderophore sample. 
3.3.4 – HRMS data to calculate potential molecular formula 
 Data from the UHPLC-MS experiment was obtained using the mass spectrometers 
highest resolution setting (resolution = 140,000), which can be used to generate a list of 
reasonable chemical formulas based on atomic constraints such as the number and 
identity of atoms the program can use to generate formulas close in mass to the masses 
observed in the spectrum. There are a number of programs that can do this task, but 
Xcalibur (Thermo Scientific) was used in this instance to generate a plausible molecular 
formula based off the masses that were representative of the iron-bound and -unbound 
siderophore species. Since this molecule class (siderophores) is not traditionally observed 
in metabolomic mass analyses, it seemed unnecessary to use the Seven Golden Rules 
method of chemical formula calculation. The Seven Golden Rules is an Excel program 
developed by Dr. Tobias Kind and Dr. Oliver Fiehn that takes certain atomic ratios that are 




Figure 3.3.4 – Mass spectrum of putative siderophore in Sulfitobacter loktanella sp. SE62 
With a similar 13C isotope ratio for these two masses, and the correct mass difference for the ions being bound and unbound 
to iron, this pair of masses have been preliminarily annotated as the putative siderophore of interest. 
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 presence of the penultimate formulae in online mass databanks before finalizing the list 
of possible chemical formulas.104 Typically, siderophores contain atoms of carbon, 
hydrogen, oxygen, nitrogen, and sulfur to a lesser extent – this lead to constraining the 
Xcalibur formula generator to these atoms and keeping the mass error below 5 ppm, as 
dictated by the instrumentation (orbitrap mass analyzer) used during mass analysis. By 
this method, the formula generator came up with 13 plausible formulas. Of the top hits 
from this list, there was a formula that aligned well with the isotopic pattern observed 
(~29-30 carbon atoms) from the HRMS analysis of this sample as well as a rough 2:1 ratio 
of oxygen to nitrogen that would be present in a peptidic carboxylate-type siderophore. 
It was this formula (C29H46N6O12) that was used to further extrapolate a potential 
molecular structure. 
3.3.5 – LC-MS-MS analysis of putative siderophore 
 Previous preparative TLC and UHPLC-MS experiments have shown that although 
the unknown iron-binding compound of interest can be partially isolated by these 
methods, it was not isolated absolutely. Data acquired from the UHPLC-MS study of the 
preparative TLC sample shows there is still much sample complexity in the total ion 
chromatogram where the characteristic iron-binding compound elutes, even after liquid 
chromatographic separation on an analytical column. In order to obtain data that could 
be used to construct a plausible structure for the unknown iron-binding compound of 
interest, tandem mass spectrometry (MS-MS) was performed on a Thermo Scientific Q-
Exactive mass spectrometer via parallel reaction monitoring (PRM). A PRM method uses 
what is known as a mass inclusion list, which is a list of masses that the ion optics isolate, 
fragment, and inject into the mass analyzer in succession in-time with the duty cycle of 
the instrument. Unlike a traditional triple-quadrupole instrument that uses the tandem 
quadrupoles to isolate, fragment, and analyze a user-selected ionic species, the Q-
Exactive uses a segmented quadrupole to select a parent ion to enter a higher-energy 
collisional dissociation cell (HCD cell) to fragment the ions prior to being introduced into 
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an orbitrap mass analyzer, which provides the high-resolution mass analysis. As 
determined by the UHPLC-MS analysis of the strongly iron-binding fraction from 
preparative TLC of a crude siderophore sample, the iron-unbound species of interest that 
was detected was 671.3230 m/z, this was the ion selected for fragmentation analysis to 
determine structural features of this unknown compound. 
3.3.6 – Scale-up purification and NMR analysis of unknown siderophore 
 Once preparative TLC was shown to be effective in isolating the mass detected in 
previous experiments showing a mass pattern indicative of a siderophore bound and 
unbound to ferric iron, it was time to apply the optimized chromatography to the rest of 
the crude siderophore extract. This was accomplished using normal-phase silica gel 
packed into a flash column, and the polarity of the most effective TLC mobile phase was 
reduced by about 60% (~10% MeOH in CHCl3 versus 25% MeOH in CHCl3) to ensure the 
chromatography was not too rushed. When adopting TLC separations to flash 
chromatography, the polarity of the mobile phase needs to be reduced because of the 
change in how the mobile phase runs through the stationary phase. In a TLC-based 
separation, mobile phase relies on capillary action to pull the liquid up and through the 
stationary phase of the plate, whereas with a flash column, the mobile phase either is 
allowed to flow through the stationary phase via gravity or is pushed through with air 
pressure. In both instances with a flash column, the retention of compounds on the 
stationary phase changes drastically compared to being “pulled up” a TLC plate, and 
therefore the mobile phase used must compensate for this change in fluid dynamics. 
Throughout the flash column, very small (5 mL) fractions were collected in clean test 
tubes and tested for their ability to bind iron via spotting each fraction onto a TLC plate, 
running the plate with the optimal TLC mobile phase, and finally staining the plate with a 
3% solution of FeCl3 in EtOH. Using this method, the fractions that gave a TLC spot with 
an equivalent Rf to that of the spot of interest in the crude mixture were pooled and 
solvent was removed prior to NMR analysis. Proton NMR (1H-NMR) revealed fairly 
237 
 
resolved peaks in the spectrum, but contained a number of peaks that looked to be 
unrelated to the compound of interest due to odd integration patterns and messy 
splitting of the proton signals (Figure 3.3.5). The sample complexity was further 
confirmed by the lack of signal intensity in the carbon NMR (13C-NMR) spectrum (Figure 
3.3.6), which was probably due in part to the small amount of sample obtained. However, 
20 mg of a pure sample in a reduced-volume NMR tube should give appreciable signal, 
especially after 1000 scans. Therefore the assumption was made that this sample was still 
complex – due to a potentially large number of carbon atoms experiencing different 
chemical environments and relaxing at a variety of frequencies, which upon subjecting to 
a large number of scans would not sum to a noticeable peak in the spectrum. 
Homonuclear correlation spectroscopy (COSY-NMR) was performed in a final attempt to 
deconvolute the data obtained from the 1H-NMR experiment on the isolated iron-binding 
species of interest (Figure 3.3.7). Solution-phase 1H-1H- COSY NMR spectrum gives the 
analyst the ability to see which neighboring proton signals are spin-coupled, which would 
give some clarity to complex splitting patterns and what proton signals are likely coming 
from a single molecule.  
3.3.7 – Data analysis and construction of a potential siderophore structure 
 Considering the exact masses of the iron-unbound parent compound and the 
masses of the fragments generated from tandem-mass analysis of the intact siderophore, 
a plausible molecular structure could be constructed from these data. Information 
gathered from the fragmentation experiment revealed there were some fragments that 
were characteristic of peptide neutral losses, so the parent compound may have been a 
peptide of some sort (Figure 3.3.8). An important neutral mass loss of ~130.05 m/z was 
observed between three of the fragments generated, indicating that there may be three 
glutamate residues present in the putative siderophore, which would make sense as these 
residues under the correct pH conditions would be ideal for chelation to ferric iron in 







Figure 3.3.5 – 1H-NMR of partially purified SE62 siderophore 
Shown above is a proton NMR spectrum of the “purified” siderophore sample with strong 
iron-binding behavior by TLC staining. Peak integrals were normalized to a single proton 
for the multiplet at 4.19 ppm, as this may be a methine unit typical of a peptide. The 








Figure 3.3.6 – 13C-NMR of partially purified SE62 siderophore 
Shown above is a carbon-13 NMR spectrum that practically shows zero signal intensity 
from the sample, and only a solvent residual peak. This may be due to the complexity of 
the isolated sample, since the concentration and number of scans taken (1000) for this 








Figure 3.3.7 – 1H-1H homonuclear correlation spectrum of partially purified SE62 
siderophore 






Figure 3.3.8 – Tandem mass spectrometric analysis of putative SE62 siderophore 
MS/MS of iron-unbound siderophore of interest showing possible peptide neutral mass losses 
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 structure, also indicating that this compound may be a peptide. By piecing together the 
data from the original UHPLC-MS analysis which detected masses of the iron-bound and 
unbound siderophore, fragments from the MS-MS experiment, keeping amino acid 
structures in mind, and calculating the remaining atoms available from the generated 
molecular formula, the cyclic hexapeptide ESEKEA (Glu-Ser-Glu-Leu-Glu-Ala) was 
constructed and has a calculated mass error of 1.63 ppm from the observed mass (Figure 
3.3.9) indicating that this combination of atoms was a likely candidate for serious 
consideration as the putative siderophore of interest, but the configuration of those 
atoms was not necessarily correct, which NMR experiments would be essential for 
determining. 
 This mass analysis alone yielded a promising conclusion for the potential 
identification of the unknown iron-binding compound present in the SE62 sample but 
needed confirmation with more analytical data better suited to give structural 
information on the isolated compound. Therefore, flash chromatography was performed 
on the SE62 sample, in order to isolate a large enough amount of this compound for NMR 
studies such as 1H-NMR, 13C-NMR and a few 2D NMR studies. Normal-phase 
chromatography was found to be better suited in the separation of iron-binding species 
than reverse-phase chromatography (C18 silica plates) by TLC analysis, so flash 
chromatography was performed on the crude SE62 siderophore extract yielding ~20 mg 
of product for NMR analysis. Unfortunately, the spectra generated from the NMR analysis 
did not give much meaningful information due to the lack of signal clarity in the 1H-NMR 
spectrum, the lack of signal intensity in the 13C-NMR spectrum, or the cross-peaks, 
although quite well-resolved, observed in the 1H-1H COSY spectrum. There was a fair 
degree of signals observed in the 1H-NMR spectrum that aligned well with a predicted 
NMR spectrum generated by ChemDraw Professional 16.0 software (Figure 3.3.10). The 
solvent setting used for predicting the 1H-NMR spectrum was CDCl3, so the predicted 





Figure 3.3.9 – Possible SE62 siderophore structure from MS data 
Using exact masses, plausible chemical formulae were calculated, and a structure was put together using MS/MS data. The 







Figure 3.3.10 – Predicted 1H-NMR spectrum of the putative SE62 siderophore structure 
A structure that was created from MS data was used to generate a predicted 1H-NMR 
spectrum to compare against the experimental spectrum. Although the experimental 
sample was taken in a different solvent than the program calculated the predicted 
spectrum, the two spectra line up fairly well, but further work needs to be done to obtain 
a spectrum with more definitive peaks and splitting patterns. 
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CD3OD. The choice of using a deuterated solvent with exchangeable deuteriums 
unfortunately would have quenched the signals arising from any exchangeable protons in 
the compound of interest, such as amines and carboxylic acids, but this solvent seemed 
to be the one that dissolved the sample the best and was therefore used. 
3.4 – Methods 
3.4.1 – Iron-limited cell culturing 
 All procedures for culturing were obtained from Dr. Gary LeCleir, a research 
scientist working under Dr. Steven Wilhelm at the University of Tennessee, where the 
culturing took place. In order to encourage the production of siderophores in sp. SE62, 
extra care was taken to limit the amount of iron present in their environment. All 
containers were acid-washed to ensure the removal of trace metals and liquid media was 
prepared with Chelex-100-treated water in order to achieve an iron-deficient culturing 
environment. A special room equipped with large high-efficiency particulate air (HEPA) 
filters was prepared in Dr. Wilhelm’s lab to simulate a “clean room” following trace metal-
free atmosphere protocol. This was done in order to minimize the incidence of 
contamination during liquid transfers; since trace amounts of iron could be introduced 
into the liquid media from sources as simples as a fleck of dust or a stray droplet of iron-
contaminated water.105-106  
 Cell cultures of Vibrio phage PWH3a-P1 (Vib1), along with Roseobacter strains 
Silicibacter pomeroyi DSS-3 (DSS3) and Sulfitobacter loktanella SE-62 (SE62), were 
prepared by personnel in the Wilhelm group adhering to the following procedure: 
Resurrection of previously collected specimen began with plating frozen bacterial isolates 
on YTSS agar (yeast, tryptone, sea salts, ~1.5% agar) to achieve viable cultures. Single 
colonies of revived organisms were transferred to plates with a defined marine media, 
“C-bud” (artificial seawater with varying levels of yeast extract and tryptone), to produce 
a batch of viable specimen to transfer into an iron-limited liquid C-bud medium.107 C-bud 
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liquid media was passed through a column of Chelex X-100 ion exchange resin to remove 
iron and were subsequently sterilized prior to inoculation. Small 50 mL batches of this 
liquid media were inoculated with cultures grown previously on C-bud agar to encourage 
iron-limited growth in a liquid medium before inoculation of a large batch (~50 L) of iron-
depleted liquid media. All cultured media (agar and liquid) were allowed to grow at room 
temperature for the duration of growth time (non-specified). 
3.4.2 – Isolation of siderophores 
 The extraction procedure that was used to preliminarily isolate the iron-binding 
compounds of interest was adopted from a previously published work by Drs. Wilhelm 
and Trick (Limnol. Oceanogr., 1994)94. Large cultures of microbes grown in large 50 L 
carboys were centrifuged at 3700 X g for about 30 minutes to pelletize a majority of the 
cells present in the liquid media, which was decanted from the cell pellet and vacuum-
filtered through a fine glass microfiber filter to remove the cells remaining in the media. 
This process allowed for the collection of extracellular siderophores solubilized in the 
liquid media, which requires further purification to extract the iron-binding compounds 
with a fair degree of selectivity. All reagents and solvents used to isolate the organic iron-
binding compounds from the growth media were treated with Chelex X-100 resin to 
remove trace amounts of iron that could be present. Isolation of the siderophores began 
with the acidification of the filtered growth media (pH ~ 2.5) in order to reduce the water-
solubility of solubilized organic compounds as well as dissociate any iron-bound 
siderophores present. The acidified medium was passed through a column of Amberlite 
XAD-16 resin, which retained the organic compounds and removed all the salts and 
organic-unbound ions present after flushing the column with several column volumes of 
Milli-Q H2O, which was previously adjusted to pH = 3.0 with HCl(aq). The organic 
components of the media along with the desired iron-binding compounds were eluted 
from the Amberlite resin by passing a few column volumes of MeOH through the resin, 
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collected, and concentrated to yield a concentrated supernatant extract, which was 
stored at -20 ˚C until it was processed further. 
 Siderophores were isolated further from the concentrated supernatant extract by 
solid-phase extraction utilizing prepacked C18 cartridges (Agilent Bond Elut C18). This was 
accomplished by taking the previously isolated concentrated methanolic supernatant 
extract and removing the remaining solvent to near-dryness and taking the sample up in 
acetonitrile to load the C18 cartridge. The loaded cartridge was eluted with aqueous 
solutions in a step-wise gradient of increasing methanol concentrations of 10%, 20%, 30%, 
and 70%. These fractions were dried in a SAVANT Speed Vac Plus SC210A. Dried fractions 
were taken up in Milli-Q H2O and subjected to CAS-agar assay to determine the presence 
of siderophores in the fractions, which were then pooled together upon a positive result 
for iron-binding species. 
 This final pooled sample was the crude siderophore extract that was received from 
the Wilhelm lab and further purified by preparative TLC. Several mobile phases of varying 
ratios of chloroform, acetic acid, and methanol were assessed to determine a 
chromatographic system of optimized selectivity (Figure 3.3.3A). Other aprotic polar 
solvents such as THF and EtOAc were also considered, but these trials proved fruitless as 
alcohols were the only solvents that would move the iron-binding compounds up the TLC 
plate. The optimal mobile phase to enforce the most separation was determined to by 
25 % MeOH in CHCl3, which was the solvent system employed during preparative TLC of 
the siderophore samples acquired from the Wilhelm lab. Once the plates were developed 
in this solvent system, the plates were reversibly stained with iodine vapor, and the 
desired spots were outlined in pencil. Once the iodine was removed from the plates with 
gentle heating, the TLC spots of interest were scraped from the plate into their respective 
1-mL Eppendorf tubes per sample, and the iron-binding compounds were extracted from 
the excised spots with 300 µL of MeOH, sonicated briefly, and centrifuged before 
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transferring the extracted samples into autosampler vials for injection onto a UHPLC-MS 
instrument. 
3.4.3 – UHPLC-MS and UHPLC-MS-MS analysis of preparative TLC samples 
 Prepared samples were subjected to the following analysis for both the crude 
siderophore extract and the prep-TLC samples. The instrumentation used was an Exactive 
Plus Orbitrap mass spectrometer with an electrospray ionization (ESI) source coupled 
with an Ultimate3000 ultra high-performance liquid chromatography (UHPLC) system 
(Thermo Scientific, Pittsburgh, PA). For each sample analysis 20 µL of sample, which were 
kept at 4 °C for the entire analysis, was injected onto a Kinetex reverse phase C18 (100 x 
2.1 mm, 2.6 µ, 100 Å) analytical column maintained at 25 ˚C and were separated by the 
following LC method: Mobile phase A was 0.1 % formic acid in H2O and Mobile phase B 
was 0.1 % formic acid in MeOH. The flow rate was 0.2 mL/min and the mobile phase 
gradient used was 0-6 min 2-30 % B, 6.01-12 min 30-70 % B, 12.01-15 min 70-100 % B, 
15.01-20 min 100% B, 20.01-25 min 100-50 % B, 25.01-30 min 50-2 % B. The ESI 
parameters were as follows: scan range 120-1800 m/z, resolution 140,000, AGC target 3.0 
x 106, MaxIT of 200 ms, sheath gas flow rate 25 units, aux gas flow rate 10 units, spray 
voltage ±4.0 kV, and capillary temperature 350 °C. The mass spectrometry method was 
operated in both positive and negative mode using full scan analysis for each sample, 
once per ionization mode, for a total run-time of 30 minutes per sample, per ionization 
mode. A post-column in-line PDA detector (Ultimate3000 PDA detector; Thermo 
Scientific, Pittsburgh, PA) was used prior to mass analysis to scan several wavelengths 
obtaining some crude structural information. Light absorption was observed at 254 nm, 
280 nm, 310 nm, and 380 nm with a bandwidth of 16 nm, a narrow slit-width, and a scan 
rate of 5 Hz. 
 For the fragmentation studies, a separate LC method was used to increase the 
number of scanning events the instrument could use during the method. Since reverse-
phase chromatography barely retained the desired compound, the instrument would 
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have a smaller time-window to isolate, fragment, and analyze the desired mass. HILIC 
chromatography was better able to retain the compound but did not give a well-resolved 
EIC for the target compound. Instead, the compound of interest smeared through the 
column during much of the chromatographic method, which provided plenty of time for 
the instrument to isolate the desired mass and perform fragmentation analysis. For this 
analysis the samples were analyzed on a Q-Exactive Orbitrap mass spectrometer coupled 
to an Ultimate3000 UHPLC system (Thermo Scientific, Pittsburgh, PA). The mass 
spectrometer was operated in parallel reaction monitoring (PRM) mode for this analysis 
scanning for masses corresponding to both the iron-bound and unbound siderophore of 
interest in both a singly charged and doubly charged state. Mobile phase A was 0.1 % 
formic acid in H2O and Mobile phase B was 0.1 % formic acid in MeOH. The flow rate was 
0.2 mL/min and the mobile phase gradient used was 0-3 min 1-10 % B, 3.01-6 min 10-50 
% B, 6.01-9 min 50-100 % B, 9.01-9.5 min 100 % B, 9.51-15 min 100-1 % B. The ESI 
parameters were as follows for each isolated mass in the PRM method; an isolation 
window of 0.4 m/z, resolution of 140,000, AGC target of 1.0 x 105, MaxIT of 100 ms, sheath 
gas flow rate of 25 units, aux gas flow rate of 10 units, spray voltage of ±4.0 kV, and a 
capillary temperature of 350 °C. The mass spectrometry method was operated in positive 
mode using full scan analysis for each isolated mass for each sample, for a total run time 
of 15 minutes. 
3.4.4 – Flash chromatography and subsequent NMR analysis 
 Normal phase flash chromatography was performed on the crude siderophore 
extract to isolate the fraction that had the strongest staining behavior when applied to a 
TLC plate and stained with an ethanolic solution of FeCl3. To achieve this, the optimal 
mobile phase form TLC separations (25 % MeOH in CHCl3) was reduced in polarity to 10 
% MeOH in CHCl3. The column (1” diameter) was packed with a slurry of silica (~50 g) and 
CHCl3 and the crude sample (~100 mg) was taken up in a minimal amount of MeOH and 
loaded onto the packed column, and mobile phase loaded into the reservoir above the 
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column. The column was not pressurized during separations and was allowed to flow 
naturally at about 5 mL per minute. Small 5 mL fractions were collected and tested for 
their ability to bind iron by spotting a TLC plate and subsequently staining the plate with 
an ethanolic solution of FeCl3. Once staining behavior was observed, TLCs were developed 
using the previously described method and the desired fraction was collected, solvent 
removed, and dried under high vacuum to give about 20 mg of “purified” compound. This 
entire sample was taken up in a small volume of deuterated methanol (~ 1 mL CD3OD) 
and placed in a reduced-volume NMR tube for NMR analysis. 1H-NMR, 13C-NMR, and COSY 
spectra were taken on an Oxford 300 MHz instrument operating at 300.08 MHz for the 
proton experiments and at 75.46 MHz for the carbon experiment. 
3.4.5 – Data analysis 
 All mass spectrometry data in this chapter was analyzed using the Thermo 
Scientific Xcalibur software package. This program was used to generate all ion 
chromatograms, photo-diode array chromatograms, and mass spectra obtained from the 
siderophore sample analyses. Xcalibur was used to also analyze tandem mass 
spectrometry data. Proton, carbon, and homonuclear correlation NMR data was analyzed 
with MestReNova computer software to annotate proton and carbon-13 signal chemical 
shifts and integrate peak areas. 
3.5 – Conclusion 
TLC analysis of extracts from three marine organisms – Vibrio phage PWH3a-P1, 
Rugeria pomeroyi DSS-3, and Roseobacter loktanella sp. SE62 – revealed there were 
differences in concentration and molecular composition for the iron-binding compounds 
present in the crude extracts. Optimization of a preparative TLC separation system 
allowed for the isolation of compounds significantly different in the sp. SE62 sample than 
the others, with this strain having an abundance of iron-binding activity compared to the 
other strains. Even within this sample’s multitude of iron-responsive compounds, there 
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was one single spot that dominated the others in strength of color, presumably by the 
high concentration of the compound and/or by being highly reactive to the ferric chloride 
staining solution. LCMS analysis of these crude extracts had shown that between the 
three marine microbes there were similar mass patterns and mass features, and to a 
lesser extent PDA-mediated photo-responsiveness, but in the sp. SE62 sample there was 
a high-intensity mass-feature that had an interesting isotope pattern characteristic of the 
natural isotopic distribution of iron, and a mass difference exactly matching that of a 
singly-charged iron-bound species. This finding solidified that the putative siderophore 
was isolated in an iron-bound and unbound state in the LCMS analysis. Their co-elution 
may have been a coincidence, or in-source fragmentation had been energetic enough to 
release the bound iron from the siderophore, giving both masses as detectable mass 
features. Upon LCMS analysis of the strongly-staining TLC spot by preparative TLC, it was 
found that the unique mass found in the crude extract analysis was in the strongly staining 
TLC spot pointing to this mass feature being the compound of interest for this study. It 
was then apparent that more work needed to be done in isolating this spot from the crude 
extract. 
Both normal-phase and reverse-phase flash chromatography was attempted on 
the crude sp. SE62 siderophore extract to isolate the compound of interest. Reverse-
phase separation provided no retention of the iron-binding species, and TLC analysis post-
column revealed that the sample flushed through the column without removing any of 
the other iron-binding compounds. Normal-phase chromatography proved to be more 
effective as the TLC separation that worked well was a normal-phase separation. Even 
though that chromatography worked well, the fractions collected that were related only 
to the single strongly-staining TLC spot proved to be very complex by LMCS analysis. 
Regardless, the 1H-NMR that was obtained to get an idea of the structural features 
present in the sample was fairly uninformative, which was due to a combination of the 
complexity of the sample as well as the limited quantity isolated for analysis. It’s not to 
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say that the NMR data was not helpful, but the messy splitting patterns and 
interconnectivities 2D-NMR experiments gave with these samples are not conclusive for 
structural elucidation and must be processed further to obtain cleaner spectra. Finally, 
the last attempt at gathering structural information from this partially purified 
siderophore sample was to perform a targeted LCMS-MS experiment to gather 
fragmentation data on the iron-unbound compound. This resulted in a complex spectrum 
with fragments that do not correspond to typical neutral mass losses, further increasing 
the complexity of this dataset, and thusly definitive structure determination. 
Though these methods of analysis resulted in the realization that more sample 
would need to be obtained to further purify and gather larger quantities for NMR studies, 
not all the work was futile. LCMS analysis gave an exact mass of the compound in an iron-
bound and unbound state, which could be then used to generate the plausible molecular 
formulas C29H43O12N6Fe and C29H46O12N6 respectively. Piecing together the molecular 
formula into a putative structure gave a cyclic hexapeptide ESEKEA, that tandem-MS 
fragmentation data did not fully corroborate, other than the few apparent fragments of 
glutamic acid. Many of the fragments were not of the typical peptide neutral mass losses 
but piecing together the fragmentation data was unsuccessful and challenging, perhaps 
due to unusual chemistries this molecule may exhibit as an ion undergoing high-energy 
collisional dissociation. 
Absolute isolation and structural elucidation of the unknown siderophore 
extracted from the marine bacterium S. loktanella sp. SE62 was not achieved, there was 
enough data gathered to generate a potential molecular formula to determine a putative 
structure for this unknown compound. Further work in isolating a large (~1 g) batch of 
crude siderophore extract will be necessary in order to purify large enough quantities of 
this compound for NMR studies. This task has been undertaken by one of the junior 




 Synthetic organic chemistry and analytical chemistry, although different in subject 
matter and philosophy, are very much intertwined and reliant on each other. This is 
especially true in the study of chemical biology, where in order to observe the effects that 
specific chemicals have on a biological system with analytical instrumentation, an organic 
chemist is called upon to synthesize a molecular probe to facilitate this work. This 
paradigm has certainly not exhausted its usefulness and will be a source of informative 
research for an unforeseeable amount of time. The work presented in these few chapters 
exemplifies the informative nature of these disciplines. Pioneering work in synthetic 
organic chemistry is not only limited to novel molecular transformations, but also includes 
investigating innovative scaffolds for drug therapies and to learn more about the 
structure-activity relationship (SAR) between chemicals and their intended biological 
targets. The knowledge attained from SAR studies leads to better-tailored molecules that 
stimulate a biological response with high specificity. These SAR studies can be extended 
to the examination of functional group involvement in spatial, kinetic, and 
pharmacodynamic conclusions, which ultimately result in medicine unparalleled in 
efficacy. Whereas within the purview of analytical chemistry, a scientist is able to utilize 
modern instrumentation to study the molecular makeup of living systems. This is not 
limited to the analysis of known compounds in metabolomic analyses, but more 
importantly the unknown space of biogenic chemical compounds. Understanding the 
chemical transformations available to a specific organism can lead to new ways to 
manage invasive species or treatment-resistant pathogens. 
 The first chapter of this document showcases how incredibly useful and versatile 
synthetic organic chemistry is in the development of optimized drug therapies. Through 
the synthesis and in vitro evaluation of previously reported N-arylpyrazolyl-based 
glucocorticoid analogues, it has been demonstrated that these molecules have great 
potential to replace some modern-day GC-based therapies. These compounds have been 
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shown to be quite effective in managing inflammation beforehand, but with the addition 
of a few novel compounds and modifications not attempted in earlier work, the literature 
will reflect a larger body of work that validates these finding. As already stated, these 
compounds have potent anti-inflammatory action, but more importantly they are also 
limiting the production of pro-inflammatory cytokines unlike currently available GC-based 
therapies. This permits a medical practitioner to administer these compounds without 
the unintended stimulation of the immune system to attack the cells that respond to 
these molecules. The application of these GCs in pancreatic organ transplants could 
revolutionize their success rate due to their lack of impact on β-cell function. Though 
these molecules have been assayed in an earlier publication, there is a lack of molecular 
modeling to describe the SARs, which engender the desired biological response. 
Computational evaluation of these compounds revealed that small aliphatic substitutions 
in conjunction with a 4-fluorophenyl group appended on the pyrazole portion of the 
Merck scaffold reduced the incidence of cytokine transcription. It was also shown by DFT 
modeling calculations that this likely had been mediated by the binding orientation of the 
GC in the GR pocket, resulting in a GC-GR complex with an appropriate shape to bind 
specifically to nuclear transcription factors that elicited the desired anti-inflammatory 
response. Higher-order computations will be needed to understand these specific GC-GR 
complex shapes and how they bind with nuclear GREs and other transcription factors to 
not only determine the mechanism of provoking the desired therapeutic response, but to 
also understand what transcription factors, previously thought to be undruggable targets 
respond best to these therapies. 
 In a separate study of how chemicals influence biology, an investigation of the 
presence of some unknown semiochemical in the soil bacterium M. xanthus lead to the 
development of a stable isotope tracer for the identification of a specific structural motif 
in routine LC-ESI-MS analyses. The application of synthetic chemistry in biology for the 
purpose of understanding how chemicals encourage a phenotype or behavioral response 
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largely involves the incorporation of a stable isotope-labeled congener to the system 
being investigated. Analytical chemistry is fraught with challenges in applying certain 
instrumentation to the analysis of analytes poorly compatible with accessible 
instruments. The analysis of isobaric compounds without the availability of a hard 
ionization source in mass spectrometry is one such case where isotope-labeled 
compounds mitigate this issue. Through the work presented in the second chapter, a 
synthetic isotope tracer (iC5-d3) was used to highlight compounds that contain a specific 
structural feature. Absorption of a labeled feedstock that is a biosynthetic precursor to 
lipid species bearing an isopropyl moiety allows for the generation of a diverse pool of 
isotopically labeled compounds. Using this strategy, it is possible to use LC-ESI-MS 
instrumentation traditionally used in lipidomic investigations to qualitatively determine 
the presence of this moiety in an untargeted fashion. The value of this methodology was 
demonstrated by confirming the presence of previously reported compounds in M. 
xanthus documented to bear a terminal isopropyl unit in homospermidine lipids. The 
degree of labeling detected established that the isotope tracer would only be 
incorporated into compounds with this specific moiety; However, it also seems that the 
tracer was incorporated into everything that could possibly bear this structural pattern. 
Though this can illuminate the presence of this single structural feature within an 
unknown mass feature, determining a structure from a mass is a daunting task. This 
method could potentially make the structural elucidation of unknown mass features in 
these experiments less intimidating. 
 The final chapter of this dissertation is an account of the processes attempted to 
isolate and elucidate the structure for an unknown biological molecule with interesting 
metal-transporting and cytotoxic properties. This compound was extracted from a marine 
bacterium belonging to the large Roseobacter clade and may have important implications 
for iron cycling in marine environments, not only for bacterial use, but ultimately for all 
marine organisms. Through TLC analysis of a crude siderophore-selective extract from S. 
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loktanella sp. SE62 (SE62), it was apparent that there were several iron-binding 
compounds present in the extract. Comparing the TLC plates from other siderophore-
producing microbes revealed that SE62 was producing a compound that stained strongly 
upon exposure to a solution of ferric chloride with a unique retention factor to the 
compounds produced by the other marine microbes. Extraction of this compound by 
preparative TLC allowed for mass analysis of the compound(s) present in the excised spot, 
which exhibited a mass pattern indicative of the excised compound in a bound and 
unbound state with ferric iron. Column chromatography of the crude siderophore extract 
was successful in isolating the single TLC spot with strong staining behavior but proved to 
be of insufficient quantity to obtain a meaningful NMR spectrum. LCMS analysis of the 
isolated compound(s) had shown that the flash column did not isolate a single compound 
but that several compounds were present in the purified sample. It was not feasible to 
try and purify the sample any further for NMR studies, as the final isolated sample was 
less than 20 mg. Work is currently being done to collect a larger sample size to be 
subjected to several columns of differing selectivity to absolutely isolate the compounds 
present in the sample with a high affinity for ferric iron. 
 Chemistry is a scientific discipline that will always be changing the world we live 
in and challenging the status-quo, from the medicines we take to the understanding of 
how living systems function. Even when solely focusing on chemistry, there is no 
conceivable end to the improvements that can be made to the specificity of chemical 
reactions or to the sensitivity of analytical instrumentation. It is a large responsibility of 
the scientific community to make logical advancements with current technology and 
techniques in order to influence future generations of scientists and to continue 
expanding human knowledge ad infinitum. The findings presented in this dissertation will 
hopefully inspire new ideas to further investigate the understanding of the few biological 
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